Georgia State University

ScholarWorks @ Georgia State University
Chemistry Dissertations

Department of Chemistry

12-14-2017

Using Different Analytical Techniques and Synthetically Tailored
Silica Nanoparticles in Drug Separations and HydrophobicityBased Detection Applications
Walid Abdelwahab

Follow this and additional works at: https://scholarworks.gsu.edu/chemistry_diss

Recommended Citation
Abdelwahab, Walid, "Using Different Analytical Techniques and Synthetically Tailored Silica Nanoparticles
in Drug Separations and Hydrophobicity-Based Detection Applications." Dissertation, Georgia State
University, 2017.
doi: https://doi.org/10.57709/11188925

This Dissertation is brought to you for free and open access by the Department of Chemistry at ScholarWorks @
Georgia State University. It has been accepted for inclusion in Chemistry Dissertations by an authorized
administrator of ScholarWorks @ Georgia State University. For more information, please contact
scholarworks@gsu.edu.

USING DIFFERENT ANALYTICAL TECHNIQUES AND SYNTHETICALLY TAILORED
SILICA NANOPARTICLES IN DRUG SEPARATIONS AND HYDROPHOBICITY-BASED
DETECTION APPLICATIONS

by

WALID ABDELWAHAB

Under the Direction of Professor Ramzia El-Bagary and Professor Gabor Patonay

ABSTRACT
The development and validation of accurate and reliable analytical methods using
techniques such as capillary electrophoresis, liquid chromatography, UV-spectrophotometry,
spectrofluorimetry and mass spectrometry for separation and determination of some selected
drugs in different matrices are presented in the first three chapters. The developed methods were
applied to the determination of these compounds in their dosage forms and/or in biological fluids
such as human plasma. The stability indicating characteristics including the analysis and
separation of certain drugs from their alkaline, acidic, oxidative, thermal or photolytic
degradation products along with the study of the degradation kinetics were also investigated. The
first chapter focuses on the liquid chromatographic methods and the second chapter covers the
capillary electrophoretic methods whereas the third chapter includes the UV-spectrophotometric

and spectrofluorimetric methods. On the other hand, the fourth chapter shows how functionalized
silica nanoparticles can be used in achieving enhanced electrophoretic separations of selected
groups of acidic and basic drugs. Finally, the fifth chapter of this dissertation presents a library of
fluorescently labeled-silica nanoparticles that can be used in certain hydrophobicity-based
detection applications such as fingerprint detection.
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1 SEPARATION AND DETERMINATION OF SELECTED PHARMACEUTICAL
COMPOUNDS USING LIQUID CHROMATOGRAPHY
1.1

Introduction
Mechanism of action for the majority of the approved drugs in the market are mediated in

one way or another through affecting the normal biological function of some endogenous
peptides such as angiotensinogen, angiotensin I, angiotensin II, renin or biogenic amines such as
noradrenaline, serotonin, histamine…etc. Some examples of these drug classes include protease
inhibitors, angiotensin II receptor blockers, angiotensin converting enzyme inhibitors, renin
inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, signal transduction inhibitors (protein
tyrosine kinase inhibitors), incretin hormone glucagon-like peptide-1 (GLP-1) agonists, α
agonists, α blockers, β agonists, β blockers, some antidepressants, some antipsychotics, some
anti-parkinsonism, antihistaminics and H1 receptor antagonists 1. Therefore, it is important to
develop and apply precise, accurate and advanced analytical techniques including capillary
electrophoresis, liquid chromatography, spectrophotometry, spectrofluorimetry and mass
spectrometry for determination of drugs such as valsartan, azilsartan moexipril and aliskiren
hemifumarate that affect endogenous peptides as well as drugs affecting biogenic amines such as
atenolol in different matrices including dosage forms and biological fluids.
It proved useful for elucidating the stability indicating characteristics of some of these
methods. In addition, these developed methods were validated according to the proper validation
guidelines.
High-pressure (high-performance) liquid chromatography (HPLC) is a separation
technique based on a liquid or solid stationary phase and a liquid mobile phase. Depending upon
the type of stationary phase used, separations are achieved by adsorption, partitioning, or ion-

2

exchange processes. The elution time of a compound is better to be described by the capacity
factor K', which depends on the nature of the analyte, the mobile phase composition, and the
surface area and structure of the stationary phase. Only compounds holding different capacity
factors can be separated by HPLC. Column length is also an important determinant of resolution.
2

.
Based on sales volumes and the scientific importance of HPLC, this is the most popular

analytical method. Its present popularity results from its effective separation of a wide range of
samples, ease of use, speed, and nanomolar detection levels 3.
Five major types of HPLC can be mentioned based on its purposes: normal phase
chromatography, reversed phase chromatography, size exclusion chromatography, ion exchange
chromatography and bioaffinity chromatography. Reversed phase HPLC (RP-HPLC) consists of
an aqueous, moderately polar mobile phase and a non-polar stationary phase. Silica is a common
stationary phase which was treated with RMe2SiCl, where R is a straight chain alkyl group such
as C8H17 or C18H37. The retention time is therefore longer for non-polar molecules, allowing
polar molecules to elute faster. Retention time is decreased by the addition of a hydrophobic
solvent to the mobile phase and increased by the addition of a more polar solvent 4.
Structural features of the analyte molecule play a crucial role in its retention behavior. In
general, an analyte with a more hydrophobic nature results in a longer retention time as it
increases the molecule's non-polar surface area, which interacts less with the polar component of
the mobile phase. On the other hand, polar groups result in a shorter retention time as they
interact well with water. Very large molecules, however, can result in a poor interaction between
the ligands alkyl chains and the large analyte surface, and can have problems accessing the pores
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of the stationary phase. Branched chain compounds elute faster than their corresponding linear
isomers because the overall surface area is lower 3.
Different applications of HPLC on the analysis of drugs in dosage forms and biological
matrices have been investigated extensively. The applications of HPLC in the field of
pharmaceutical analysis are expected to continue to grow mainly supported by the recent
advances in instrumentations. Improvements made in HPLC include changes in packing
material, hyphenated detection systems, automation, and computer-assisted optimization. These
improvements facilitate its introduction into high assay volume situations such as clinical
laboratories and quality control 5-9.
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1.2

Stability-Indicating RP-LC Method for Determination of Azilsartan medoxomil and
Chlorthalidone in Pharmaceutical Dosage Forms: Application to Degradation
Kinetics

Copyright © Springer-Verlag Berlin Heidelberg 2014
Analytical and Bioanalytical Chemistry (2014) 406:6701–6712
DOI 10.1007/s00216-014-8085-0

A RP-LC method was developed and validated for simultaneous determination of the
active components, azilsartan medoxomil (AZL) and chlorthalidone (CLT), in their
antihypertensive combined recipe. The chromatographic separation was achieved on Eclipse
XDB-C18 (4.6 x 150 mm, 5 µm) column using a mobile phase consisting of methanol:
potassium hydrogen phosphate buffer (pH 8, 0.05 M) (40:60, v/v) in isocratic mode. The flow
rate was maintained at 0.8 mL min-1 at ambient temperature. Detection was carried out at 210
nm. The method was validated according to ICH guidelines. Linearity, accuracy and precision
were satisfactory over the concentration range of 5.0–50.0 and 2.5-25.0 µg mL-1 for AZL and
CLT, respectively (r2 = 0.9999). LODs for AZL and CLT were 0.90 and 0.32 µg mL-1 whereas
LOQs were 2.72 and 0.98 µg mL-1, respectively. Both drugs were subjected to forced
degradation studies under hydrolysis (neutral, acidic and alkaline), oxidative and photolytic
extensive stress conditions. The proposed method is stability-indicating by the resolution of the
investigated drugs from their degradation products. Moreover, the kinetics of the acidic
degradation of AZL as well as the kinetics of the alkaline degradation of CLT were investigated.
Arrhenius plots were constructed and the apparent first-order rate constants, half-life times,
shelf-life times and the activation energies of the degradation processes were calculated. The
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method was successfully applied for the determination of the studied drugs simultaneously in
their co-formulated tablet. The developed method is specific and stability indicating for the
quality control and routine analysis of the cited medications in their pharmaceutical preparations.
1.2.1 Introduction
Azilsartan medoxomil (AZL), is chemically designated as ((5-Methyl-2-oxo-1,3-dioxol4yl) methyl 2-ethoxy-1-((2`-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) biphenyl-4-yl) methyl)1H-benzimidazole-7-carboxylate), (Fig. 1.2.1a). Azilsartan, the active metabolite of AZL, is a
novel non-peptide angiotensin II type 1 (AT1) receptor blocker (ARB), was recently approved for
treatment of hypertension 10. It has a superior ability to control systolic blood pressure relative to
other widely used ARBs. Greater antihypertensive effects of AZL might be due in part to its
unusually potent and persistent ability to inhibit binding of angiotensin II to AT1 receptors
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.

Preclinical studies have indicated that AZL may also benefit cellular mechanisms of cardiometabolic disease and insulin sensitizing activity
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. There is only one reported method
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for

determination of AZL alone and it was applied to its analysis in plasma. Chlorthalidone (CLT),
(2-chloro-5- (1-hydroxy-3-oxoiso-indolin-1-yl) benzenesulfonamide), (Fig. 1.2.1b), is an orally
taken thiazide-like diuretic for controlling hypertension and edema, including that associated
with heart failure

14

. CLT has been determined in different matrices either alone or in

combination with other medications using LC

15,

16

, LC-MS/MS

17

, HPTLC

18,

19

,

chemiluminometry 20, spectrophotometry 21 and CE 22 techniques. Binary combination therapies
of AZL and CLT proved to induce significant reductions in systolic and diastolic blood pressure
in patients with mild to severe hypertension
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. Regarding simultaneous determination of CLT

and AZL, there is only one LC reported method
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, done on a symmetry C18 column with a

mobile phase consisting of methanol: Water: Acetonitrile: 0.1% o-phosphoric acid (30:35:15:5,
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v/v/v/v) at λ of 251 nm. To the best of our knowledge, the present study is the first reported
stability-indicating LC method for the determination of AZL and CLT in tablets. The parent drug
stability test guideline Q1A (R2) issued by International Conference of Harmonization (ICH)
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suggests that, stress studies should be carried out on a drug to establish its inherent stability
characteristics. Accordingly, the aim of the present study was to establish the inherent stability of
AZL and CLT through stress studies under a variety of ICH recommended test conditions, and to
develop the first stability-indicating assay method for their determination in their commercially
available tablets. In the present work, AZL and CLT were subjected to forced degradation
studies under an extensive stress testing. These studies included the effects of hydrolysis
(neutral, acidic and alkaline), oxidation and photolysis. The currently developed LC method
effectively separated the two investigated drugs from their degradation products (DPs).
Furthermore, the proposed LC method was applied to study the degradation kinetics of AZL and
CLT under acidic and alkaline degradation stress conditions, respectively. Arrhenius plots were
constructed and the apparent first-order rate constants, half-life times, shelf-life times and the
activation energies of the degradation processes were calculated. The described method
demonstrates its novelty and pros by combining several advantages in one method: the limit of
detections for AZL and CLT were as low as 0.9 and 0.3 µg mL-1, respectively. The method was
able to simultaneously determine the two drugs in their pharmaceutical preparation. Moreover,
the present work was designed to detect and analyze AZL and CLT in presence of their potential
DPs using a stability indicating accurate, inexpensive and simple procedure. Another added
advantage of the current method resides in its ability to study the kinetics of degradation
processes of AZL and CLT which were obtained by subjecting them to acidic and alkaline stress
conditions, respectively.
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1.2.2
1.2.2.1

Experimental
Instruments
Separations were performed using Agilent HPLC system 1200 chromatograph (USA)

equipped with a quaternary pump G1311A and a Rheodyne injector valve with a 20 μL loop and
a G1315D MWD detector. Mobile phases were degassed using a G1322A solvent degasser.
Agilent Chemstation for LC systems [Rev.B.03.01-SR1 (317)] PC program was used for the
instrument control, data analysis and acquisition. A SympHonly (SB20) pH-meter (Thermo
Orion, MA, USA) was used for pH adjustment. Nano pure water was prepared using a Barnstead
NANO pure DIamond Analytical ultrapure water system (Fischer Scientific, NJ, USA). Fisher
Biotech UV fluorescent lamp, model FBUVLS-80 dual wavelength (254/366) was used in the
photo-stability studies (Fisher Scientific, PA, USA). The LC–MS studies was performed using
an Agilent 1200 ultra-high pressure liquid chromatography system (USA) consisting of a binary
pump (G1312A) with a degasser, autosampler (G1329A) and a DAD (Agilent 1100, G1315B)
using a mobile phase composed of water and methanol (20: 80, v/v) coupled to a 3200 Q TRAP
mass spectrometer (AB Sciex; CA, USA) fitted with a TurboV ion source operating in negative
and positive electrospray ionization (ESI) mode. The data were acquired and processed using
Analyst® 1.6.1 Software (AB Sciex; Ontario, Canada). MS source parameters were set at:
desolvation temperature (TEM): 200 °C, high voltage: -4500 V (ESI -), 4500 V (ESI +), curtain
(CUR) and nebuliser (GS1 and GS2) gases: nitrogen; 20, 40, and 50 psi; respectively, nitrogen
collision gas pressure: 5 mTorr.
1.2.2.2 Materials and reagents
All the chemicals used were of Analytical Reagent grade, and the solvents were of HPLC
grade. AZL (certified to contain 98%) was supplied by D-L Chiral Chemicals, LLC., NJ 08540
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USA. CLT (certified to contain 98%) was supplied by Ark Pharm. Inc., IL 60048 USA.
Edarbcyclor® 40-25 mg tablets; batch # NDC 64764-0994-30 (Takeda Pharmaceutical Company
Limited, Tokyo, Japan) each labeled to contain 42.68 mg of azilsartan kamedoxomil (equivalent
to 40 mg AZL) and 25 mg CLT were purchased from commercial sources in the local market.
Sodium hydroxide, potassium hydroxide, acetic acid and dipotassium hydrogen orthophosphate
were obtained from J.T. Baker, NJ, USA. Orthophosphoric acid 85%, hydrochloric acid and
ammonium acetate (Fisher Scientific, NJ, USA) were also used. Methanol and hydrogen
peroxide (30% w/v) (Sigma-Aldrich, MO, USA).
1.2.2.3 Chromatographic conditions
A mixture of methanol: dipotassium hydrogen phosphate buffer (PBS) (pH 8±0.1,
0.05M) (40:60, v/v) was prepared. Flow rate was maintained at 0.8 mL min-1. All analyses were
performed at ambient temperature. The system was equilibrated and saturated with the mobile
phase for 30 min before the injection of the solutions. Quantification was achieved with UV
detection at 210 nm based on peak area. Twenty L of the solutions were injected with a 50 l
Agilent analytical syringe in triplicates.
1.2.2.4

Standard solutions
Ten mg of each of AZL and CLT were accurately weighed and transferred in to 10 mL

volumetric flasks separately. Then, they were dissolved and made up to volume with methanol to
give final concentrations of 1000 g mL-1 for each. The solutions were stable for at least 14 days
without alteration when kept in the refrigerator at 4 ◦C and protected from light.
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1.2.2.5 Procedures
1.2.2.5.1 Construction of the calibration graphs
Accurate aliquots from the standard solutions were transferred separately into a series of
10 mL Fisherbrand disposable tubes. Then, the volumes were completed to the mark with the
mobile phase so that the final concentrations were in the range of 5.0-50.0 and 2.5-25.0 µg mL-1
for AZL and CLT, respectively. Aliquots of 20 µL were injected (triplicate) and eluted with the
mobile phase under the optimum chromatographic conditions using UV detection at 210 nm. The
average peak area versus the final concentration of the drug in µg mL-1 was plotted.
Alternatively, the corresponding regression equations were derived.
1.2.2.5.2 Preparation of the laboratory prepared mixtures
Accurate aliquots of AZL and CLT standard solutions were transferred into a series of 10
mL Fisherbrand disposable tubes keeping the medicinally recommended ratio of 1.6:1 for
AZL/CLT mixture to give final concentrations of 8, 16, 24 µg mL-1 for AZL and 5, 10, 15 µg
mL-1 for CLT. The above procedure described under “section 2.5.1” was then applied. The
recovery percentage was calculated using the corresponding regression equation.
1.2.2.5.3 Analysis of the studied drugs in their pharmaceutical preparation
Ten tablets of Edarbcyclor® 40-25mg were weighed, finely pulverized and thoroughly
mixed. After calculating the average tablet weight, amounts of powder equivalent to 40 and 25
mg of AZL and CLT, respectively, were accurately weighed and transferred into a 25 mL
measuring flask. Twenty milliliters of methanol were added and the solution was sonicated for
30 min then completed to volume with the same solvent. The solution was filtered through a
Whatman filter paper and then filtered again using 0.2µm a Whatman inorganic membrane filter.
For analyses, different aliquots from the prepared sample solutions were chromatographed using
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the same procedure described under “section 2.5.1”. The recovery percentage was calculated by
referring to the corresponding regression equations.
1.2.2.5.4 Procedures for the extensive stress stability studies
1.2.2.5.4.1 Stress degradation by hydrolysis under acidic and alkaline conditions
Aliquots of AZL and CLT standard solutions equivalent to 500 and 400 μg, respectively,
were transferred separately into Fischerbrand disposable tubes; treated with 2 mL of 0.1 M
NaOH or 0.1M HCl and heated at 80 and 100 oC for 1 h, respectively. After the specified time,
the contents of each tube were cooled and neutralized to pH 7.0 with 0.1 M HCl or 0.1 M NaOH,
respectively. The solutions were then transferred into 10-mL volumetric flasks. Five milliliters
methanol were added to each flask and completed to the volume with Nano pure water. Two
milliliters of the resulting solutions were then transferred into Fischerbrand disposable tubes and
diluted to 4 mL with the mobile phase (final concentrations were 25 and 20 µg mL-1 as
equivalent to AZL and CLT, respectively, before degradation) and filtered before injection into
the column. The above procedure described under “section 2.5.1” was then applied.
1.2.2.5.4.2 Procedure for oxidative and wet heat induced degradations
Aliquots of AZL and CLT standard solutions equivalent to 500 and 400 μg, respectively,
were transferred separately into Fischerbrand disposable tubes; 2 mL aliquots of 6% H 2O2 or
Nano pure water were added and heated at 80 and 100 oC for 1 h for AZL and CLT, respectively.
After the specified time, the resulting solution was cooled and transferred into 10-mL volumetric
flasks. Five milliliters methanol were added to each flask and completed to the volume with
Nano pure water. Two milliliters of the resulting solutions were then transferred into
Fischerbrand disposable tubes and diluted to 4 mL with the mobile phase (final concentrations
were 25 and 20 µg mL-1 as equivalent to AZL and CLT, respectively, before degradation) and

11

filtered before injection into the column. The above procedure described under “section 2.5.1”
was then applied.
1.2.2.5.4.3 Procedure for photolytic degradation
The photo degradation study was performed by subjecting 4 mL from each of AZL (100
μg mL-1) and CLT (80 μg mL-1), prepared in methanol and placed in 1-cm stoppered quartz cells
to direct UV radiation (UV lamp set at 254 nm) at room temperature for 24 h at a distance of 10
cm. Protected samples, wrapped in aluminum foil in order to protect them from light, were
submitted to identical conditions and used as control. One milliliter of the resulting solutions
were then transferred into Fischerbrand disposable tubes and diluted to 4 mL with the mobile
phase (final concentrations 25 and 20 µg mL-1 as equivalent to AZL and CLT, respectively,
before degradation) and filtered before injection into the column. The above procedure described
under “section 2.5.1” was then applied.
1.2.2.5.5 Kinetics investigation
1.2.2.5.5.1 Study of the acidic induced degradation of AZL at different temperatures
Aliquots of AZL standard solution (equivalent to 500 μg) were transferred into
Fischerbrand disposable tubes. Two milliliters of 0.1 M HCl were added for each tube. The tubes
were heated at different temperatures (50, 60, 70, 80 oC) for different time intervals (15–60 min).
At the specified time interval, the contents of each tube were cooled and neutralized to pH 7.0
with 0.1 M NaOH. The solutions were then transferred into 10-mL volumetric flasks. Five
milliliters methanol were added to each flask and completed to the volume with Nano pure
water. Two milliliters of the resulting solutions were then transferred into Fischerbrand
disposable tubes and diluted to 4 mL with the mobile phase (final concentration was 25 μg mL-1
as equivalent to AZL before degradation) and filtered before injection into the column. The
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above procedure described under “section 2.5.1” was then applied. The concentration of the
remaining drug was calculated for each temperature and time interval. Data were further
processed and degradation constants were calculated for each temperature to construct the
Arrhenius plot. An Arrhenius plot was constructed and the apparent first-order rate constants,
half-life times, shelf-life times and the activation energy of the degradation process were then
calculated. All solutions were filtered through 0.2 µm membrane filters and degassed for 5 min
before injection to the LC system.
1.2.2.5.5.2 Study of the alkaline induced degradation of CLT at different temperatures
Aliquots of CLT stock solutions (equivalent to 400 μg) were transferred into
Fischerbrand disposable tubes. Two milliliters of 0.1 M NaOH were added for each tube. The
tubes were heated at different temperatures (70, 80, 90, 100 oC) for different time intervals (30–
120 min). At the specified time interval, the contents of each tube were cooled and neutralized to
pH 7.0 with 0.1 M HCl. The solutions were then transferred into 10-mL volumetric flasks. Five
milliliters methanol were added to each flask and completed to the volume with Nano pure
water. Two milliliters of the resulting solutions were then transferred into Fischerbrand
disposable tubes and diluted to 4 mL with the mobile phase (final concentration was 20 μg mL-1
as equivalent to CLT before degradation) and filtered before injection into the column. The
above procedure described under “section 2.5.1” was then applied. The concentration of the
remaining drug was calculated for each temperature and time interval. Data were further
processed and degradation constants were calculated for each temperature to construct the
Arrhenius plot. An Arrhenius plot was constructed and the apparent first-order rate constants,
half-life times, shelf-life times and the activation energy of the degradation process were then
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calculated. All solutions were filtered through 0.2 µm membrane filters and degassed for 5 min
before injection to the LC system.
1.2.3 Results and discussion

The proposed method permitted the separation and quantitation of the studied drugs in a
short time <9 min. Furthermore, the suggested procedure was applied for the quality control of
commercial dosage form (Fig. 1.2.2). The proposed LC method allows the separation of AZL
and CLT from all possible degradation products. Fig. (1.2.3b-f) as well as (1.2.4b-f) show good
resolution of AZL and CLT from each of its alkaline, acidic, oxidative, thermal (wet heat) and
photolytic degradation products, respectively. The stability studies for the acidic degradation
kinetics of AZL as well as the alkaline degradation kinetics of CLT were successfully conducted.

1.2.3.1 Optimization of experimental conditions
Several trials were carried out to achieve the best chromatographic conditions for the
simultaneous determination of AZL and CLT as well as their separation from their degradation
products. Three columns were tested for performance investigation, including: Ultrasphere ODS
column (4.6 mm ×250 mm, 5 μm particle size), Beckman, Fullerton, CA, USA, Eclipse XDBC18 column (4.6 x 150mm, 5 µm) Agilent, East Windsor, NJ, USA and Spherex 10 phenyl
column (250 mm x 2.0 mm i.d.), Phenomenex, CA, USA. The experimental studies revealed
that, the second column was the most suitable one since it produced symmetrical peaks with high
resolution and within a reasonable analytical run time. AZL is practically insoluble in water,
freely soluble in methanol, dimethylsulfoxide, soluble in acetic acid, slightly soluble in acetone,
and acetonitrile and sparingly soluble in tetrahydrofuran and 1-octanol
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. Methanol and

acetonitrile were examined as the organic modifiers and acetonitrile was found to cause splitting
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for the peak of AZL due to its poor solubility in that solvent so methanol was chosen as the
organic modifier in this study. Water, 1% acetic acid, ammonium acetate buffer (pH 5.5; 0.05 M)
and PBS (pH 8; 0.05 M) were tested as the aqueous component in the mobile phase. The use of
buffer is necessary in this method in order to enhance the ionization of the analytes, obtain
proper separation and increase the sharpness of peaks. Both ammonium acetate buffer and PBS
are able to achieve proper separation. PBS was selected as it was able to produce sharper and
more symmetric peaks than ammonium acetate buffer. Then, effect of pH on the separation of
the analytes was studied. The higher the pH of the used buffer the lower the retention time with
sharp and symmetric peak for AZL so pH 8 was selected as it achieved satisfactory separation at
a reasonable run time (<9 min) and with satisfactory resolution between all of the analytes, (Fig.
1.2.2). Ratio of aqueous to organic component in the mobile phase system was also studied and a
ratio of (60:40, v/v) was selected. Increasing the ratio of the aqueous component will produce
significant delay and broadening of peaks meanwhile increasing the ratio of the organic
component will cause overlap between the studied analytes. Different flow rates were studied as
it affects both resolution and shape of peaks and flow rate of 0.8 mL min-1 was selected. Proper
choice of the detection wavelength is crucial for sensitivity of the method. Quantitation was
achieved with UV-detection at 210 nm based on good peak area for each of the analyzed drugs.
System suitability tests were used to verify that the conditions of the chromatographic system
were adequate for the separation and hence for the analysis 26, (Table 1.2.1).
1.2.3.2

Method validation
The validity of the proposed LC method was assessed according to ICH guidelines in

terms of linearity, range, limit of detection, limit of quantification, accuracy, precision,
robustness, specificity and stability 26.
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1.2.3.2.1 Linearity and range
Under the above described experimental conditions, linear relationships were established
by plotting the peak area versus the corresponding concentration in μg mL-1. The graphs were
found to be rectilinear over the concentration ranges cited in table 1.2.2. Statistical analysis of
the data gave high value of the correlation coefficient (r) of the regression equation, small values
of the standard deviation of residuals (Sy/x), of intercept (Sa), and of slope (Sb), and small value
of the percentage relative standard deviation and the percentage relative error, (Table 1.2.2).
These data indicated the linearity of the calibration graphs.
1.2.3.2.2 Limit of quantitation (LOQ) and limit of detection (LOD)
LOQs and LODs were calculated according to ICH Q2 (R1) recommendations using the
following equation 26: LOQ = 10 Sa /b and LOD = 3.3 Sa /b, where Sa = standard deviation of the
intercept and b = slope of the calibration curve. Results are given in (Table 1.2.2).
1.2.3.2.3 Accuracy and precision
The satisfactory recovery results for the assay of AZL and CLT in their laboratory
prepared mixtures indicate the accuracy of the method, (Table 1.2.3). Repeatability (intraday)
and intermediate precision (inter-day) were assessed using three concentrations and three
replicates of each concentration. The relative standard deviations were found to be very small
indicating reasonable repeatability and intermediate precision of the proposed method (Table
1.2.4).
1.2.3.2.4 Stability of standard solutions and mobile phase
Stability of the standard solutions of AZL and CLT stored at 4 ◦C, were evaluated at
various time points over one month. The concentrations of freshly prepared solutions and those
aged for one month were calculated by the method developed and the difference between them
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was found to be non-significant (% RSD <2%). Similarly, the stability of the mobile phase was
checked for two weeks. The results obtained in both cases proved that the samples solutions and
mobile phase used during the assay were stable for the specified durations, when kept in the
refrigerator at 4 ◦C.
1.2.3.2.5 Robustness of the method
Minor deliberate changes in different experimental parameters such as flow rate (±0.1
mL min-1), pH (±0.1) and ratio of mobile phase components (±2%) did not significantly affect
resolution of the analyzed compounds indicating that the proposed method is robust, (Table
1.2.5).
1.2.3.2.6 Specificity
The specificity is the ability of the analytical method to assess unequivocally the analyte
in the presence of components which may be expected to be present. The specificity of the
method was investigated by observing any interference encountered from common tablet
excipients and it was confirmed that the signals measured was caused only by the analytes. The
inactive ingredients in Edarbcylor® are: mannitol, microcrystalline cellulose, fumaric acid,
sodium hydroxide, hydroxypropyl cellulose, crospovidone, magnesium stearate, hypromellose
2910, talc, titanium dioxide, ferric oxide red, polyethylene glycol 8000, and printing ink gray F1.
It was found that the excipients did not interfere with the results of the proposed method. As
shown in (Fig. 1.2.2) the chromatograms of the combined formulations did not show any
additional peaks when compared with the chromatograms of the laboratory prepared mixtures
which confirm the specificity of the developed method. Specificity of the method was also
confirmed by its ability to measure AZL and CLT in the presence of all of their degradation
products, as revealed by the results of the stability study (Fig. 1.2.3b–3f and 1.2.4b-4e).
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1.2.3.3 Application of the proposed method for quality control of AZL and CLT in their
combined commercial dosage form
The proposed method was applied to determine AZL and CLT in their commercially
available tablets. Satisfactory recoveries were obtained and the results are given in (Table 1.2.3).
1.2.3.4 Forced degradation studies
AZL and CLT were subjected to forced decomposition by alkali, acidic, wet heat, light
and oxidation, as suggested in the International Conference on Harmonization (ICH) Q1A (R2)
and (Q1B) guideline 25, (Fig. 1.2.4).
1.2.3.4.1 Alkaline Induced Degradation
AZL showed high stability to alkaline degradation. Only 3.1 % degradation was observed
as evidenced by the decrease in the parent drug peak area upon the addition of 2 mL 0.1 M
NaOH to the drug and boiling at 80 oC for 1 h, (Fig. 1.2.3b). On the contrary, CLT was found to
undergo alkaline degradation very readily after addition of 2 mL 0.1 M NaOH to the drug and
boiling at 100 oC for 1 h. 69.0 % degradation was observed as evidenced by the decrease in the
parent drug peak area, and the appearance of two major DPs with peaks at 3.8 min and 4.9 min,
(Fig. 1.2.4b).
1.2.3.4.2 Acid induced degradation
AZL was found to undergo acid degradation very readily upon the addition of 2 mL 0.1
M HCl to the drug and boiling at 80 oC for 1 h. 94.7 % degradation was observed as evidenced
by the decrease in the parent drug peak area, (Fig. 1.2.4c) and the appearance of one major DP
peak at 2.7 min, (Fig. 1.2.3c). On the contrary, CLT was found to show high stability to acidic
degradation upon the addition of 2 mL 0.1 M HCl to the drug and boiling at 100 oC for 1 h. Only
3.6 % degradation was observed as evidenced by the decrease in the parent drug peak area, (Fig.
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1.2.4c).
1.2.3.4.3 Hydrogen Peroxide and thermal (wet heat) induced degradation:
Oxidative and thermal (wet heat) degradation of AZL and CLT were also studied. AZL
was found to show certain stability to oxidative and thermal (wet heat) degradation upon the
addition of 2 mL of 6% H2O2 or water, respectively, to the drug and boiling at 80 oC for 1 h.
Only 19.2 and 2.6 % degradation was observed as evidenced by the decrease in the parent drug
peak area, (Fig. 1.2.3d, 3e). Also, CLT showed certain stability to oxidative and thermal (wet
heat) degradation upon the addition of 2 mL of 6% H2O2 or water, respectively, to the drug and
boiling at 100 oC for 1 h. Only 7.7 and 0.7 % degradation was observed as evidenced by the
decrease in the parent drug peak area, (Fig. 1.2.4d, 4e).
1.2.3.4.4 Photolytic degradation
The effect of UV-light on the stability of AZL and CLT were studied. It was found that
99.1% and 96.1% degradation was observed after exposure of the drug to 254 nm light for 1 day
at room temperature, respectively, (Fig. 1.2.3f, 4f).
1.2.3.5

Identification of the potential acid degradation product for AZL
As shown in scheme 1.2.1, the LC-MS total ion chromatograms (negative mode) for the

intact AZL and its acidic induced degradation after 1 h boiling at 80 °C, a predominant DP was
found to be present with a molecular ion at m/z 539. It is postulated that the drug degraded
through cleavage of the ether linkage attached to the benzodiazole moiety. This DP showed a
fragment at m/z 427 due to cleavage of the ester bond. Then, further fragmentation occurred
through opening of the oxadiazole ring and losing CO2 molecule to give a fragment at m/z 383.
This anticipation was supported by the disappearance of the peaks at δ= 1.3 and 4.6 of the ethyl
group in the 1H NMR spectrum (400 MHz, DMSO) of AZL DP and by the appearance of new
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peaks at δ= 5.5 and 11.4 of the resonating iminol group in the benzdiazole ring.
1.2.3.6 Identification of the potential alkaline degradation product for CLT
The LC-MS total ion chromatogram (negative mode) for the intact CLT and its alkaline
degradation after 1 h boiling at 100 °C revealed some distinguishable molecular ion peaks at m/z
375, 339, 356, 294 and 258 from that of the ion chromatogram of the intact drug. Also, it showed
many peaks for dimer adducts. As demonstrated in scheme 1.2.2, we have two anticipated
pathways for the alkaline induced degradation of CLT. The first one is through hydrolytic
cleavage of the amide bond in the isoindole ring with a molecular ion at m/z 356 followed by
removal of the ammonia group to form a stable benzophenone derivative with m/z at 339.
Further fragmentation of that DP was proposed to be via decarboxylation to give a fragment at
m/z 294. The second pathway is through direct opening of the isoindole ring to form amido
benzophenone derivative at m/z 339. Further fragmentation of that DP was through removal of
sulphonamide moiety to form a fragment at m/z 258. The second anticipated pathway was
supported by the disappearance of the peaks at δ= 8.1 and 9.4 of the hydroxyl and the secondary
amino groups in the 1H NMR spectrum (400 MHz, DMSO) of CLT DP and by the appearance of
a new peak at δ= 6.1 of the amide group.
1.2.3.7 Degradation kinetics for AZL and CLT
The experimental investigation of the possible breakdown of the drugs is usually studied
to produce more stable preparations and to assist the pharmacists and physicians regarding the
proper storage and handling of the medicinal agents. Degradation reaction rates are affected by
temperature, as suggested by the Arrhenius equation 27:
𝐿𝑜𝑔 𝐾 = 𝐿𝑜𝑔 𝐴 −

𝐸𝑎 1
2.303 𝑅𝑇
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Where: K = specific reaction rate at temperature T, A = Arrhenius factor (collision
factor) constant, Ea = energy of activation (the minimum kinetic energy a molecule must possess
in order to undergo reaction), R = gas constant, and T = absolute temperature in Kelvin.
In this study, the constant A and Ea were evaluated by determining K for the acid
degradation of 25 µg mL-1 of AZL in 0.1 M HCl at different temperatures (50, 60, 70, and 80 oC)
as well as for the alkaline degradation of 20 µg mL-1 of CLT in 0.1 M NaOH at different
temperatures (70, 80, 90, and 100 oC). As shown in Fig. 1.2.5 the degradation was found to be
temperature dependent.
The apparent first order degradation rate constant, half-life time (t1/2), shelf-life (t90) and
the activation energy Ea were calculated (Table 1.2.6). By plotting log Kobs values versus 1/T,
Arrhenius plot was obtained (Fig. 1.2.6) and the resulting lines were extrapolated at room
𝑜
temperature to obtain 𝐾25
, which is used as a measure of the stability of the drug under ordinary

shelf conditions. Arrhenius equations

27

were found to be: (Log K = 11.482 + 4.5441 x 103/T)

for AZL as well as (Log K = 10.235 + 4.4562 x 103/T) for CLT. Where; K is the specific
reaction rate, T is the absolute temperature.
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Table 1.2.1 System Suitability data for the RP-LC Method
Item

AZL

CLT

N

4422

4185

K`

2.63

1.89

T

1.19

1.22

R

3.88

α

1.26

(N: number of theoretical plates; K`: capacity factor; R: resolution factor; T: tailing factor; :
relative retention time)

Table 1.2.2 Characteristics and Results of the Proposed RP-LC Method
Item

AZL

CLT

Limit of detection, LOD (µg mL-1)

0.90

0.32

Limit of quantitation, LOQ (µg mL-1)

2.72

0.98

Intercept (a)

-189.71

-72.54

Slope (b)

175.78

193.75

Correlation coefficient (r)

0.9999

0.9999

S.D. of residuals (Sy/x)

61.09

24.24

S.D. of intercept (Sa)

47.84

18.99

S.D. of slope (Sb)

1.71

1.36

% Error

1.02

0.83

% RSD

2.27

1.86

Linearity range (µg/mL)

5.00-50.00

2.50-25.00

Mean %recovery ± S.D.

100.83 ± 2.29

99.48 ± 1.85
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Table 1.2.3 Assay results for the determination of the studied drugs in their laboratory prepared
mixtures and dosage forms
Ratio

Compound

AZL

Laboratory prepared mixtures
Amount

Amount

%

Amount

Amount

taken

found

Found

taken

found

(g mL-1)

(g mL-1)

(g mL-1)

(g mL-1)

8.00

8.10

101.25

8.00

8.22

102.75

16.00

15.98

99.88

16.00

16.19

101.19

24.00

23.93

99.71

24.00

24.10

100.42

Mean
recovery%

(1.6:1.0)

(AZL:CLT)

± %RSD

CLT

Dosage form
%
Found

100.28

101.45

0.84

1.17

5.00

5.04

100.80

5.00

5.06

101.20

10.00

10.03

100.30

10.00

9.99

99.90

15.00

14.60

97.33

15.00

15.28

101.87

Mean
recovery%

99.48

100.99

± %RSD

1.88

0.99

Each result is the average of three separate determinations.
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Table 1.2.4 Assay results for the determination of the studied drugs in their laboratory prepared
mixtures and dosage forms
AZL

CLT

Intra-day

Inter-day

Intra-day

Inter-day

Conc. of

assay

assay

Conc. of

assay

assay

AZL (g mL-1)

Recovery % ±

Recovery % ±

CLT (g mL-1)

Recovery % ±

Recovery % ±

%RSD a

%RSD a

%RSD a

%RSD a

12.50

100.48 ± 0.96

101.50 ± 1.25

7.50

100.65 ± 0.75

101.59 ± 0.88

25.00

98.87 ± 1.22

100.17 ± 1.25

12.50

98.67 ± 1.08

99.61 ± 1.75

40.00

100.32 ± 0.94

101.55 ± 1.05

20.00

98.12 ± 0.61

99.03 ± 0.96

99.15 ± 1.34

100.08± 1.34

Mean
recovery% ±
%RSD
a

Mean
99.89 ± 0.89

101.07± 0.77

recovery% ±
%RSD

Mean and relative standard deviation of three determinations
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Table 1.2.5 Results of the robustness study
Flow rate
pH
Standard
Parameter

Mobile phase Composition

(mL min-1)

Drug
Method
0.7

0.9

7.9

PBS : Methanol

PBS : Methanol

(62:38)

(58:42)

8.1

Retention time

AZL

7.0

8.1

6.4

7.3

6.8

5.7

8.8

(min)

CLT

5.6

6.4

5.0

5.7

5.5

4.8

6.5

Resolution

CLT/AZL

3.7

3.8

3.7

3.9

3.7

2.7

4.9

Table 1.2.6 Kinetics data of AZL and CLT degradation

CLT in 0.1N NaOH

AZL in 0.1N HCl

Drug

Temperature (°C)

K x 10-4 (min-1)

t1/2 (min)

50

27.64

250.8

60

89.82

77.2

70

158.91

43.6

80

476.72

14.5

Value at 25 °C

1.96

-

70

16.12

429.9

80

55.27

125.4

90

115.15

60.2

100

177.33

39.1

Value at 25 °C

0.22

-

t90 (min)

Ea (k cal mol-1)

537.8

35.34

4834.9

20.39
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Figure 1.2.1 The structural formulae of the studied drugs; (a) azilsartan medoxomil (AZL), and
(b) chlorthalidone (CLT)

Figure 1.2.2 A typical LC chromatogram for Edarbcyclor® tablets: 24 µg mL-1 AZL (6.9 min),
and 15 µg mL-1 of CLT (5.5 min) under the descried chromatographic conditions
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Figure 1.2.3 LC chromatograms of 25 µg mL-1 AZL under different stress degradation
conditions: (a) control, (b) alkaline (0.1N NaOH), (c) acidic (0.1N HCl), (d) oxidative (6% H2O2,
w/v), (e) thermal (wet heat) and (f) photolytic (254 nm) using the described degradation and
chromatographic conditions
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Figure 1.2.4 LC chromatograms of 20 µg mL-1 CLT under different stress degradation
conditions: (a) control, (b) alkaline (0.1N NaOH), (c) acidic (0.1N HCl), (d) oxidative (6% H2O2,
w/v), (e) thermal (wet heat) and (f) photolytic (254 nm) using the described degradation and
chromatographic conditions
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Figure 1.2.5 Percentage of degradation of 25 µg mL-1 of AZL and 20 µg mL-1 of CLT under
different stress degradation conditions
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Figure 1.2.6 Effect of different heating times with 0.1 M HCL and 0.1 M NaOH on the rate of
degradation of (a) AZL (25 µg mL-1) and (b) CLT (20 µg mL-1), respectively
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Figure 1.2.7 Arrhenius plots for AZL (25 µg mL-1) and CLT (20 µg mL-1)

31

Scheme 1.2.1 Proposed structure for the acid induced degradation product of AZL

Scheme 1.2.2 Proposed structures for the alkaline induced degradation products of CLT
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1.3

Synchronized Separation of Seven Medications Representing Most Commonly
Prescribed Antihypertensive Classes using RP-LC: Applied to Analysis in Their
Combined Formulations

Copyright ©2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Journal of Separation Science (2014) 37:748–757
DOI 10.1002/jssc.201301298

A reversed phase high performance liquid chromatography method was developed for
simultaneous determination of the diuretic, hydrochlorothiazide, along with six drugs
representing most commonly prescribed antihypertensive pharmacological classes such as
atenolol, a selective β1 blocker, amlodipine besylate, a calcium channel blocker, moexipril
hydrochloride, an ACE inhibitor, valsartan and candesartan cilexetil which are angiotensin II
receptor blockers and aliskiren hemifumarate, a renin inhibitor, using irbesartan as an internal
standard. The chromatographic separation was achieved using acetonitrile: sodium phosphate
dibasic buffer (0.02 M, pH 5.5) at a flow rate of 1 mL min-1 in gradient elution mode at ambient
temperature on a stationary phase composed of Eclipse XDB-C18 (4.6 x 150 mm, 5 µm) column.
UV detection was carried out at 220 nm. The method was validated according to ICH guidelines.
Linearity, accuracy and precision were satisfactory over the concentration ranges of 2-40 µg mL1

for hydrochlorothiazide and candesartan cilexetil, 20-200, 10-160, 5-40, 20-250 and 5-50 µg

mL-1 for atenolol, valsartan, moexipril hydrochloride, aliskiren hemifumarate and amlodipine
besylate, respectively. The method was successfully applied for the determination of each of the
studied medications in their combined formulations with hydrochlorothiazide. The developed
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method is suitable for the quality control and routine analysis of the cited drugs in their
pharmaceutical dosage forms.
1.3.1 Introduction

Hydrochlorothiazide (HCZ) is an orally potent diuretic which inhibits active chloride
reabsorption and thus increases the excretion of sodium chloride and water 28. It is chemically 6chloro-1, 1-dichloro-3, 4, dihydro-2H-1, 2, 4-benzoliadiazine-7-sulphanomide1, 1-dioxide
(Fig.1.3.1a). Atenolol (ATN), (2-[4-[(2RS)-2-hydroxy-3-[(1-methylethyl) amino] propoxy]
phenyl] acetamide (Fig. 1.3.1b), is a cardioselective β1 blocker used in the management of
hypertension, angina pectoris, cardiac arrhythmias, and myocardial infarction
used in the prophylactic treatment of migraine

30

29

. It may also be

. Valsartan (VAL), (S)-N-valeryl-N-([2'-(1H-

tetrazol-5-yl)biphenyl-4-yl]-methyl)-valine (Fig. 1.3.1c), and candesartan cilexetil (CND), ± (1cyclohexyloxycarbonyloxy) ethyl-2-ethoxyl ([20-(1H-tetrazol-5-yl) biphenyl-4-yl]-methyl)-1Hbenzimidazole-7-carboxylate (Fig. 1.3.1d), are potent, highly selective, and orally active non
peptide antagonist on AT1-receptor subtype
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. Angiotensin receptor blockers (ARBs) are a

major class of antihypertensive therapies due to their powerful lowering effects on blood
pressure and excellent tolerability. Recent clinical trials have shown the added benefits of ARBs
in hypertensive patients (reduction in left ventricular hypertrophy, improvement in diastolic
function, decrease in ventricular arrhythmias, reduction in microalbuminuria, and improvement
in renal function), and cardioprotective effect in patients with heart failure
hydrochloride

(MXP),
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.

Moexipril

(3S)-2-[(2S)-2-{[(1S)-1-(ethoxycarbonyl)-3-phenyl-propyl]amino}-1-

oxopropyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride (Fig.
1.3.1e), is a new potent orally active non-sulfhydryl angiotensin-converting enzyme (ACE)
inhibitor for the treatment of hypertension and congestive heart failure
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. Aliskiren

34

hemifumarate (ALS), (2(S), 4(S), 5(S), 7(S)-N-(2-carbamoyl- 2- methylpropyl) -5-amino-4hydroxy

2,7

diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)

phenyl]

octanamide

hemifumarate) (Fig 1.3.1f) is the first direct renin inhibitor suitable for oral administration. By
achieving more complete renin–angiotensin system inhibition, direct renin inhibitors may afford
greater protection from hypertensive complications

34

. Present evidence indicates that ALS

reduces baseline systolic and diastolic blood pressure and that it is as effective as other first-line
antihypertensive agents. Extra advantages can be reached when it is used in combination therapy
34

. Amlodipine besylate (AML), (3-Ethyl 5-methyl (4RS)-2-[(2-aminoethoxy)methyl]-4-(2-

chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate benzenesulphonate) (Fig. 1.3.1g)
is a long acting dihydropyridine calcium channel blocker that prevents the transmembrane influx
of calcium ions into vascular smooth muscles and cardiac muscles
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. Also, it is a direct

peripheral arterial vasodilator that reduces peripheral vascular resistance and hence lowers blood
pressure

36

. Binary combination therapies of HCZ with each of ATN

37

, MXP

38

and CND

39

induce significant reductions in systolic and diastolic BP from in patients with mild to severe
hypertension. Also, triple combination therapies of ALS, AML and HCZ

40

as well as VAL,

AML and HCZ 41 proved to be effective and well tolerated in treatment of hypertensive high-risk
patients. So, it is necessary to develop a validated analytical method for assay of the cited drugs
in combination with HCZ in their pharmaceutical preparations. Literature review revealed some
published methods for simultaneous determination of one or more of the studied drugs in
combination with HCZ using different analytical techniques such as LC-UV: ATN 42-44, VAL 4552

, MXP 53, 54, ALS

51, 55-58

, AML 48, 50, 52, 55, 56, 58, CND 49, 59-62, LC/MS/MS: ATN 63, VAL 63, 64,

CND 65, UV-spectrometry: ATN 44, 66, 67, VAL 44, 68, 69, MXP 70, ALS 71, AML 66, 68, 69, CND 72, 73
and CE: ATN 74, VAL 75, ALS 76, CND 75. To the best of our knowledge there is no method was
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developed to separate the cited seven drugs. Thus, the aim of this method was to develop and
validate an analytical method using the most preferable RP-LC technique for the simultaneous
determination of the well-known diuretic HCZ, along with commonly prescribed
antihypertensive drugs from different pharmacological classes as mentioned before, namely;
ATN, VAL, MXP, ALS, AML and CND. Irbesartan (Fig. 1.3.1h) was used as an internal
standard in this method. This method is characterized by simplicity, accuracy, preciseness
besides its wide range of applications as it can be used for routine analysis and quality control of
the cited drugs separately or in combinations in more than 17 combined therapies, (Table 1.3.1).
Also, this method is able to separate the seven analytes along with IS in a short run time of about
12 minutes in agreement with system suitability parameters.

1.3.2 Experimental
1.3.2.1

Materials and reagents

All the chemicals used were of analytical reagent grade, and the solvents were of HPLC
grade. HCZ (certified to contain 99.93%) and CND ((certified to contain 99.95%) were supplied
by AstraZeneca - Cairo - Egypt. Pharmaceutical grade VAL USP was supplied by Zydus, batch
No.: VSK1MK A02B (certified to contain 99.40%). ALS (certified to contain 99.51%) was
supplied by Novartis Pharmaceuticals Corporation East, New Jersey, USA, 07936. AML
(certified to contain 99.75%) was kindly supplied by Global Nabi Co., (Giza -Egypt). ATN
(certified to contain >98%), MXP (certified to contain >98%), sodium 1-heptanesulphonate and
acetonitrile were obtained from (Sigma-Aldrich, MO, U.S.A).

Amturnide® 300-10-25 mg

tablets; batch # NDC 0078-0614-15 (Novartis Pharmaceuticals Corporation East, New Jersey,
USA 07936) each labeled to contain 332 mg ALS, 13.9 mg AML and 25 mg HCZ, Exforge
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HCT® 160/10/12.5 mg tablets; batch # NDC 0078-0614-15 (Novartis Pharmaceuticals
Corporation, East Hanover, NJ, 07936 USA) each labeled to contain 160 mg VAL, 13.9 mg
AML and 12.5 mg HCZ, Uniretic® 15/12.5 mg tablets; batch # NDC 68462-0206-01
(SCHWARZ PHARMA, LLC a subsidiary of UCB, Inc. Smyrna, GA 30080, USA) each labeled
to contain 15 mg MXP and 12.5 mg HCZ, and Atacand HCT® 16/12.5 mg tablets; batch # NDC
60505-3758-09 (AstraZeneca - Cairo, - Egypt) each labeled to contain 16 mg CND and 12.5 mg
HCZ were purchased from commercial sources in the local market. Sodium hydroxide, sodium
phosphate dibasic and o-phosphoric acid 85% (Fisher Scientific, NJ, USA) were used.

1.3.2.2

Instrumentation
Separations were performed using Agilent HPLC system 1200 chromatograph (USA)

equipped quaternary pump G1311A and with a Rheodyne injector valve with a 20 μL loop and a
G1315D MWD detector. Mobile phases were degassed using G1322A solvent degasser. Agilent
chemstation for LC systems [Rev.B.03.01-SR1 (317)] PC program was used for the instrument
control, data analysis and acquisition. Separation and quantitation were made on Agilent Eclipse
XDB-C18 (4.6 x 150mm, 5 µm) column. A SympHonly (SB20) pH-meter (Thermo Orion
Beverly, MA, U.S.A) was used for pH measurements. Deionized water was prepared using a
Barnstead NANO pure DIamond Analytical (USA) ultrapure water system. The mobile phase
was filtered through 0.2 µm Anatop 25 Whatman inorganic membrane filter (Maidstone,
England) and degassed using Branson Ultrasonic 5510 degasser (Danbury, CT, U.S.A).
1.3.2.3 Chromatographic conditions
A mixture of sol-A: sodium phosphate dibasic buffer (pH 5±0.1, 0.02M): sol-B:
acetonitrile in gradient elution mode (0-3 min. sol-A: 95-65; 3-6 min. sol-A: 65-65; 6-10 min.
sol-A: 65-20; 10-15 min. sol-A: 20-95) was used. Flow rate was maintained at 1 mL min-1. All
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determinations were performed at ambient temperature. The system was equilibrated and
saturated with the mobile phase for 30 min before the injection of the solutions. Quantification
was achieved with UV detection at 220 nm based on peak area. Twenty L of the solutions were
injected with a 50 l Agilent analytical syringe in triplicates.
1.3.2.4 Standard stock solutions preparation
10 mg of each of MXP and IS as well as 20 mg of each of HCZ, ATN, VAL, ALS, AML
and CND were accurately weighed and transferred in to 10 mL volumetric flasks separately.
Then, they were dissolved in a solvent composed of acetonitrile and water (50:50, v/v) and the
solutions were made up to volume with the same solvent to give final concentrations of 1000 g
mL-1 of MXP and IS as well as 2000 g mL-1 for HCZ, ATN, VAL, ALS, AML and CND.
Further dilutions were made to prepare 200 g mL-1 of HCZ, AML and CND in the same diluent.
1.3.2.5 Procedure
1.3.2.5.1 Construction of calibration graphs
Accurate aliquots of HCZ, ATN, VAL, MXP, ALS, AML and CND from the suitable
stock solutions were transferred into a series of 10 mL Fisherbrand disposable tubes so that the
final concentrations were in the range of 2–40 µg mL-1 for HCZ and CND as well as 20–200, 10160, 5-40, 20-250 and 5-50 µg mL-1 for ATN, VAL, MXP, ALS and AML, respectively. A
constant 80 µL IS stock solution was added and the volume was diluted to 4 mL with a solvent
composed of acetonitrile and phosphate buffer (50:50, v/v). Each solution (n=5) was injected in
triplicates and chromatographed under the described chromatographic conditions. The peak area
ratio (peak area of the studied drug/ peak area of IS) was plotted versus the concentration of each
drug in µg mL-1 to get the calibration graphs and the corresponding regression equations were
derived.
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1.3.2.5.2 Preparation of the laboratory prepared mixtures
Accurate aliquots of ATN, VAL, MXP and ALS stock solutions as well as HCZ, AML
and CND working solutions were transferred into a series of 10 mL Fisherbrand disposable tubes
keeping the pharmaceutical ratios of 1:1.8:23.9 for AML/HCZ/ALS, 1:1.1:12.8 for
HCZ/AML/VAL, 1:1.2 for HCZ/MXP, 1:4 for HCZ/ATN and 1:1.28 for HCZ/CND mixtures,
diluted to 4 mL with a solvent composed of acetonitrile and phosphate buffer (50:50, v/v) after
addition of 80µL IS and mixed well. The percentage recoveries were calculated using the
corresponding regression equations.
1.3.2.5.3 Samples preparation
A composite of ten tablets of Amturnide®, Exforge HCT®, Uniretic®, and Atacand HCT®
tablets were ground to fine and uniform size powder (after removing the coat from the first three
dosage forms by rubbing with a tissue moistened with methanol). Then, they were triturated
using mortar and pestle. After calculating the average tablet weight, amounts of powder
equivalent to (5.00, 64.00, 6.00, 66.40 and 6.40 mg) for HCZ, VAL, MXP, ALS and CND,
respectively, as well as 2.78 and 5.50 mg for AML in Amturnide® and Exforge HCT®,
respectively, of each type of tablets were accurately weighed and transferred separately in to 25
ml volumetric flasks and completed to volume with a solvent composed of acetonitrile and water
(50:50, v/v). The solutions were sonicated for 30 min then filtered through a Whatman filter
paper and then filtered again using 0.2µm Whatman inorganic membrane filter. For analysis,
different aliquots from the prepared sample solution, spiked with 80 µL IS stock solution, were
diluted to 4 mL using a solvent composed of acetonitrile and phosphate buffer (50:50, v/v). The
percentage recoveries were calculated by referring to the corresponding regression equations.
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1.3.3 Results and discussion
The aim of this method was to develop and validate a simple and fast RP-LC method for
the simultaneous determination of HCZ, along with commonly prescribed antihypertensive drugs
from different pharmacological classes as mentioned before. The proposed method permitted the
separation of the seven drugs in a reasonable run time less than 12 min. (Fig. 1.3.2), shows a
typical chromatogram for a synthetic mixture of the seven drugs under the described
chromatographic conditions. It also permitted the quantification of the drugs in their laboratory
prepared mixtures and co-formulated tablets.
1.3.3.1 Optimization of chromatographic conditions
Several trials were carried out to obtain a simple, rapid, accurate, precise and reliable LC
method for the simultaneous determination of the seven antihypertensive drugs with low cost and
available accessories such as column and detector used. Different columns with different length
and internal diameter were tried and a satisfactory separation was obtained on Agilent Eclipse
XDB-C18 (4.6 x 150 mm, 5 µm) column. Isocratic mode of elution was tried and it was found
that it is difficult to be used with such number of analytes as many compounds will overlap
together so gradient elution mode was attempted. Methanol and acetonitrile were examined as
organic modifiers and acetonitrile was found to be more suitable as it allowed appropriate
separation of the seven analytes. The use of buffer was necessary in this method in order to keep
the pH constant as ATN elution is affected by the mobile phase composition, pH and by the
properties of the combined analytes, (Fig. 1.3.3 and 1.3.4).

Different gradient elution modes

were tested in order to achieve proper separation of the cited analytes in a reasonable run time,
(Fig. 1.3.5). The described gradient elution mode (0-3 min. sol-A: 95-65; 3-6 min. sol-A: 65-65;
6-10 min. sol-A: 65-20; 10-15 min. sol-A: 20-95) was selected. Then, the effect of pH on the
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separation of the analytes was studied. It was found that pH lower than 5.5 and higher than 7.5
were not suitable as shown in (Fig. 1.3.3) as it results in poor separation of the analyzed
compounds. pH 5.5 was finally selected as it achieved the best separation between the seven
analytes in a reasonable run time (<12min) and with good resolution between all peaks especially
between HCZ and VAL, (Fig. 1.3.3). Different flow rates were studied and flow rate of 1 mL
min-1 was found to be the optimum. Proper choice of the detection wavelength is crucial for
sensitivity of the method. Quantitation was achieved with UV-detection at 220 nm based on
satisfactory peak area for each of the analyzed drugs especially for HCZ, (Fig. 1.3.6). Many trials
were done to enhance symmetry and sharpness of peaks and hence improve the resolution of the
cited drugs. Increasing the ionic strength of phosphate buffer up to 60mM as well as addition of
0.25mM heptane 1-sulphonate, as ion pairing agent, did not produce significant improvement.
The analytes were first dissolved in a solvent composed of acetonitrile and water (50:50, v/v).
This solvent allowed proper dissolution for the analyzed compounds as ALS and ATN are
sparingly soluble in acetonitrile while VAL and HCZ are sparingly soluble in water. Then
aliquots withdrawn were completed to volumes with a solvent composed of acetonitrile and
phosphate buffer (50:50, v/v) which successfully achieved significant enhancement in peaks
symmetry as well as sharpness of peaks and hence improved the resolution between the studied
analytes, (Fig. 1.3.2). The use of IS is recommended to compensate for injection errors, minor
fluctuations effect of the retention time and to improve the quantitative analysis. Irbesartan was
chosen as the IS in this study IS and itself is another antihypertensive drug belonging to ARBs so
it can be determined selectively using this developed method. The retention times for ATN,
HCZ, VAL, MXP, ALS, AML, CND and IS were 3.37, 4.62, 5.36, 6.49, 7.33, 8.59, 11.25 and
7.79 min, respectively.
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1.3.3.2

Validation of the method
Validation of the proposed CZE method was performed according to ICH guidelines

[http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4
/Q2_R1__Guideline.pdf] with respect to stability, linearity, range, specificity, limit of detection
(LOD), limit of quantitation (LOQ), accuracy, precision and robustness.
1.3.3.2.1 Linearity
A linear relationship was established by plotting the peak area ratio (the studied drug
peak area/IS peak area) against the corresponding drug concentration in the range of 2–40 µg
mL-1 for HCZ and CND as well as 20–200, 10-160, 5-40, 20-250 and 5-50 µg mL-1 for ATN,
VAL, MXP, ALS and AML, respectively. Statistical analysis of the data gave high value for the
correlation coefficient (R2) of the regression equation, small values of the standard deviation of
residuals (Sy/x), of intercept (Sa), and of slope (Sb), as well as small value of the percentage
relative standard deviation and % Error, (Table 1.3.2). These data indicate the linearity of the
calibration graphs.
1.3.3.2.2 Limit of quantitation (LOQ) and limit of detection (LOD)
LOD was considered as the minimum concentration with a signal to noise ratio of at least
three (S/N˜3), while LOQ was taken as a minimum concentration with a signal to noise ratio of
at least ten (S/N˜10). Results are given in (Table 1.3.2).
1.3.3.2.3 Accuracy and precision
The good recovery results obtained from the assay of HCZ, ATN, VAL, MXP, ALS,
AML and CND indicate the accuracy of the proposed method, (Table 1.3.3 and 1.3.4).
Repeatability (intra-day) and intermediate precision (inter-day) were assessed using
three concentrations and three replicates of each concentration. The good relative standard
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deviations indicate good precision of the proposed method, (Table 1.3.3).
1.3.3.2.4 Stability
Stability of the standard stock solutions of HCZ, ATN, VAL, MXP, ALS, AML and
CND, stored at 2-8 ◦C, were evaluated at various time points over 2 months. The concentrations
of freshly prepared solutions and those aged for 2 months were calculated by the method
developed and the difference between them was found to be less than 1% for HCZ, AML, VAL
and less than 2% for MXP, CND, ALS and ATN. Also, the solutions prepared for analysis were
found to be stable for at least 3 days at 2-8 °C and for a day at room temperature. These solutions
can therefore be used during this interval of time without the results being affected.
1.3.3.2.5 Specificity
The specificity of the method was investigated by observing any interference
encountered from common tablet excipients and it was confirmed that the signals measured was
caused only by the analytes. The inactive ingredients in the four analyzed dosage forms were:
colloidal anhydrous silicon dioxide, crospovidone, hypromellose, magnesium stearate,
carboxymethylcellulose calcium, hydroxypropyl cellulose, corn starch, povidone, talc, titanium
dioxide, hypromellose, macrogol 4000, polyethylene glycol 6000, lactose, magnesium oxide,
gelatin, iron oxide red, iron oxide yellow and iron oxide black. Also, ATN and HCZ were
analyzed in their in-house prepared formulation with some of the common excipients such as
anhydrous silica, magnesium stearate, microcrystalline cellulose, lactose, polyethylene glycol
and talc, (Fig. 1.3.8). It was found that the excipients did not interfere with the results of the
proposed method, (Table 1.3.5). As shown in (Fig. 1.3.8) the chromatograms of the combined
formulations did not show any additional peaks when compared to the chromatograms of their
laboratory prepared mixtures which confirms the specificity of the developed method, (Fig.
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1.3.7).
1.3.3.2.6 Robustness
Minor deliberate changes in different experimental parameters such as flow rate (±0.2
mL min-1) and pH (±0.1) did not significantly affect resolution of the analyzed compounds
indicating that the proposed method is robust, (Table 1.3.6).
1.3.3.2.7 System suitability testing
The results of the system suitability tests assure the adequacy of the proposed RP-LC
method for routine analysis of the seven investigated analytes, (Table 1.3.7). The values of the
capacity factor (k) indicate that all peaks are well resolved with respect to the void volume. The
values of % RSD of six consecutive injections performed for each analyte show good injection
repeatability. The tailing factors (T) reflect good peak symmetry. The values for resolution (Rs)
indicate good separation of the investigated analytes. The theoretical plate numbers (N)
demonstrate good column efficiency.
1.3.3.3 Application of the proposed method for the analysis of HCZ in combination with one
or more of either ATN, VAL, MXP, ALS, AML and CND in their laboratory prepared
mixtures and combined formulations
The proposed RP-LC method was applied to the simultaneous determination of HCZ with
one or more of the other antihypertensive drugs in their laboratory prepared mixtures in the
medicinally

recommended

ratios

of

1:1.8:23.9

for

AML/HCZ/ALS,

1:1.1:12.8

for

HCZ/AML/VAL, 1:1.2 for HCZ/MXP, 1:4 for HCZ/ATN and 1:1.28 for HCZ/CND mixtures,
(Fig. 1.3.7). Furthermore, the proposed method was successfully applied for their determination
in co-formulated tablets, (Fig. 1.3.8).
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1.3.3.4 Comparison methods and statistical analysis
The results shown in Table 1.3.5 for the analysis of the cited medications in their
combined formulations are in good agreement with those obtained using the reported methods
for each combination. The reported method for simultaneous determination of HCZ, AML and
ALS ternary mixture was based on an ion pairing RP-LC-UV technique using acetonitrile: 25
mM octane sulphonic acid sodium salt monohydrate in water (60: 40, v/v) as the mobile phase 58,
whereas the proposed method is more conventional for analysis of that mixture. Regarding the
reported method for simultaneous determination of HCZ, AML and VAL, it was based also on a
RP-LC technique using acetonitrile, methanol and 50 mM phosphate buffer adjusted to pH 3
with orthophosphoric acid as the mobile phase in the ratio of (20: 50: 30, v/v) and the eluents
were monitored at 239 nm
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. On the other hand, Erturk et al. reported a RP-LC method for

simultaneous determination of HCZ and MXP in tablets which was performed using a mobile
phase consisting of acetonitrile and phosphate buffer (pH 4) (50: 50, v/v)
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. Also for HCZ and

ATN simultaneous determination in tablets, Zaveri et al. reported a RP-LC method for analysis
of that mixture using a mobile phase consisting of water: phosphate buffer: methanol (50:35:15,
v/v)
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. Finally, Qutab et al. reported a RP-LC method for simultaneous determination of HCZ

and CND in their combined formulation and they used phosphate buffer (pH 6), methanol and
triethylamine (25:75:0.2, v/v) as the mobile phase

62

. The newly developed method is reliable,

simple, rapid and selective in comparison to all of the reported methods for determination of the
selected drug combinations in their pharmaceutical dosage forms. Statistical analysis of the
results obtained using Student’s t-test and variance ratio F-test revealed no significant difference
between the performance of the methods regarding the accuracy and precision, respectively.
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Table 1.3.1 Examples for some prescribed antihypertensive dosage forms available in the market
Dosage form

Active ingredients

Amturnide® tablets

ALS, AML and HCZ

Exforge HCT® tablets

VAL, AML and HCZ

Ziblok-H® tablets

ATN and HCZ

Diovan HCT® tablets

VAL and HCT

Uniretic® tablets

MXP and HCZ

TeKturna® tablets

ALS and HCZ

Atacand HCT® tablets

CND and HCZ

Amlokind-AT® tablets

ATN and AML

Exforge® tablets

VAL and AML

Tekamlo® tablets

ALS and AML

Tenormin® tablets

ATN

Aquazide® tablets

HCZ

Diovan® tablets

VAL

Univasc® tablets

MXP

Tekturna® tablets

ALS

Norvasc® tablets

AML

Atacand® tablets

CND

46

Table 1.3.2 Characteristics and results of the proposed RP-LC method
Item

HCZ

ATN

Linearity range (µg mL-1)

2-40

LOD (µg mL-1)

0.34

4.86

LOQ (µg mL-1)

1.02

14.72

VAL

MXP

ALS

AML

CND

5-40

20-250

5-50

2-40

3.22

0.41

4.06

1.35

0.23

9.75

1.26

12.31

4.09

0.71

20-120 10-160

Intercept (a)

0.0552 -0.0139 0.6631 0.0094 0.0628 -0.0038 0.0077

Slope (b)

0.0614

0.0043

0.0395 0.0315 0.0101

0.0201

0.0509

Correlation coefficient (R2) 0.9999

0.9996

0.9998 0.9999 0.9999

0.9997

1.000

S.D. of residuals (Sy/x)

0.0093

0.0067

0.0545 0.0046 0.0161

0.0105

0.0053

S.D. of intercept (Sa)

0.0063

0.0063

0.0385 0.0040 0.0124

0.0082

0.0036

S.D. of slope (Sb)

0.0003

0.0001

0.0004 0.0002 0.0001

0.0003

0.0002

% Error

1.33

1.57

1.01

0.73

0.69

1.19

2.18

%RSD

2.99

3.54

2.24

1.63

1.55

2.64

0.97

Accuracy

99.39

99.28

100.41

99.70

99.64

100.92

99.53
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Table 1.3.3 Accuracy and precision results for the proposed RP-LC method
Intra-day assay

Inter-day assay

Recovery % ±

Recovery % ±

%RSDa

%RSDa

15.00

99.37 ± 1.79

101.63 ± 1.96

20.00

98.51 ± 1.48

25.00
Mean

Conc. of
HCZ (g mL-1)

Conc. of
ATN (g mL-1)

Inter-day assay

Recovery % ±

Recovery % ±

%RSDa

%RSDa

143.00

100.62 ± 0.66

100.41 ± 0.25

100.15 ± 1.68

191.00

101.58 ± 0.95

100.80 ± 0.77

100.60 ± 0.92

100.77 ± 0.58

215.00

100.26 ± 1.23

99.56 ± 0.66

99.49 ± 1.06

100.85 ± 0.74

Mean

100.82 ± 0.68

100.26 ± 0.63

Intra-day assay

Inter-day assay

Intra-day assay

Inter-day assay

Recovery % ±

Recovery % ±

Recovery % ±

Recovery % ±

%RSD

a

%RSD

a

ALS (g mL-1)

Conc. of
AML (g mL-1)

%RSD

a

%RSDa

60.00

99.32 ± 1.19

99.44 ± 0.81

8.25

101.13 ± 1.79

100.53 ± 2.16

80.00

99.00 ± 1.62

98.71 ± 0.45

11.00

100.72 ± 0.45

100.72 ± 1.80

100.00

98.50 ± 1.92

99.90 ± 1.40

13.75

99.88 ± 0.42

100.36 ± 2.05

Mean

98.94 ± 0.42

99.35 ± 0.60

Mean

100.58 ± 0.63

100.54 ± 0.18

Intra-day assay

Inter-day assay

Intra-day assay

Inter-day assay

Recovery % ±

Recovery % ±

Recovery % ±

Recovery % ±

%RSDa

%RSDa

%RSDa

%RSDa

96.00

99.33 ± 1.29

99.33 ± 2.72

6.40

100.68 ± 1.23

99.45 ± 1.17

128.00

100.72 ± 1.21

100.42 ± 1.58

19.20

100.89 ± 0.86

100.31 ± 0.67

160.00

101.01 ± 1.12

101.39 ± 0.59

32.00

101.22 ± 0.14

100.75 ± 0.43

Mean

100.35 ± 0.89

100.38 ± 1.03

Mean

100.93 ± 0.27

100.17 ± 0.66

Intra-day assay

Inter-day assay

Recovery % ±

Recovery % ±

Conc. of
VAL (g mL-1)

Conc. of
MXP (g mL-1)

a

Intra-day assay

Conc. of

%RSD

a

Conc. of
CND (g mL-1)

%RSDa

18.00

98.82 ± 1.41

97.18 ± 1.53

24.00

97.45 ± 1.56

99.40 ± 1.96

30.00

97.56 ± 1.51

98.86 ± 1.10

Mean

97.94 ± 0.78

98.48 ± 1.18

Mean and relative standard deviation of three determinations
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Table 1.3.4 Assay and statistical results for the determination of the studied drugs in their
laboratory prepared mixtures by the proposed method and comparison methods
(HCZ:AML:ALS)
(1.8:1:23.9)
Mean recovery%
± S.D.
Student t test
(2.78)*
F value (19)*

(HCZ:AML:VAL)
(1:1.1:12.8)
Mean recovery%
± S.D.
Student t test
(2.78)*
F value (19)*
(HCZ:MXP)
(1:1.2)
Mean recovery%
± S.D.
Student t test
(2.78)*
F value (19)*
(HCZ:ATN)
(1:4)
Mean recovery%
± S.D.
Student t test
(2.78)*
F value (19)*
(HCZ:CND)
(1:1.28)
Mean recovery%
± S.D.
Student t test
(2.78)*
F value (19)*

HCZ
The developed
Comparison
RP-LC method
method [31]
100.45±2.15

100.23±1.49

AML
The developed
Comparison
RP-LC method
method [31]
99.54±2.12

ALS
The developed
Comparison
RP-LC method
method [31]

98.41± 0.88

101.05±1.45

100.09±1.99

0.14

1.36

0.68

1.01

5.82

1.88

HCZ
The developed
Comparison
RP-LC method
method [25]

AML
The developed
Comparison
RP-LC method
method [25]

VAL
The developed
Comparison
RP-LC method
method [25]

99.94±1.67

99.52±1.91

99.66±0.53

100.66± 0.74

98.47±1.21

99.74± 1.53

0.38

1.20

0.34

3.38

6.45

1.26

HCZ
The developed
Comparison
RP-LC method
method [26]

MXP
The developed
Comparison
RP-LC method
method [26]

98.47±0.84

100.43±0.66

100.21±2.00

100.13 ± 1.72

3.18

0.05

1.64

1.36

HCZ
The developed
Comparison
RP-LC method
method [15]

ATN
The developed
Comparison
RP-LC method
method [15]

99.89±1.48

98.94±2.26

98.76±1.48

100.27± 1.14

0.61

1.41

2.35

1.69

HCZ
The developed
Comparison
RP-LC method
method [35]

CND
The developed
Comparison
RP-LC method
method [35]

100.45±1.19

99.49±1.31

100.31±0.67

99.80± 0.40

0.94

1.13

1.21

2.70

Each result is the average of three separate determinations.
The values between parentheses are the tabulated t and F values at P = 0.05.
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Table 1.3.5 Assay results for the determination of the studied drugs in their co-formulations
Amturnide® 300-10-25mg
tablets
(HCZ:AML:ALS)
(1.8:1:23.9)
Mean recovery% ± S.D.

HCZ

AML

ALS

Proposed

Comparison

Proposed

Comparison

Proposed

Comparison

method

method [31]

method

method [31]

method

method [31]

97.70 ± 1.42

99.43 ± 1.58

99.50 ± 1.99

100.89±1.34

99.78 ± 1.83

101.37 ±
1.21

Student t test (2.78)*

1.42

1.39

0.85

F value (19)*

1.24

2.71

1.86

HCT®

HCZ

AML

VAL

Exforge

160/10/12.5mg tablets
(HCZ:AML:VAL)
(1:1.1:12.8)
Mean recovery% ± S.D.

Proposed

Comparison

Proposed

Comparison

Proposed

Comparison

method

method [25]

method

method [25]

method

method [25]

98.59 ± 0.7

99.75 ± 2.00

99.82 ± 1.38

98.80±1.08

99.78 ± 1.01

101.80 ±
1.64

Student t test (2.78)*

1.85

1.19

1.32

F value (19)*

1.06

1.79

1.44

HCZ

MXP

Uniretic®

100/25mg

tablets
(HCZ:MXP)
(1:1.2)
Mean recovery% ± S.D.

Proposed

Comparison

Proposed

Comparison

method

method [26]

method

method [26]

97.59 ± 1.15

101.60 ± 1.07

98.01 ± 2.25

99.20 ± 1.06

Student t test (2.78)*

1.55

0.82

F value (19)*

1.09

4.09

In house formulation

HCZ

ATN

(HCZ:ATN)

Proposed

Comparison

Proposed

Comparison

(1:4)

method

method [15]

method

method [15]

Mean recovery% ± S.D.

98.82 ± 1.11

100.51 ± 1.11

98.42 ± 0.67

98.88 ± 1.56

Student t test (2.78)*

1.86

0.47

F value (19)*

2.79

5.51

HCZ

CND

Atacand

HCT®

16/12.5mg

tablets (HCZ:CND)

Proposed

Comparison

Proposed

Comparison

(1:1.28)

method

method [35]

method

method [35]

Mean recovery% ± S.D.

98.17±1.74

101.39 ± 0.76

100.54±1.99

100.63 ± 1.12

Student t test (2.78)*

1.79

021

F value (19)*

1.75

6.82

Each result is the average of three determinations and values between parentheses are the
tabulated t and F values at P = 0.05.
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Table 1.3.6 Results of the robustness Study for the proposed RP-LC method

Resolution

Retention time (min)

Parameter

Drug

Standard
Method

ATN

Flow rate (mL min-1)

pH

0.8

1.2

5.4

5.6

3.4

4.1

2.9

3.3

3.4

HCZ

4.6

5.5

4.0

4.6

4.6

VAL

5.4

6

4.8

5.6

5.3

MXP

6.5

7.3

5.7

6.5

6.5

ALS

7.3

8.0

6.2

7.2

7.4

IS

7.9

8.9

6.8

8.0

7.8

AML

8.6

9.3

7.2

8.6

8.7

CND

11.2

12.0

10.7

11.3

11.1

ATN/HCZ

10.2

11.3

9.1

10.9

10.0

HCZ/VAL

5.4

4.3

5.9

5.5

5.2

VAL/MXP

7.0

7.5

6.6

6.5

6.7

MXP/ALS

4.5

5.4

4.9

4.2

4.6

ALS/IS

2.5

2.9

2.3

3.1

2.0

IS/AML

4.9

5.2

3.9

4.6

5.4

AML/CND

22.0

23.5

24

22.3

20.9
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Table 1.3.7 System suitability data for the proposed RP-LC method
Item

ATN

HCZ

VAL

MXP

ALS

IS

AML

CND

N

18133

16751

27039

18151

24906

28634

58809

194583

K`

0.94

1.56

1.98

2.60

3.06

3.33

3.77

4.45

Tailing factor (T)

1.56

0.86

1.08

1.05

1.45

1.22

1.44

1.19

%RSD of 6 injections

2.27

2.95

0.25

1.92

1.29

2.32

2.25

2.56

R
α

10.24
1.37

5.38

6.99

4.45

2.47

4.89

21.80

1.16

1.21

1.13

1.06

1.10

1.31

(N: number of theoretical plates; K`: capacity factor; R: resolution factor; T: tailing factor;
selectivity factor)
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Figure 1.3.1 The structural formulae of the studied medications; (a) hydrochlorothiazide (HCZ),
(b) atenolol (ATN), (c) valsartan (VAL), (d) candesartan cilexetil (CND), (e) Moexipril HCl
(MXP), (f) aliskiren hemifumarate (ALS), (g) amlodipine besylate (AML), and (h) Irbesartan
(IS)
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Figure 1.3.2 Typical chromatogram of 80 µg mL-1 ATN (3.37 min), 40 µg mL-1 for each of
HCZ (4.62 min), VAL (5.36 min), MXP (6.49 min), ALS (7.30 min), AML (8.59 min), CND
(11.25 min) and IS 20 µg mL-1 (7.79 min) under the described chromatographic conditions
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Figure 1.3.3 LC chromatograms of 10.0, 40.0, 128.0, 60.0, 239.0, 11.0, 12.8 and 20.0 µg mL-1 of
HCZ, ATN, VAL, MXP, ALS, AML, CND and IS, respectively, dissolved in a solvent
composed of acetonitrile and water (50:50, v/v) at different pH values of the phosphate buffer
using the described chromatographic conditions
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Figure 1.3.4 LC chromatograms of 200µg mL-1 ATN dissolved in a solvent composed of
acetonitrile and water (50:50 v/v) at different pH values of the phosphate buffer using the
described chromatographic conditions
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Figure 1.3.5 LC chromatograms using mobile phase consisting of sol-A: phosphate buffer (pH
5.5) and sol-B: acetonitrile at flow rate of 0.8 ml min-1 and at λ=220 nm in different gradient
modes where (a)- 0-3 min. sol-A: 95-65; 3-6 min. sol-A: 65-65; 6-10 min. sol-A: 65-20; 10-15
min. sol-A: 20-95. (b)- 0-2 min. sol-A: 95-65; 2-5.5 min. sol-A: 65-65; 5.5-8.5 min. sol-A: 6520; 8.5-15 min. sol-A: 20-95. (c)- 0-3 min. sol-A: 95-65; 3-10 min. sol-A: 65-20; 10-15 min. solA: 20-95. (d)- 0-12 min. sol-A: 90-60; 12-16 min. sol-A: 20-90. (e)- 0-12 min. sol-A: 90-50;
12-14 min sol-A: 50-20; 12-18 min. sol-A: 20-90. (f)- 0-3 min. sol-A: 90-65; 3-6 min. sol-A: 6565; 6-12 min. sol-A: 65-30; 12-16 min. sol-A: 30-90
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Figure 1.3.6 LC chromatograms of 10.0, 40.0, 128.0, 60.0, 239.0, 11.0, 12.8 and 20.0 µg mL-1 of
HCZ, ATN, VAL, MXP, ALS, AML, CND and IS, respectively, dissolved in a solvent
composed of acetonitrile and water (50:50 v/v) using mobile phase consisting of sol-A:
phosphate buffer (pH 5.5) and sol-B: acetonitrile, flow rate of 0.7 ml min-1 at variable detection
wavelengths where the gradient elution mode was as follow: 0-2 min. sol-A: 95-65; 2-5.5 min.
sol-A:65-65; 5.5-10.5 min. sol-A: 65-20; 10.5-15 min. sol-A: 20-95
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Figure 1.3.7 LC chromatograms of different laboratory prepared mixtures using the described
chromatographic conditions where; (a)- 16.2, 215, 9, 20 µg mL-1 of HCZ, ALS, AML and IS,
respectively, (b)- 7.5, 96, 8.25, 20 µg mL-1 of HCZ, VAL, AML and IS, respectively, (c)- 20, 24,
20 µg mL-1 of HCZ, MXP and IS, (d)- 15, 60, 20 µg mL-1 of HCZ, ATN and IS, respectively,
and (e)- 15, 19.2, 20 µg mL-1 of HCZ, CND and IS, respectively
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Figure 1.3.8 LC chromatograms of the analyzed combined formulations using the described
chromatographic conditions where; (a)- Amturnide® tablets: 16.2, 215, 9, 20 µg mL-1 of HCZ,
ALS, AML and IS, respectively, (b)- Exforge HCT® tablets: 7.5, 96, 8.25, 20 µg mL-1 of HCZ,
VAL, AML and IS, respectively, (c)- Uniretic® tablets: 20, 24, 20 µg mL-1 of HCZ, MXP and IS,
(d)- In house formulation: 15, 60, 20 µg mL-1 of HCZ, ATN and IS, respectively, and (e)Atacand HCT® tablets: 15, 19.2, 20 µg mL-1 of HCZ, CND and IS, respectively
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1.4

Validated Ion-Pair LC Method for Simultaneous Determination of Aliskiren
hemifumarate, Amlodipine besylate and Hydrochlorothiazide in Pharmaceuticals

Copyright © Springer-Verlag Berlin Heidelberg 2013
Chromatographia (2014) 77: 257
DOI 10.1007/s10337-013-2592-6

A rapid and precise LC method was developed for the simultaneous determination of
aliskiren hemifumarate (ALS), amlodipine besylate (AML) and hydrochlorothiazide (HCZ)
using acetonitrile: 25 mM octane sulphonic acid sodium salt monohydrate in water (60: 40 v/v)
as the mobile phase. The flow rate was maintained at 1.2 mL min-1 on a stationary phase
composed of Supelco, discovery HS (C18) column (25cm x 4.6mm, 5m). Isocratic elution was
applied throughout the analysis. Detection was carried out at  max (232 nm) at ambient
temperature. The method was validated according to ICH guidelines. Linearity, accuracy and
precision were satisfactory over the concentration ranges of 32 – 320, 2 – 44 and 4 – 64 g mL-1
for ALS, AML and HCZ, respectively. LOD and LOQ were estimated and found to be 0.855 and
2.951 g mL-1, respectively, for ALS, 0.061 and 0.202 g mL-1, respectively, for AML as well as
0.052 and 0.174 g mL-1, respectively, for HCZ. The method was successfully applied for the
determination of the three drugs in their co-formulated tablets. The results were compared
statistically with reference methods and no significant difference was found. The developed
method is specific and accurate for the quality control and routine analysis of the cited drugs in
pharmaceutical preparations.
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1.4.1

Introduction

Aliskiren hemifumarate, (2(S), 4(S), 5(S), 7(S)-N-(2-carbamoyl- 2- methylpropyl) -5amino-4-hydroxy2,7

diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)

phenyl]

octanamide

hemifumarate) (Fig 1.4.1a), is the first direct renin inhibitor suitable for oral administration. By
achieving more complete renin–angiotensin system inhibition, direct renin inhibitors may afford
greater protection from hypertensive complications

77

. Present evidence indicates that ALS

reduces baseline systolic and diastolic blood pressure and that it is as effective as other first-line
antihypertensive agents. Extra advantages can be reached when it is used in combination therapy
77

. Amlodipine besylate (AML), (3-Ethyl 5-methyl (4RS)-2-[(2-aminoethoxy)methyl]-4-(2-

chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate benzenesulphonate) (Fig 1.4.1b)
is a dihydropyridine long-acting calcium channel blocker that inhibits the transmembrane influx
of calcium ions into vascular smooth muscle and cardiac muscle 78. AML is a peripheral arterial
vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral
vascular resistance and reduction in blood pressure

79

. Hydrochlorothiazide is a potent orally

diuretic and antihypertensive agent which inhibits active chloride reabsorption and thus increases
the excretion of sodium chloride and water

80

. It is chemically 6-chloro-1, 1-dichloro-3, 4,

dihydro-2H-1, 2, 4-benzoliadiazine-7-sulphanomide1, 1-dioxide (Fig 1.4.1c). Triple combination
therapy of ALS, AML and HCZ proved to be effective and well tolerated in treating hypertensive
high-risk patients 81. Literature survey revealed LC

82-85

, CE 86, UV-spectrophotometric 87, 88 and

spectroflourimetric 89, 90 methods reported for the estimation of aliskiren hemifumarate alone or
in combination with other anti-hypertensive agents. Methods such as LC 91-93, LC/MS/MS 78, CE
94

, UV-spectrophotometric

95-97

and spectroflourimetric

98, 99

are reported for estimation of

amlodipine alone or in combination with other agents. Methods such as LC 100-105, LC-MS 106-109,
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UPLC 110 and UV- spectrophotometric methods 111 are reported for the estimation of HCZ alone
or in combination with other anti-hypertensive agents. The aim of the present study was to
develop a reliable and validated chromatographic procedure for analysis of ALS, AML and HCZ
in bulk drug samples and in combined dosage formulation. The developed RP-LC method has
the advantages of being simpler, more sensitive and faster for quality control and routine analysis
of ALS, HCZ and AML triple mixture in comparison with the reported methods 112, 113.

1.4.2

Experimental

1.4.2.1 Materials and reagents

Working standards of ALS (certified to contain 99.51%) was supplied by Novartis
Pharmaceuticals Corporation East, New Jersey, USA 07936, AML (certified to contain 99.75%)
was kindly supplied by Global Nabi Co., (Giza -Egypt). HCZ (certified to contain 99.93%) was
supplied by AstraZeneca - Cairo, - Egypt (Under license of AstraZeneca, Sweden). Amturnide®
300-10-25 mg tablets; batch # NDC 0078-0614-15 (Novartis Pharmaceuticals Corporation East,
New Jersey, USA 07936) were purchased from commercial sources in the USA market. Each
labeled to contain 331 mg ALS (equivalent to 300 mg aliskiren as a free base), 13.9 mg AML
(equivalent to 10 mg amlodipine as a free base) and 25 mg HCZ. Acetonitrile (HPLC grade) and
octane sulphonic acid sodium salt monohydrate were obtained from Sigma-Aldrich, MO, USA.

1.4.2.2

Instrument and conditions
The LC system consisted of a (Younglin instrument Acme 9000, Korea) equipped with

vacuum degasser, mixer, gradient pump and UV/Vis detector. Separation and quantitation were
made on Supelco, Discovery HS (C18) column (25cm x 4.6mm, 5m). A Soniclean120T
ultrasonic processor was also used.
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The mobile phase was filtered through 0.45 m membrane filter and degassed using
ultrasonic bath. The flow rate was 1.2 mL min-1. The solutions were injected (30 l) with a 100
l Agilent analytical syringe. All determinations were performed at ambient temperature. The
system was equilibrated and saturated with the mobile phase for 30 min before the injection of
the solutions. Quantification was achieved with UV detection at 232 nm based on peak area.
Data acquisition was performed on Autochrome 3000 LC younglin software.
1.4.2.3 Preparation of mobile phase
A mixture of acetonitrile: 25 mM octane sulphonic acid sodium salt monohydrate in
water (60: 40 v/v) was prepared.
1.4.2.4 Standard stock solutions preparation
40 mg of ALS, 10 mg of AML and HCZ were accurately weighed and transferred in to
50 mL volumetric flasks separately. Then, they were dissolved in a solvent composed of
acetonitrile and water (60:40 v/v) and the solutions were made up to volume with the same
solvent to give final concentrations of 800 g mL-1 of ALS and 200 g mL-1 of both AML and
HCZ.
1.4.2.5 Procedure
1.4.2.5.1 Construction of calibration graphs
Different solutions containing 32 – 320, 2-44 and 4 – 64 µg mL-1 of ALS, AML and
HCZ, respectively, were prepared in 10 mL volumetric flasks and completed to volume with the
mobile phase. A volume of 30µL of each solution was injected in triplicates into the
chromatogram. The chromatographic conditions were adjusted. The resulting chromatograms,
retention times (tr) of the peaks and the areas under the peaks (AUPs) were recorded. The

64

recorded AUPs of ALS, AML and HCZ were plotted versus the concentrations of ALS, AML
and HCZ (µg mL-1) to obtain the calibration curves.

1.4.2.5.2 Application of the proposed methods to dosage form
Twenty tablets of Amturnide 300-10-25 mg tablets were weighed and finely powdered.
A portion of the powder equivalent to ALS (166.5 mg), AML (6.95 mg) and HCZ (12.5 mg) was
introduced into a 100 mL beaker and sonicated with 50 mL acetonitrile for 15 min. The extract
was filtered. Further dilutions of the filtrate were carried out with acetonitrile. The general
procedure for LC method was followed and the concentrations of the examined drugs were
calculated using the corresponding regression equation.
1.4.2.6 Validation

The suggested analytical method was validated according to ICH guidelines

114

with

respect to certain parameters such as linearity, accuracy, LOD and LOQ, precision, specificity,
stability and robustness.

1.4.2.6.1 Linearity

The linearity of the method was established by spiking a series of standard mixtures in
the range 32 – 320, 2-44 and 4 – 64 µg mL-1 of ALS, AML and HCZ, respectively. Above
solutions were injected onto the LC system. Calibration curves were constructed for standard
solutions by plotting their response ratios (ratios of the peak area of the analytes) against their
respective concentrations. Linear regression was applied and standard deviation of slope (Sb),
standard deviation of intercept (Sa), correlation coefficient (r) and standard error (Es) were
determined.
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1.4.2.6.2 Limit of detection and limit of quantification

Detection and quantification limits were determined through dilution method using S/N
approach by injecting a 30 μl sample. LOD was considered as the minimum concentration with a
signal to noise ratio of at least three (S/N˜3), while LOQ was taken as a minimum concentration
with a signal to noise ratio of at least ten (S/N˜10) 114.

1.4.2.6.3 Accuracy

Accuracy was determined in terms of percent recovery. A set of standard mixtures at six
different concentration levels 48, 96, 144, 176, 224, 288 µg mL-1 of ALS, 4, 12, 20, 28, 36, 40
µg mL-1 of AML and 12, 20, 32, 48, 56, 60 µg mL-1 of HCZ were prepared and injected onto the
LC system in triplicate. The general procedure for LC method was followed and the percentage
recoveries of ALS, AML and HCZ were calculated.

1.4.2.6.4 Precision

Method precision was determined both in terms of repeatability (intra-day
reproducibility) and intermediate precision (inter-days reproducibility) using three different
concentration levels 72, 176, 224 µg mL-1 of ALS, 12, 28, 36 µg mL-1 of AML and 12, 32, 48 µg
mL-1 of HCZ.

1.4.2.6.5 Specificity

Specificity was examined by analyzing ALS, AML and HCZ in laboratory prepared
mixtures and pharmaceutical dosage form to detect any interference caused by the combined
drugs present in dosage formulations or the co-formulated excipients.
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1.4.2.6.6 Robustness

The robustness of the developed method was investigated by evaluating the influence of
small deliberate variations in procedure variables like flow rate (±0.1 mL min-1) and mobile
phase components` ratio (±2%). Retention time, peak area and resolution between fumaric
acid/HCZ, HCZ/ALS and ALS/AML were recorded.

1.4.2.6.7 Stability

The stability studies of ALS, AML and HCZ samples were carried out over a period of
72h at 2–8 0C (refrigerator) and standard stock solutions for one month at 2–8 0C.

1.4.3 Results and discussion

The goal of the present investigation was to develop a well validated, sensitive, simple
and quick analytical method for the simultaneous determination and quantification of ALS, AML
and HCZ in pharmaceutical preparations. Concerning ALS, AML and HCZ simultaneous
analysis, only two LC methods to the best of our knowledge have been reported for the
simultaneous determination of the triple mixture. Rao et al

112

described a LC method for

determination of the drugs in their dosage form using C18 column and a mobile phase consisting
of acetonitrile: methanol: 50mM phosphate buffer (pH 3) in the ratio of 20:50:30% v/v. The
linearity range of ALS practically will not allow proper simultaneous determination of the three
drugs in their co-formulated tablets. Also, Selvakumar et al

113

reported a LC method using 20

mM potassium dihydrogen phosphate buffer (pH 6.5): methanol: acetonitrile (55:10:35 v/v) as
the mobile phase for determination of the triple mixture in their pure form only. The samples
were separated with poor sensitivity on C8 column within a long run time of 18 min. The newly

67

developed method has distinct advantages regarding simplicity, reliability and suitability to be
applied for the simultaneous analysis of the cited drugs either in pure form or in their coformulated tablets.

1.4.3.1 Method development
Various reversed phase chromatographic columns and a series of aqueous mobile phases
containing different organic modifiers were tested to adjust the optimum conditions. Mobile
phase systems such as phosphate and acetate buffers were tried at different pH values along with
different organic modifiers such as methanol and acetonitrile in different ratios and flow rates.
None of them achieved proper resolution and symmetric peaks. Since the analyzed compounds
are ionic, the use of conventional RP-HPLC is somewhat restricted. Ionic suppression approach
based on pH adjustment was examined to separate these charged analytes but it couldn`t achieve
proper resolution with sharp and symmetric peaks. Ion Pair Chromatography is a more reliable
approach that allows the separation of complex mixtures of ionic compounds. The separation
pattern is determined by the mobile phase composition where an organic modifier is combined
with a specific ion-pairing reagent in a certain ratio. The ion-pairing reagents are large ionic
molecules having a charge opposite to the analytes of interest, as well as a hydrophobic region to
interact with the stationary phase. The counter-ion combines with the ions of the eluent,
becoming ion pairs in the stationary phase. This results in enhanced symmetry and sharpness of
the peaks and hence increasing the reliability and reproducibility of the method. Using of ion
pairing agents to achieve such goals and reduce tailing was examined. Triethylamine made the
separation worse as it is basic ion pairing agent and the analyzed compounds need oppositely
charged anionic alkyl sulphonate ion pairing agent. Also, the concentrations of both the ion pair
agent and the organic modifier in the mobile phase are crucial for proper elution. It is worth
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noting that the separation was improved with the relative increase of the percentage of the
aqueous to organic phases. A satisfactory separation was obtained on a Supelco, Dicovery HS
(C18) column (25cm x 4.6mm, 5m) with a mobile phase consisting of acetonitrile: 25 mM
octane sulphonic acid sodium salt monohydrate in water (60: 40 v/v). Good separation of the
cited compounds with good peaks’ shape and minimum retention times (< 5 min) were obtained
with that mobile phase at a flow rate 1.2 mL min-1. Proper choice of the detection wavelength is
crucial for sensitivity of the method. Quantitation was achieved with UV detection at 232 nm
based on good peak area for each of the analyzed drugs. The retention times were 2.25, 3.13 and
3.92 min for HCZ, ALS and AML, respectively, (Fig 1.4.2). In the course of optimizing the
conditions of the proposed method, different parameters affecting the chromatographic
separation were studied. The system suitability tests were used to verify that the conditions of the
chromatographic system were adequate for the resolution and hence for the analysis
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(Table

1.4.1).
1.4.3.2 LC method validation
1.4.3.2.1 Linearity and range

Linear relationships between the recorded AUPs of ALS, AML and HCZ versus their
concentrations were obtained. The regression equation y = bC ± a for each drug was also
computed. In this study, 6 concentrations for each compound were used. The linearity of the
calibration curves was validated by the high value of correlation coefficients. The analytical data
of the calibration curves including standard deviations for the slope and intercept (Sb, Sa) are
summarized in (Table 1.4.2). The calibration ranges were established within protocol range
necessary, according to the intact drugs’ concentrations in pharmaceutical product to give
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accurate and precise results. The calibration ranges of the proposed procedure are given in (Table
1.4.2).

1.4.3.2.2 Limit of detection and limit of quantification

Lower limit of detection (LOD) and lower limit of quantification (LOQ) for each drug
were calculated. Results are given in (Table 1.4.2).

1.4.3.2.3 Accuracy

Accuracy of the results was calculated by % recovery of 6 different concentrations of the
three drugs analyzed by the proposed LC method. The results obtained including the mean of the
recovery and standard deviation were displayed in (Table 1.4.2).

1.4.3.2.4 Precision

Repeatability (intra-day, n=3) and intermediate precision (inter-day, n=3) were checked
using three different concentrations at low, medium and high level of the standard curve. The
relative standard deviation and SE were calculated to check the precision of the method, (Table
1.4.3).

1.4.3.2.5 Specificity

Specificity was checked by analyzing ALS, AML and HCZ in laboratory prepared
mixtures. Good resolution and absence of interference between drugs being analyzed and
fumarate were shown in (Fig. 1.4.2, 1.4.3). Moreover, there was no interference observed from
other materials in the pharmaceutical formulations (Fig. 1.4.2) confirming the specificity of the
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method. Good recoveries were obtained in the sample indicating specificity of the proposed
method, (Table 1.4.2).

1.4.3.2.6 Robustness

Minor deliberate changes in different experimental parameters such as flow rate (±0.1
mL min-1) and mobile phase components` ratio (±2%) did not significantly affect resolution,
peak area and retention time of the three drugs indicating that the proposed method is robust,
(Table 1.4.4).

1.4.3.2.7 Stability

Results from the stability studies of working and stock solutions indicated that working
solutions were stable for 72 h when stored at refrigerator (2–8 0C) while the stock solutions were
stable for one month at 2–8 0C with satisfactory recovery % of about 98%.

1.4.3.3 Statistics

Statistical analysis of the results obtained using Student`s t-test and variance ratio F-test
revealed no significant difference between the performance of the proposed methods and
reported methods 83, 115, 116 regarding accuracy and precision (Table 1.4.5).
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Table 1.4.1 System Suitability Tests for the LC Method Applied for the Determination of ALS,
AML and HCZ
Item

Fumaric acid

HCZ

ALS

AML

N

2870

4043

4000

3781

R

5.769

5.212

3.466

α

1.484

1.393

1.250

T

1.17

1.00

1.08

1.19

%RSD of 6 injections

-----

1.695

1.899

1.798

(N: number of theoretical plates; R: resolution factor; T: tailing factor; : selectivity factor)
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Table 1.4.2 Characteristics and Results of the Proposed LC Method for Simultaneous
Determination of ALS, AML and HCZ
Item

ALS

AML

HCZ

Linearity range (g/mL)

32 – 320

2 – 44

4 – 64

LOD (g mL-1)

0.885

0.061

0.052

LOQ (g mL-1)

2.951

0.202

0.174

Regression equation (Y) a: Slope (b)

10.986

23.740

44.965

Standard deviation of slope (Sb)

0.127

0.151

0.609

Confidence limit of the slope b

10.986  0.353

23.740  0.148

44.965 ± 1.691

Intercept (a)

+ 0.2838

+ 9.3369

- 0.0094

Standard deviation of intercept (Sa)

27.064

3.823

23.972

Confidence limit of the intercept b

0.2838  75.147 9.3369  10.615 0.0094 ± 66.557

Regression coefficient (r2)

0.9995

0.9993

0.9993

Standard error of estimation

29.492

5.252

32.023

Drug in bulk

100.26 + 1.29

99.79 ± 1.13

99.10 + 1.58

Amturnide® 300-10-25 mg tablets

100.06± 1.32

99.86± 0.99

99.98± 0.17

Accuracy ± S.D.

a

Y=a+bC, where C is the concentration in g mL-1 and Y is the peak area.

b

95% confidence limit.
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Table 1.4.3 Intra-and Inter-day Validation for the Determination of ALS, AML and HCZ
Concentration of

Inter-day assay

ALS (g mL-1)

Found ± R.S.D a

SE

Found ± R.S.D a

SE

72.000

72.438 ± 0.51

0.21

72.822 ± 1.00

0.42

176.000

173.255 ± 0.33

0.18

171.637 ± 0.43

0.43

224.000

221.172 ± 0.96

1.22

217.782 ± 1.58

1.98

Concentration of

Intra-day assay

Inter-day assay

AML (g mL-1)

Found  R.S.D a

SE

Found ± R.S.D a

SE

12.000

11.431 ± 1.60

0.11

11.798 ± 2.00

0.14

28.000

27.960 ± 1.16

0.19

28.482 ± 1.60

0.26

36.000

34.934 ± 1.24

0.25

36.035 ± 1.74

0.36

Concentration of

a

Intra-day assay

Intra-day assay

Inter-day assay

HCZ (g mL-1)

Found ± R.S.D a

SE

Found ± R.S.D a

SE

12.000

12.210 ± 0.66

0.05

12.443 ± 1.57

0.11

32.000

31.019 ± 0.48

0.09

31.258 ± 0.98

0.18

48.000

46.414 ± 1.69

0.45

46.047 ± 1.81

0.48

Mean and standard deviation of three determinations
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Table 1.4.4 Robustness Study for the Determination of ALS, AML and HCZ
Retention time
(min.)

Parameters

Mobile phase

Fumaric
acid/HCZ

5.21

3.47

5.77

705

4.80

3.54

5.61

167

686

4.80

3.50

5.80

1993

182

728

4.40

3.20

5.45

2046

182

754

5.70

3.80

5.96

ALS

3.13

3.92

2.25

1921

175

712

1.1

3.35

4.23

2.46

1915

174

1.3

2.82

3.57

2.06

1867

62:38

2.90

3.60

3.21

58:42

3.25

4.23

2.28

composition

Resolution
ALS/AML

ALS AML HCZ
Standard

Flow rate
(mL min-1)

Area under the peak
AML HCZ HCZ/ALS

(acetonitrile:
25mM
sodium
octane
sulphonate)
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Table 1.4.5 Statistical Comparison between Analysis Results of Pure Samples of the Studied
Drugs using HPLC Method and those of the Reference Methods
ALS
Statistical Term

AML

HCZ

Reference

HPLC

Reference

HPLC

Reference

HPLC

method (7)

method

method (39)

method

method (40)

method

Mean

101.10

100.26

99.90

99.79

100.64

99.10

±S.D.

1.64

1.29

1.59

1.13

1.22

1.58

±S.E.

0.73

0.53

0.71

0.46

0.55

0.65

%RSD

1.62

1.29

1.59

1.13

1.21

1.59

n

5.00

6.00

5.00

6.00

5.00

6.00

V

2.69

1.66

2.53

1.27

1.49

2.44

0.93

0.11

1.81

(1.83*)

(1.83*)

(1.83*)

1.62

1.99

1.68

(6.26*)

(6.26*)

(6.26*)

Student`s t test

F-test

* Figures in parentheses are the theoretical t and F values at (p= 0.05) and n is the number of
experiments.
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(a)

(b)

(c)

Figure 1.4.1 Chemical structures of aliskiren hemifumarate (a), amlodipine besylate (b) and
hydrochlorothiazide (c)
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Figure 1.4.2 A typical LC chromatogram of 30 µL injector for a tablet sample of the triple
mixture: HCZ 15 μg mL-1 (tr= 2.25 min) (A), ALS 199.8 μg mL-1 (tr= 3.13 min) (B) and AML
8.4 μg mL-1 (tr= 3.92 min) (C)
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Figure 1.4.3 A typical LC chromatogram of 30 µL injector of fumaric acid 8 μg mL-1 (tr =1.81
min)
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1.5

Simultaneous determination of aliskiren hemifumarate, amlodipine besylate and
hydrochlorothiazide in spiked human plasma using UPLC-MS/MS

Copyright © The Author 2015. Published by Oxford University Press. All rights reserved.
Journal of Chromatographic Science (2015) 53(7):1178-84
DOI 10.1093/chromsci/bmu213

A sensitive UPLC-MS/MS method was developed and validated for simultaneous
estimation

of

aliskiren

hemifumarate

(ALS),

amlodipine

besylate

(AML)

and

hydrochlorothiazide (HCZ) in spiked human plasma using valsartan as an internal standard (IS).
Liquid-liquid extraction was used for purification and pre-concentration of analytes. The mobile
phase consisted of 0.1% formic acid in ammonium acetate buffer (0.02 M, pH=3.5) and
methanol (25: 75, v/v), flowing through XBridge BEH (50 mm x 2.1 mm ID, 5 µm) C18 column,
at a flow rate of 0.6 mL min-1. Multiple reaction monitoring (MRM) transitions were measured
using an electrospray source in the positive ion mode for ALS and AML, while HCZ and IS were
measured in negative ion mode. Validation of the method was performed as per US-FDA
guidelines with linearity in the range of 2.0 – 400.0, 0.3 – 25.0 and 5.0 – 400.0 ng mL-1 for ALS,
AML and HCZ, respectively. In human plasma, ALS, AML and HCZ were stable for at least
one month at -70 ± 5 °C and for at least 6 hours at ambient temperature. After extraction from
plasma, the reconstituted samples of ALS, AML and HCZ were stable in auto sampler at ambient
temperature for 6 hours. The LC-MS/MS method is suitable for bioequivalence and
pharmacokinetic studies of this combination.
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1.5.1 Introduction

Aliskiren hemifumarate, (2(S), 4(S), 5(S), 7(S)-N-(2-carbamoyl- 2- methylpropyl) -5amino-4-hydroxy2,7

diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)

phenyl]

octanamide

hemifumarate) (Fig. 1.5.1a). Aliskiren is the first orally taken direct renin inhibitor simulating
endogenous peptides approved for clinical use. By achieving more complete renin–angiotensin
system inhibition, direct renin inhibitors may afford greater protection from hypertensive
complications 117. Present evidence indicates that aliskiren reduces baseline systolic and diastolic
blood pressure and that it is as effective as other first-line antihypertensive agents. Extra
advantages can be reached when it is used in combination therapy

117

. Amlodipine besylate

(AML), (3-Ethyl 5-methyl (4RS)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4dihydropyridine-3,5-dicarboxylate benzenesulphonate) (Fig. 1.5.1b) is a dihydropyridine longacting calcium channel blocker that inhibits the transmembrane influx of calcium ions into
vascular smooth muscle and cardiac muscle

118

. Amlodipine is a peripheral arterial vasodilator

that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular
resistance and reduction in blood pressure

119

. Hydrochlorothiazide (HCZ) is a potent diuretic

and antihypertensive agent which inhibits active chloride reabsorption and thus increases the
excretion of sodium chloride and water 80. It is chemically 6-chloro-1, 1-dichloro-3, 4, dihydro 2H-1, 2, 4-benzoliadiazine-7-sulphanomide1, 1-dioxide (Fig. 1.5.1c). Triple combination therapy
of ALS, AML and HCZ proved to be effective and well tolerated in treating hypertensive highrisk patients 120. Literature survey revealed some LC 83, 121-126, CE 127, UV-spectrophotometric 128,
129

and spectroflourimetric

130-132

methods for estimation of ALS alone or in combination with

other anti-hypertensive agents. Methods such as LC
spectrophotometry

137-139

and spectroflourimetry

126, 133-135

140, 141

, LC-MS/MS

118

, CE

136

, UV-

were reported for estimation of AML
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only or in combination with other agents. Moreover, methods such as LC
151

142-147

, LC-MS/MS 148-

, UPLC 152 and UV- spectrophotometry 153 were reported for the estimation of HCZ alone or in

combination with other anti-hypertensive agents. Regarding the simultaneous determination of
ALS, HCZ and AML triple mixture, there are four reported LC methods
detection and one reported CE method

157

125, 154-156

with UV

for their determination in pharmaceutical dosage

forms. LC methods with UV detection are not sensitive enough to measure ALS, AML or HCZ
in human plasma, while the use of GC-MS/MS requires derivatization steps prior to analysis.
Amongst the reported LC-MS/MS methods, there was no developed one for simultaneous
determination of ALS, AML and HCZ in biological fluids. Thus, the aim of the present work
was to develop a highly selective and sensitive LC-MS/MS method with good precision and
accuracy, besides a simple sample treatment procedure, for simultaneous estimation of ALS,
AML and HCZ in human plasma, using valsartan as the internal standard (IS). A detailed
validation of the proposed method was performed in accordance with US-FDA guidelines

158

to

yield reliable results. Moreover, the developed method can be successfully applied for further
research to assess for instance the pharmacokinetics of ALS, AML and HCZ in combination.

1.5.2
1.5.2.1

Experimental
Materials and reagents

Working standards of ALS (certified to contain 99.51%) was supplied by (Novartis
Pharmaceuticals Co., NJ, USA), AML (certified to contain 99.75%) was kindly supplied by
(Global Nabi Co., Giza, Egypt). HCZ (certified to contain 99.93%) was supplied by
(AstraZeneca, Cairo, Egypt). Pharmaceutical grade valsartan USP (certified to contain 99.40%)
was supplied by (Zydus Pharmaceuticals, NJ, USA). Methanol HPLC grade, Methyl tert-butyl
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ether and ammonium acetate were obtained from Sigma-Aldrich, USA. Formic acid was
obtained from El-Nasr Pharmaceutical Chemicals Co., Egypt. Human plasma was obtained from
VACSERA Blood Bank, Egypt. Deionized and purified water produced in-house from
Millipore's Milli-Q System (USA) was used throughout the analysis.

1.5.2.2

Instrument and conditions
Quantitation was performed via MS/MS detection using Waters ACQUITY triple

quadrupole LC-MS/MS mass spectrometer (Waters Corp., Milford, MA, USA). A Waters series
UPLC system (Waters Corp., Milford, MA, USA) equipped with degasser, electrospray interface
(ESI) and a solvent delivery unit along with an auto-sampler were used to inject 10 μL aliquots
of the processed samples. The chromatographic separation was carried out on XBridge BEH (50
mm x 2.1 mm ID, 5 µm) C18 column obtained from Waters. Soniclean120T ultrasonic processor
(Australia), Eppendorf Vacufuge 5301 Vacuum Centrifuge Concentrator (Germany) and Vortex2 G-560 Lab Shaker Mixer (USA) were used as well.
Chromatographic elution was performed with a mobile phase consisted of 0.1% formic
acid in 20 mM ammonium acetate and methanol, pH 3.5 (25: 75, v/v) pumped through the
column at a flow rate of 0.6 mL min-1. The column temperature was maintained at 30 °C. Under
these conditions, the retention times for the HCZ, AML, ALS and IS were at 1.20, 2.91, 3.21 and
2.04 min, respectively (Fig. 1.5.2). The injection volume was 10 µL. The LC-MS/MS system
allowed using the positive ion mode for monitoring ALS and AML as well as the negative ion
mode for monitoring HCZ and IS simultaneously in each run. Multiple reaction monitoring
(MRM) is a highly sensitive method of targeted mass spectrometry that can be used to
selectively detect and quantify specific molecules in a complex mixtures based on the screening
of specified precursor molecule-to-fragment ion transitions

159

. MRM transitions were measured
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at positive mode at m/z 552.7 → 117.1, CV=35V, CE=40eV for ALS and at m/z 409.4 → 238.2,
CV=15V, CE=10eV for AML, while HCZ was measured at negative mode at m/z 296.2 →
269.1, CV=35V, CE=20eV and at m/z 434.3 → 179.2, CV=40V, CE=30eV for the IS, where;
CV is the cone voltage and CE is the value of collision energy for MRM acquisition, with a 20
ms dwell time of all analytes. The capillary voltage was set at +4000 V for both of ALS and
AML, while it was set at -4000V for HCZ and IS. The cone gas flow was set at 40 L h-1 at 4 psi,
and temperature at 350 °C with nozzle voltage of 2900 V. Nitrogen (99.99% purity) was used in
the ion source and the collision cell. Quantitation of the analytes in spiked human plasma was
based on the peak area ratio of cited drugs to IS. Data acquisition and processing were performed
using Empower2 software (Waters Corp., MA, USA).

1.5.2.3 Standard stock solutions preparation
Standard stock solutions of 200 g mL-1 of ALS and HCZ as well as 100 g mL-1 of
AML and IS were prepared separately in methanol. Appropriate further dilutions were prepared
in the same solvent. All solutions were stored under refrigeration (2-8 ◦C) when not in use.
1.5.2.4 Procedure
1.5.2.4.1 Calibration and quality control samples preparation
Seven non-zero calibration standard solutions ranging from 20-4000 ng mL-1 for ALS, 3250 ng mL-1 for AML and 50-4000 ng mL-1 of HCZ were prepared in 10 ml volumetric flasks
where 100 µL of IS stock solution was added to each flask and completed to the mark with
methanol. 50 µL of each working solution was added to 450 µL of drug free human plasma
containing EDTA as anticoagulant. The quality control samples (QC) were prepared in the same
manner similar to the calibration standards at three concentration levels; low, medium and high
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(60, 1600 and 3200 ng mL-1), (9, 100 and 200 ng mL-1), (150, 1600 and 3200 ng mL-1) for ALS,
AML and HCZ, respectively. All samples were vortexed to ensure complete mixing. During each
run, five replicates of the QC samples were used along with the calibration standards to verify
the repeatability and integrity of the method.

1.5.2.4.2 Sample preparation
To 500 μL of each spiked calibration plasma standard or QC sample, 4 mL of methyl tertbutyl ether was added. It was then vortexed for 30 sec. and centrifuged at 4000 rpm, at 4 °C for 5
min. 1350 μL of the supernatant was collected and evaporated using an Eppendorff concentrator.
The residue was reconstituted in 150 μL of the mobile phase and transferred to a glass vial for
LC-MS/MS analysis.

1.5.3

Discussion and Method development

To the best of our knowledge there is no reported method for simultaneous determination
of ALS, AML and HCZ in human plasma using LC-MS/MS, so the aim of the present work was
to simultaneously determine ALS, AML and HCZ using UPLC system interfaced with tandem
mass spectrometry to attain higher sensitivity and selectivity for detection and quantitation of the
cited drugs in human plasma with a rapid and affordable extraction procedure. Moreover, the
proposed method should be suitable for human clinical pharmacology, bioavailability and
bioequivalence studies requiring simultaneous pharmacokinetic evaluation of ALS, AML and
HCZ either separately or in combination in human plasma. Peak plasma concentrations for ALS
reach 186±91 ng mL-1 following oral administration of a single oral dose (300 mg) of ALS

160

.

Also, peak plasma concentrations for AML and HCZ reach 6.7±1.2 ng mL-1 and 131±4 ng mL-1
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following oral administration of single oral doses (10 mg and 25 mg) of AML

161

and HCZ

162

,

respectively. Based on the Cmax value of each drug, suitable linearity ranges of 2.0 – 400.0 ng
mL-1, 0.3 – 25.0 ng mL-1 and 5.0 – 400.0 ng mL-1 for ALS, AML and HCZ, respectively, were
selected. For sample preparation, extraction methods including direct precipitation and liquidliquid extraction were studied. Liquid-liquid extraction using 4 mL methyl tert-butyl ether as the
extraction solvent has the advantage of better deproteinization of the plasma samples, lower cost
and good recovery results for the cited drugs, (Table 1.5.1). The use of C18 column was suitable
for optimum separation of ALS, AML and HCZ. During the optimization cycle, various mobile
phase compositions of ammonium acetate buffer, 0.1% formic acid in water, 0.1% formic acid in
20 mM ammonium acetate buffer, methanol and acetonitrile, in different proportions were tried
in an isocratic mode. It was found that methanol allowed good elution of the analytes with better
responses. The use of 0.1% formic acid in 20 mM ammonium acetate buffer was to obtain higher
detection response through assisting the ionization of the cited drug molecules especially AML.
Thus, the optimized conditions allowed the proposed method to be selective, sensitive, rapid and
suitable for human clinical pharmacology, bioavailability and bioequivalence studies requiring
pharmacokinetic simultaneous evaluation of ALS, AML and HCZ combination in human
plasma.

1.5.4

Results and Bio-analytical method validation

1.5.4.1 Calibration, linearity and limit of quantitation

Blank samples (matrix samples processed without internal standard) and zero samples
(matrix samples processed with internal standard) were analyzed. To establish the linearity,
seven non-zero samples covering the expected range of each drug were prepared and added to
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drug free human plasma then analyzed. Calibration curves were constructed by plotting peak
area ratio of cited drug to the IS versus the corresponding concentration of each cited drug.
Satisfactory linearity was obtained in the concentration range of 2.0 – 400.0, 0.3 – 25.0 and 5.0 –
400.0 ng mL-1 for ALS, AML and HCZ, respectively. The lowest standard on the calibration
curve was to be accepted as the lower limit of quantitation (LLOQ) if the analytes response in
the standard was at least five times more than that of drug free (blank) plasma 158. In addition, the
analyte peak in LLOQ sample was identifiable, discrete, and reproducible with satisfactory
precision and accuracy (Table 1.5.2). A correlation coefficient of more than 0.998 for each of the
analytes was obtained (Table 1.5.3). The regression equation for each of the cited drugs was also
computed (Table 1.5.3).

1.5.4.2 Specificity

Six randomly selected drug free human plasma samples were processed by the similar
liquid-liquid extraction procedure and analyzed. No endogenous plasma components showed
interference at retention time of any analyte or of the IS.

1.5.4.3 Recovery (extraction efficiency) from human plasma matrix

Recovery of ALS, AML and HCZ were evaluated by comparing the mean peak responses
of five extracted quality control (QC) samples of low, medium and high concentrations to mean
peak responses of five plain standards of equivalent concentration. Similarly, the recovery of IS
was also evaluated at the concentration of 100 ng mL-1. The recovery of the analytes was
consistent, precise and reproducible. The mean recovery results for the cited drugs in human
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plasma are listed in table 1.5.1. The recovery for the IS from plasma was found to be 88.54 ±
1.91 (mean recovery % ± S.D.).

1.5.4.4

Accuracy and precision (inter- and intra-day)

The satisfactory recovery percentage results obtained from the assay of ALS, AML and
HCZ indicate the accuracy of the proposed method, (Table 1.5.4). Repeatability (intra-day) and
intermediate precision (inter-day) were assessed using three concentrations and three replicates
of each concentration. The intermediate precision it was performed over three different days.
The acceptable values for the coefficient of variation indicate good precision of the proposed
method, (Table 1.5.4).

1.5.4.5 Stability

Three aliquots each of the low and high unprocessed QC samples of ALS, AML and
HCZ were stable at -70 ± 5 °C for 36 days (long term stability) in human plasma, (Table 1.5.5).
Also, three aliquots each of the low and high unprocessed QC samples of ALS, AML and HCZ
were found to be stable over 6.0 hours in human plasma at room temperature (23-30 °C) (short
term stability). After 6.0 hours the samples were processed, analyzed and compared with
nominal concentrations, (Table 1.5.5). Auto-sampler stability was determined by analyzing three
aliquots each of low and high QC samples of ALS, AML and HCZ that were stable for 6.0 hours
after sample processing, (Table 1.5.5). Three aliquots each of low and high unprocessed quality
control samples were stored at -70 ± 5 °C and subjected to three freeze and thaw cycles. After
the completion of third cycle the samples were processed, analysed and results were compared
with nominal values, (Table 1.5.5). Working solutions of 320 ng mL1 of ALS and HCZ as well
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as 20 ng mL1 and 100 ng mL-1 of AML and IS, respectively, were found to be stable for 6 days at
2-8 °C and at room temperature (23-30 °C) for 6 hours, (Table 1.5.6).
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Table 1.5.1 Recovery results for ALS, AML and HCZ from spiked human plasma
QC

Concentration of drug

sample

in plasma (ng mL-1)

Mean Recovery %

CV

n

ALS

AML

HCZ

ALS

AML

HCZ

ALS

AML HCZ

Low

6.00

0.90

15.0

88.32

86.63

83.84

2.56

4.08

2.66

5

Medium

160.00

10.00 160.0

90.36

88.32

85.37

4.50

5.28

3.02

5

High

320.00

20.00 320.0

92.85

90.05

88.62

2.02

2.74

2.30

5

CV, coefficient of variation; n, number of determinations.
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Table 1.5.2 Summary for ALS, AML and HCZ calibration standards results in spiked human
plasma
Conc. of drug in

Mean conc. found

plasma (ng mL-1)

(ng mL-1)

± S.D.

CV

Recovery %

n

ALS

AML

HCZ

ALS

AML

HCZ

ALS

AML

HCZ

ALS

AML

HCT

ALS

AML

HCT

2.00

0.30

5.00

2.16

0.30

4.73

0.14

0.02

0.06

9.63

13.03

16.98

108.15

99.33

94.50

5

6.00

0.90

15.00

6.05

0.92

14.52

0.12

0.01

0.02

4.04

4.26

4.60

100.75

102.67

96.82

5

40.00

5.00

40.00

39.14

4.78

40.83

0.90

0.09

0.03

6.02

8.20

3.03

97.84

95.5

102.08

5

80.00

10.00

80.00

79.38

10.00

79.83

2.05

0.09

0.09

7.18

3.91

5.99

99.23

99.96

99.78

5

160.00

15.00

160.00

160.49

15.07

157.81

1.67

0.14

0.23

2.70

4.05

8.93

100.31

100.49

98.63

5

320.00

20.00

320.00

328.49

20.25

323.45

2.80

0.30

0.47

2.33

6.77

9.28

102.65

101.25

101.08

5

400.00

25.00

400.00

400.19

25.72

396.13

2.85

0.37

0.36

1.92

6.64

5.84

100.05

102.87

99.03

5

S.D., standard deviation; CV, coefficient of variation; n, number of determinations
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Table 1.5.3 Characteristics and results of the proposed LC-MS/MS method for simultaneous
determination of ALS, AML and HCZ in spiked human plasma
Item

ALS

AML

HCZ

2.0 – 400.0

0.30– 25.0

5.0 – 400.0

Regression equation (Y) a: Slope (b)

0.374

0.221

0.373

Intercept (a)

0.301

0.064

0.850

Regression coefficient (r2)

0.9997

0.9989

0.9998

Linearity range (ng mL-1)

a

Y=a+bC, where C is the concentration in ng/ml and Y is the peak area ratio.
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Table 1.5.4 Intra-day and inter-day results of ALS, AML and HCZ in human plasma
QC
sample

Conc. Of
ALS
(ng mL-1)

Intra-day assay
Found ± S.D.

CV

Inter-day assay
Recovery
%

Found ± S.D.

CV

Recovery
%

Low

6.00

6.48 ± 0.03

0.42

107.97

6.60 ± 0.19

2.83

110.01

Medium

160.00

149.52 ± 1.53

1.02

93.45

146.61 ± 6.46

4.40

91.63

High

320.00

290.52 ± 4.56

1.57

90.79

298.71 ± 7.33

2.45

93.35

Conc. of
AML
-1

(ng mL )

Intra-day assay
Found ± S.D.

CV

Inter-day assay
Recovery
%

Found ± S.D.

CV

Recovery
%

Low

0.90

0.85 ± 0.03

3.41

94.43

0.82 ± 0.02

2.49

91.18

Medium

10.00

9.24 ± 0.49

3.63

92.39

9.27 ± 0.30

2.98

92.66

High

20.00

18.03 ± 2.69

0.73

90.15

18.27 ± 0.33

1.83

91.34

Conc. of HCZ

Intra-day assay

(ng mL-1)

Found ± S.D.

CV

Low

15.00

13.61 ± 0.25

1.87

Medium

160.00

148.87 ± 0.51

High

320.00

283.99 ± 3.78

Inter-day assay
Recovery

Recovery

Found ± S.D.

CV

90.71

13.50 ± 0.40

2.99

89.97

0.34

92.28

143.38 ± 4.60

3.21

89.01

1.33

88.74

293.47 ± 4.44

1.51

91.71

S.D., standard deviation; CV, coefficient of variation.

%

%
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Table 1.5.5 Summary of stability data of ALS in spiked human plasma

Long term (36 days)

6.00
320.00

Mean conc.
found (ng
mL-1)
5.85
289.27

Short term (6 hours)

6.00
320.00

6.16
295.22

0.11
2.83

1.62
0.96

102.67
92.26

3
3

Auto-sampler (6
hours)

6.00
320.00

6.09
294.76

0.05
1.93

0.72
0.65

101.56
92.11

3
3

Freeze and thaw

6.00
320.00

5.67
288.42

0.31
7.18

4.60
2.49

94.50
90.13

3
3

Long term (36 days)

0.90
20.00

0.82
17.98

0.02
0.72

2.66
4.00

90.76
89.88

3
3

Short term (6 hours)

0.90
20.00

0.81
18.09

0.03
0.28

4.19
1.54

90.26
90.44

3
3

0.90
20.00

0.81
18.14

0.02
0.47

1.95
2.61

89.92
90.68

3
3

Freeze and thaw

0.90
20.00

0.80
17.81

0.03
0.22

3.50
1.21

88.79
89.05

3
3

Long term (36 days)

15.00
320.00

13.49
295.14

0.26
5.31

1.94
1.80

89.91
92.23

3
3

Short term (6 hours)

15.00
320.00

13.41
285.59

0.10
3.49

0.77
1.22

89.38
89.25

3
3

15.00
320.00

13.51
284.88

0.12
3.51

0.91
1.23

90.09
89.03

3
3

15.00
320.00

13.15
286.82

0.29
6.32

2.22
2.20

87.67
89.63

3
3

Stability term

HCZ

AML

ALS

Drug

Auto-sampler
(6hours)

Auto-sampler
(6hours)
Freeze and thaw

Conc.
(ng mL-1)

S.D.±

CV

Mean recovery %

n

0.17
3.95

2.61
1.36

97.50
90.40

3
3

S.D., standard deviation; CV, coefficient of variation; n, number of determinations
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Table 1.5.6 Summary of the stability data of ALS, AML, HCZ and internal standard in solution
Stability

Conc.

Mean peak

Mean peak

Mean peak

of stock

(ng mL-1)

area at 25 ◦C

area at (2-8

area of freshly

solution

after 6 hours

◦

C) after 6

prepared

days

solution

Bias (%) at 25
◦

Bias (%) at

C after 6

(2-8 ◦C)

hours

after 6 days

n

ALS

320.00

241.1 x 104

239.9 x 104

242.1 x 104

0.40

0.89

3

AML

20.00

10.4 x 104

10.3 x 104

10.4 x 104

0.41

1.62

3

HCZ

320.00

10.2 x 104

10.0 x 104

10.3 x 104

0.81

2.18

3

IS

100.00

2.1 x 104

2.1 x 104

2.2 x 104

1.27

0.59

3

n, number of determinations.
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Figure 1.5.1 Chemical structures of aliskiren hemifumarate (a), amlodipine besylate (b) and
hydrochlorothiazide (c)
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Figure 1.5.2 LC-MS/MS chromatogram of a 10 μL injection of quality control high sample
showing elution of 20 ng mL-1 AML at 2.91 min, 160 ng mL-1 HCZ at 1.20 min, 160 ng mL-1
ALS at 3.20 min and 100 ng mL-1 IS at 2.04 min.
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1.6

Conclusions
The study presented in section 1.2 represents the first report of a stability-indicating LC

method for determination of AZL and CLT in their commercially available tablets. The proposed
method has the advantages of being simple, specific, accurate and selective, so that, it was
applied to the analysis of the studied drugs in their pharmaceutical dosage forms. Moreover, the
suggested method permits separation of the studied drugs from their alkaline, acidic, oxidative,
thermal (wet heat) or photolytic degradation products within a reasonable time. Furthermore, the
proposed method was successfully applied to study the kinetics of the acidic degradation
processes in the case of AZL as well as the kinetics of the alkaline degradation processes in the
case of CLT, and to derive the first order degradation rate constant, half-life time (t1/2), shelf-life
(t90) and the activation energy Ea of the investigated drugs.
The study presented in section 1.3 represents rapid, selective, specific and validated RPLC method which was developed and validated for the simultaneous determination of the most
important diuretics, HCZ, along with most commonly prescribed antihypertensive drugs
representing different pharmacological classes, namely; ATN, VAL, MXP, ALS, AML and
CND. This method is characterized by simplicity, accuracy, preciseness besides its wide range of
applications, and it can be used for routine analysis and quality control of the cited drugs
separately or in combinations in many dosage forms.
The proposed ion pair LC method in section 1.4 found to be reliable, simple, quick,
sensitive and accurate for simultaneous determination of ALS, AML and HCZ in pharmaceutical
preparation. Therefore, the proposed method can be used routinely for quality control of the cited
drugs.
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The proposed bio-analytical method in section 1.5 was specific, sensitive accurate and
precise enough to be successfully applied to human clinical pharmacology, bioavailability, and
bioequivalence studies requiring pharmacokinetic evaluation. The method employed sample
preparation by liquid-liquid extraction with adequate recovery results, followed by isocratic
HPLC coupled with tandem mass spectrometric detection. The LC-MS/MS method was rapid
enough and capable of simultaneous estimation of ALS, AML and HCZ in human plasma with
satisfactory sensitivity and precision.
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2 SEPARATION AND DETERMINATION OF SELECTED PHARMACEUTICAL
COMPOUNDS USING CAPILLARY ELECTROPHORESIS
2.1 Introduction
Capillary electrophoresis (CE) is a separation technique depends on different migration
of solutes in an electric field. Electrophoresis is performed in narrow-bore capillaries filled with
background electrolyte (BGE). Driving forces in CE are electrophoretic migration and the
electro-osmotic flow (EOF) 1, 2.
Compared with other techniques, the instrumentation of CE is simple consisting of
electrodes, sample introduction systems, a capillary column, a power supply, a detector, and
liquid-handling

systems.

Detection

can

be

achieved

with

on-line

(UV/diode-array

spectrophotometric, spectrofluorimetric or electrochemical detectors) or external detectors (mass
spectrometer) 3.
There are five major modes of operation of CE: capillary zone electrophoresis (CZE,
based on analytes’ charge-to-size ratios) also referred to as free solution or free flow capillary
electrophoresis, micellar electrokinetic chromatography (MEKC, based on chromatographic
partition of analytes between micelles and the BGE), capillary isoelectric focusing (CIEF, based
on analytes’ isoelectric points), capillary gel electrophoresis (CGE, based on analytes’
size/molecular weight ratio) and capillary isotachophoresis (CITP, based on moving boundaries)
3, 4

.
Separation in CZE mode is based upon differences in charge-to-size ratios for each

analyte in the sample. The larger this ratio, the higher the mobility and the faster an ion migrates
in the applied electrical field 2. The migration velocity v of an ion (cm/sec) in an electric field is
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equal to the product of the field strength E and the electrophoretic mobility ep. The
electrophoretic mobility is in turn proportional to the ionic charge on the analyte and inversely
proportional to frictional retarding factors. The electric field acts only on ions 4. If two ionized
species differ either in charge or in the frictional forces they experience in moving through the
buffer because of the structural variations, they will migrate in a different velocity and separate
from each other. Neutral species are not separated using CZE. When a high potential is applied
across a capillary column containing a BGE, EOF is usually produced, in which the BGE
migrates toward the cathode or the anode. EOF is caused by the electric double layer that occurs
at the silica/solution interface. Above pH 3, the inside wall of a silica capillary is negatively
charged due to ionization of the surface silanol groups (Si-OH). Buffer cations accumulate in an
electrical double layer adjacent to the negative surface of the silica capillary. The cations in the
diffuse outer layer are attracted toward the cathode dragging the bulk solvent along with them.
The rate of EOF is generally higher than the electrophoretic migration nobilities of the analyzed
ions 2, 4. Figure (1) represents a simplified diagram of CZE system 5.
Capillary electrophoresis has grown from a simple to a sophisticated method because of
several innovations during recent decades. This growth has expanded applications of CE to
various analytes including pharmaceuticals.
A major advantage of CE is the availability of various modes, which enable the
separation and analysis of different compounds ranging from inorganic species to biopolymers. It
is well accepted that CZE and MEKC are still mainly employed for drug analysis. Nevertheless,
various techniques have been established to improve CE selectivity, sensitivity, efficiency,
applicability, or flexibility.
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Figure 2.1.1 Simplified diagram for typical CE Instrument Configuration

Numerous applications of CE in drug analysis are reported daily and reviews on CE for
drug analysis are regularly published. In 2011, Hendrickx et al.

6

surveyed the applicability of

capillary electrophoresis to analyze drug impurity mixtures, formulations, biological samples,
and chiral compounds. Suntornsuk

3

reviewed the recent advances of CE in pharmaceutical

analysis and their applications in assay of active pharmaceutical ingredients, drug impurity
testing, chiral drug separation, and determination in biological fluids between 2008 to 2009. In
2009, Gilpin and Gilpin

7

reported separation-based (including CE), and other methods for

analysis of active ingredients and related drugs in bulk and formulations during 2007 - 2008.
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Separation Science and Technology published a series of reviews on CE including the role
of CE in drug substance and drug product development 8, the need for CE methods in
pharmacopeial monographs 9, CE in impurity profiling of drugs
biopharmaceutical development and quality control

11

10

, and the role of CE in

. In 2007, Suntornsuk

12

surveyed recent

applications of CE in pharmaceutical analysis published during 2005–2007. Altria et al.

13

reviewed use of CE for analysis of small-molecule pharmaceuticals in 2006. CE reviews on some
classes of drugs have also been published, for example metal-based drugs 14, and sulfonamides 15.
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2.2

Simultaneous determination of valsartan, amlodipine besylate and
hydrochlorothiazide using capillary zone electrophoresis (CZE)

Copyright © 2015 Avoxa - Mediengruppe Deutscher Apotheker GmbH
Pharmazie (2015) 70: 368–373
DOI 10.1691/ph.2015.4134

A capillary zone electrophoresis method was developed for simultaneous determination
of valsartan (VAL), amlodipine besylate (AML) and hydrochlorothiazide (HCZ) in their
combined tablets. Separation was achieved on fused silica capillary by applying a potential of 15
kV (positive polarity) and a running buffer containing 40 mM phosphate buffer at pH 7.5 with
UV detection at 230 nm. The samples were injected hydrodynamically for 3 s at 0.5 psi and the
temperature of the capillary cartridge was kept at 25 °C. Pyrazinoic acid was used as an internal
standard. The method was validated according to ICH guidelines regarding specificity, linearity,
limits of detection and quantitation, accuracy and precision. The method showed satisfactory
linearity in the ranges of 10-200, 2-20 and 2-20 µg mL-1 with LODs of 1.82, 0.39, 0.65 µg mL-1
and LOQs of 5.51, 1.17, 1.96 µg mL-1 for VAL, AML and HCZ, respectively. The proposed
method was successfully applied for the analysis of the studied drugs in their laboratory prepared
mixtures and co-formulated tablets. The results were compared with reported methods and no
significant difference was found statistically. The proposed method can be used for quality
control of the cited medications in ordinary laboratories.
2.2.1 Introduction
Valsartan

(VAL)

chemically,

(S)-N-valeryl-N-([2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-

methyl)-vali ne (Fig. 2.2.1a), is a potent, highly selective, and orally active non peptide
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antagonist on AT1-receptor subtype

16

. Angiotensin receptor blockers are a major class of

antihypertensive therapies due to their powerful lowering effects on blood pressure and excellent
17

tolerability

.

Amlodipine

besylate

(AML),

(3-Ethyl

5-methyl

(4RS)-2-[(2-

aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
benzenesulphonate) (Fig.2.2.1b) is a long acting dihydropyridine calcium channel blocker that
prevents the transmembrane influx of calcium ions into vascular smooth muscles and cardiac
muscles

18

. Also, it is a direct peripheral arterial vasodilator that

resistance and hence lowers blood pressure

19

reduces peripheral vascular

. Hydrochlorothiazide (HCZ) is an orally potent

diuretic and antihypertensive agent which inhibits active chloride reabsorption and thus increases
the excretion of sodium chloride and water
dihydro

-2H-1,

2,

20

. It is chemically 6-chloro-1, 1-dichloro-3, 4,

4-benzothiadiazine-7-sulphanomide1,

1-dioxide

(Fig.2.2.1c).

Triple

combination therapy of VAL, AML and HCZ proved to be effective and well tolerated in
treating hypertensive high-risk patients 21. Literature survey revealed methods using HPLC
LC-MS

25-27

, CE

28, 29

, UV spectrophotometric

30, 31

and spectroflourimetric

32

22-24

,

techniques

reported for estimation of VAL either alone or in combination with other agents. Methods such
as HPLC

33-35

, LC/MS/MS

36, 37

, CE 38, UV-spectrophotometry 39-41 and spectroflourimetry 32, 42

are reported for estimation of AML either alone or in combination with other agents. Also,
methods such as HPLC

43-48

, LC-MS

49-51

, UPLC

52

and UV- spectrophotometry

53

are reported

for the estimation of HCZ alone or in combination with other anti-hypertensive agents. There are
many methods reported for the simultaneous determination of the three medications in different
matrices such as HPLC 44, 54, 55, and UV-spectrophotometry 56. To the best of our knowledge, no
capillary electrophoresis method was reported yet for the simultaneous determination of the
studied medications either in pharmaceutical preparations or in biological fluids. CE has a lot of
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proved successful applications in the field of pharmaceutical analysis such as assay of drugs,
determination of impurities, chiral separation, and in the analysis of pharmaceutical excipients.
The advantages of using CE for pharmaceutical analysis include its reliability and low cost of
analysis, reductions in solvent consumption and disposal, and the possibility of rapid method
development and feasibility of a high degree of automation. Moreover, CE allows a single set of
separation conditions to be applied for a wide range of analyses, introducing efficiency savings
57, 58

. Recently, CE techniques have been applied for the simultaneous determination of co-

formulated medication in their dosage forms 29, 38.

2.2.2 Investigation, results and discussion
The goal of this study was to develop and validate a reliable, accurate, inexpensive,
selective and efficient method using capillary electrophoresis that could be used for routine
quality control analysis of VAL, AML and HCZ simultaneously in their co-formulated tablets.
VAL, AML and HCZ are co-formulated in a medicinally recommended ratio of 12.8:1.1:1.
Analysis of such mixture with strong spectral overlapping is challenging. The proposed CZE
method allowed the separation and simultaneous quantification of the three medications in a
reasonable time less than 15 min with satisfactory accuracy and precision in their co-formulated
dosage form.
Figure 2.2.2, shows a typical electropherogram for a laboratory prepared mixture of the
three drugs under the described electrophoretic conditions. The migration times for VAL, AML
and HCZ were 12.74, 5.21 and 6.45 min., respectively.
The proposed CZE method was applied to the simultaneous determination of VAL, AML
and HCZ in laboratory prepared mixtures in the medicinally recommended ratio of 12.8:1.1:1.
Furthermore, the proposed method was successfully applied for their determination in their co-
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formulated tablets (Fig. 2.2.3). The results shown in (Tables 2.2.1, 2.2.2) are in good agreement
with those obtained using the comparison method 55. The comparison method was performed on
RP-C18 column using a mobile phase consisting of acetonitrile: methanol: 50 mM phosphate
buffer adjusted to pH 3 with orthophosphoric acid (20: 50: 30, v/v/v) at a flow rate of 1.0 mL
min−1 in and the eluents were monitored at 239 nm. Statistical analysis of the results obtained
using Student’s t-test and variance ratio F-test revealed no significant difference between the
performance of the methods regarding the accuracy and precision, respectively.

2.2.2.1 Optimization of the CE conditions
In CZE, the background electrolyte (BGE) type as well as its pH and its concentration are
crucial for optimizing the separation of the ionizable analytes as they determine the degree of the
analyte ionization, its electrophoretic mobility and the magnitude of the electroosmotic flow
(EOF). As AML has pKa value of 9.5 and HCZ has pKa values of 8.8 and 9.9, they are positively
charged at pH 7.5. On the other hand, VAL has pKa values of 3.6 and 4.7 and it is negatively
charged at the same pH. Several capillaries of different length and internal diameter as well as
different pHs and molarities of phosphate buffer were tested for CZE analysis and the results
were evaluated taking into consideration different parameters such as migration time, resolution,
peak shape, height, baseline noise and the electric current produced.
2.2.2.1.1 Effect of phosphate buffer pH
The effect of buffer pH was investigated within the range of 5.0–8.0 at a 40mM
phosphate buffer concentration. Electropherograms showed in (Fig. 2.2.4) demonstrated that the
four compounds needed longer time to be separated at pH lower than 6.5. Also, both resolution
and migration times decreased with increasing the pH. Taking into consideration the ionization
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percentage of the analytes, resolution, peak symmetry and migration time, pH 7.5 was selected as
the optimum pH for separation (Fig. 2.2.4).
2.2.2.1.2 Effect of phosphate buffer concentration

Buffer concentration has also a significant effect on the separation performance through
its influence on the EOF and the current produced in the capillary. The effect of phosphate
running buffer concentrations was examined by varying the concentration from 5 to 50 mM with
the increase in phosphate buffer concentration, both resolution and migration times increased. A
40mM concentration of phosphate buffer was chosen in order to achieve reliable electrolyte
background for analysis while maintaining reasonable run time, good resolution and acceptable
current (≈ 78µA), (Fig. 2.2.5).
2.2.2.1.3 Effect of applied voltage

The applied voltage effect was investigated under the optimized conditions selected
above from 5 to 20 kV. As expected, increasing the applied voltage increases the EOF, leading to
shorter separation time and higher efficiencies. However, lowering the applied voltage than 15
kV decreases the EOF so the separation time will be high and increasing the applied voltage
exhibits higher currents and produces Joule’s heating. To limit this heating inside the capillary,
the maximum applied voltage was chosen from an Ohm’s plot (current versus voltage) and it was
found to be 15 kV (current (≈ 78µA)).
2.2.2.1.4 Effect of injection time

Injection time affects the peak width and peak height. Sample solutions were
hydrodynamically injected at 0.5 psi while the injection time was varied from 1.0 to 4.0 s. After
3.0 s, the peak widths of VAL, HCZ and IS were increased and the peak shapes were deformed,
so 3.0 s was selected as the optimum injection time, (Fig. 2.2.6).
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2.2.2.1.5 Selection of the internal standard (IS)

The use of IS is recommended to compensate for injection errors, minor fluctuations
effect of the migration time and improve the quantitative analysis. Then pyrazinoic acid was
chosen as it possesses pKa value 2.9
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and its molecular weight is less than VAL so it will be

negatively charged under the optimized condition and as expected it eluted after VAL.
2.2.2.1.6 Selection of the detection wavelength

In order to optimize sensitivity and detection limit of the method, a multiwavelength
detection system (190 – 300 nm) was used in the CE system. For simultaneous determination of
VAL, AML and HCZ, reasonable detection sensitivities were obtained at 230 nm (bandwidth 20
nm), (Fig. 2.2.7, Table 2.2.3).
2.2.2.2 Validation of the method
Validation of the proposed CZE method was performed with respect to stability, linearity,
range, specificity, limit of detection (LOD), limit of quantitation (LOQ), accuracy and precision
according to the ICH Guidelines
[http://www.fda.gov/downloads/Regulator%20yInformation/Guidances/UCM128049.pdf].
2.2.2.2.1 Linearity
A linear relationship was established by plotting the peak area ratio (the studied drug
peak area/IS peak area) against the corresponding drug concentration in the range of 10–200, 220 and 2-20 µg mL-1 for VAL, AML and HCZ, respectively. Statistical analysis of the data gave
high value for the correlation coefficient (r) of the regression equation, small values of the
standard deviation of residuals (Sy/x), of intercept (Sa), and of slope (Sb), and small value of the
percentage relative standard deviation, (Table 2.2.4). These data proved the linearity of the
calibration graphs.
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2.2.2.2.2 Limit of quantitation (LOQ) and limit of detection (LOD)
LOQ and LOD were calculated according to ICH Q2 (R1) recommendations. Results are
given in (Table 2.2.4).
2.2.2.2.3 Accuracy and precision
To prove the accuracy of the proposed method, the recovery percentage results of the
assay of VAL, AML and HCZ were compared with those of the reference methods

60, 61

.

Statistical analysis of the results using Student's t-test and variance ratio F-test revealed no
significant difference between the performance of the two methods regarding accuracy and
precision, (Supplementary materials Table 2.2.5). The reference methods depend on the analysis
of VAL, AML and HCZ using HPLC. Repeatability (intra-day) and intermediate precision (interday) were assessed using three concentrations and three replicates of each concentration.
The relative standard deviations were found to be very small indicating reasonable repeatability
and intermediate precision of the proposed method, (Table 2.2.1).
2.2.2.2.4 Stability
Stability of the standard solutions of VAL, AML and HCZ, stored at 2 ◦C, were evaluated
at various time points over 3 months. The concentrations of freshly prepared solutions and those
aged for 2 months were calculated by the method developed and the difference between them
was found to be less than 0.3 %. These solutions can therefore be used during this interval of
time without the results being affected.
2.2.2.2.5 Specificity
The specificity of the method was investigated by observing any interference
encountered from common tablet excipients and it was confirmed that the signals measured was
caused only by the analytes. Each film-coated tablet of Exforge HCT® contains the following
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inactive ingredients: colloidal silicon dioxide, crospovidone, hypromellose, iron oxide red, iron
oxide yellow, iron oxide black, magnesium stearate, microcrystalline cellulose, polyethylene
glycol, povidone, talc, and titanium dioxide. It was found that the excipients did not interfere
with the results of the proposed method. As shown in (Fig. 2.2.3) the tablets electropherogram
did not show any additional peaks when compared to VAL, AML and HCZ laboratory prepared
mixture electropherogram which confirm the specificity of the method.
2.2.3 Experimental
2.2.3.1 Instruments
The assay was developed and validated using a Beckman P/ACE 5510 system (Fullerton,
CA, U.S.A) equipped with an autosampler, a photodiode array (PDA) detector, a temperature
controlling system(4 - 40 oC) and power supply able to deliver up to 30 kV. Beckman P/ACETM
station software (version 1.2) was used for the instrument control, data acquisition and analysis.
Electrophoretic analyses were performed in a fused silica capillary (Polymicro Technologies,
Phoenix, AZ, U.S.A) of 57.0-cm-long (50.0-cm effective length) and 75.6 µm i.d. in normal
mode, applying a voltage of 15 kV. The wavelength for analysis was 230 nm, hydrodynamic
injection of samples for 3 s under a pressure of 0.5 psi and the temperature of the capillary
cartridge was 25 oC.
The BGE was filtered using 0.2 µm Anatop 25 Whatman inorganic membrane filter
(Maidstone, England) and degassed using Branson Ultrasonic 5510 degasser (Danbury, CT,
U.S.A). A SympHonly (SB20) pH-meter (Thermo Orion Beverly, MA, U.S.A) was used for pH
measurements. Deionized water was prepared using a Barnstead NANO pure DIamond
Analytical (USA) ultrapure water system.
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2.2.3.2 Materials and reagents
All the chemicals used were of Analytical Reagent grade, and the solvents were of HPLC
grade. Pharmaceutical grade valsartan USP was supplied Zydus, batch Number: VSK1MK A02B
(certified to contain 99.40%). Amlodipine besylate (certified to contain 99.75%) was kindly
supplied by Global Nabi Co., (Giza -Egypt). Hydrochlorothiazide (certified to contain 99.93%)
was supplied by AstraZeneca - Cairo, - Egypt (Under license of AstraZeneca, Sweden).
Methanol and Pyrazinoic acid (certified to contain 99%) were obtained from (Sigma-Aldrich,
MO, U.S.A). Exforge HCT® 160/10/12.5 mg tablets each labeled to contain 160 mg Valsartan,
13.9 mg amlodipine besylate and 12.5 mg hydrochlorothiazide were purchased from commercial
sources in the local market. Sodium hydroxide, sodium dihydrogen phosphate (J.T. Baker,NJ,
U.S.A) and Orthophosphoric acid 85% (Fisher Scientific, NJ, U.S.A) ) and methanol (SigmaAldrich, MO, U.S.A) were used.
2.2.3.3 Standard and working solutions
2.2.3.3.1 Standard solutions
Stock solutions 2000 µg mL-1 of VAL and 1000 µg mL-1 of AML, HCZ and IS were
prepared in a solvent composed of methanol and water (10: 90, v/v), 10% methanol. Working
solutions were prepared by further dilution of AML and HCZ stock solutions with 10% methanol
to give a final concentration of 200 µg mL-1.
2.2.3.3.2 Background running electrolyte (BGE)
The optimized BGE solution consisted of 40 mM sodium dihydrogen phosphate buffer
adjusted to pH 7.5 with 1M NaOH and filtered through a 0.2 µm membrane filter.
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2.2.3.4 Electrophoretic procedure
Before the first use, the capillary was conditioned by flushing with 1M NaOH for 90 min,
then with water for 30 min and BGE for 30 min at 0.5 psi pressure. At the beginning of each
working day, the capillary was rinsed with 0.1M NaOH for 10 min, water for 5 min and then
with BGE for 5 min at 20 psi pressure. Before each injection, the capillary was preconditioned
with 0.1M NaOH (5 min), water (5 min) and BGE (5 min) at 20 psi pressure to maintain proper
reproducibility of run-to-run injections. Injection was carried out under hydrodynamic pressure
at 0.5 psi for 3 s. A diode-array UV detector was set at 230 nm with a bandwidth of 20 nm. The
capillary temperature was kept constant at 25 ◦C and a voltage of 15 kV was applied.
2.2.3.5 Procedures
2.2.3.5.1 Construction of the calibration graphs

Accurate aliquots of VAL stock solution as well as AML and HCZ working solutions
were transferred into a series of 4-mL vials so that the final concentrations were in the range of
10-200 µg mL-1 for VAL, 2-20 µg mL-1 for AML and 2-20 µg mL-1 for HCZ. A constant 100µL
IS stock solution was added and the volume was diluted to 4 mL with 10% methanol. The peak
area ratio (peak area of the studied drug/ peak area of IS) was plotted versus the final
concentration of each drug in µg mL-1 to get the calibration graphs. Alternatively, the
corresponding regression equations were derived.
2.2.3.5.2 Analysis of VAL/AML/HCZ laboratory prepared mixture

Accurate aliquots of VAL stock solution as well as AML and HCZ working solutions
keeping the pharmaceutical ratio of 12.8:1.1:1 were transferred into a series of 4-mL vials,
diluted with 10% methanol after addition of 100µL IS and mixed well. The above procedure
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described under "section 2.5.1" was then applied. The percentage recoveries were calculated
using the corresponding regression equations.
2.2.3.5.3 Analysis of the studied drugs in their co-formulated tablets

Ten tablets of Exforge HCT® 160-10-12.5 were weighed and then crushed to a fine
powder. An accurately weighed amount of the finely powdered tablets, equivalent to 50.00 mg
VAL, 4.30 mg AML and 3.91 mg HCZ, was transferred to 25 mL volumetric flask. Twenty
milliliters of methanol were added and the solution was sonicated for 30 min. The solution
was completed to volume with the same solvent and then filtered through Whatman filter
paper and filtered again using 0.2 µm Whatman inorganic membrane filter. For analysis,
different aliquots from the prepared sample solution, spiked with 100 µL IS stock solution, were
diluted to 4 mL using 10% methanol. The above procedure described under "section 2.5.1" was
then applied. The percentage recoveries were calculated by referring to the corresponding
regression equations.
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Table 2.2.1 Accuracy and precision data for the determination of VAL, AML and HCZ by the
proposed CZE method

a

Concentration of

Intra-day assay

Inter-day assay

Comparison method

VAL (g mL-1)

Recovery % ± S.D a

Recovery % ± S.D a

Recovery %

32.00

101.42 ± 1.40

100.90 ± 0.57

98.04

96.00

99.44 ± 0.32

100.26 ± 1.16

100.64

128.00

99.38 ± 1.35

99.71 ± 1.60

98.66

Mean ± S.D.

100.08 ± 1.16

100.29 ± 0.60

99.11 ± 1.36

Student t test

0.94 (2.78)

1.38 (2.78)

F

1.37 (19.00)

5.21 (19.00)

Concentration of

Intra-day assay

Inter-day assay

Comparison method

AML (g mL-1)

Recovery % ± S.D a

Recovery % ± S.D a

Recovery %

2.75

101.60 ± 1.71

99.63 ± 2.96

102.20

8.25

99.56 ± 2.05

99.56 ± 2.48

99.70

13.75

101.52 ± 0.59

100.54 ± 1.49

100.09

Mean ± S.D.

100.89 ± 1.16

99.91 ± 0.55

100.66 ± 1.35

Student t test

0.23 (2.78)

0.89 (2.78)

F

1.37 (19.00)

6.10 (19.00)

Concentration of

Intra-day assay

Inter-day assay

Comparison method

HCZ (g mL-1)

Recovery % ± S.D a

Recovery % ± S.D a

Recovery %

2.50

100.31 ± 0.88

98.84 ± 1.35

100.28

7.50

100.84 ± 0.59

99.96 ± 0.78

99.77

12.50

99.65 ± 0.89

100.94 ± 1.16

100.07

Mean ± S.D.

100.27 ± 0.60

99.91 ± 1.05

100.04 ± 0.26

Student t test

0.60 (2.78)

0.20 (2.78)

F

5.26 (19.00)

16.33 (19.00)

Mean and standard deviation of three determinations
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Table 2.2.2 Assay results for the determination of the studied drugs in Exforge HCT®
160/10/12.5 mg tablets
Proposed method

Compound

VAL

Amount taken
(g mL-1)
32.00
64.00
96.00
128.00
160.00

Amount found
(g mL-1)
32.26
64.97
97.42
127.64
163.18

Comparison method
Recovery %

100.80
101.52
101.48
99.72
101.99
Mean ± S.D.
101.10 ± 0.88
Student t test
2.21 (2.31)
F
1.30 (6.39)
AML
2.75
2.82
102.59
5.50
5.58
101.55
8.25
8.35
101.21
11.00
11.03
100.30
13.75
13.96
101.52
Mean ± S.D.
101.43 ± 0.82
Student t test
2.26 (2.31)
F
2.82 (6.39)
HCZ
2.50
2.57
102.96
5.00
5.07
101.37
7.50
7.63
101.72
10.00
10.06
100.57
12.50
12.84
102.71
Mean ± S.D.
101.87 ± 0.98
Student t test
2.13 (2.31)
F
4.15 (6.39)
Each result is the average of three separate determinations.
The values between parentheses are the tabulated t and F values at P = 0.05.

Recovery %
99.41
99.28
101.58
99.32
99.32
99.78 ± 1.01

97.93
99.95
101.78
99.97
99.45
99.82 ± 1.38

97.20
99.52
102.67
100.34
99.00
99.75 ± 2.00
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Table 2.2.3 Effect of detection wavelength on VAL, AML, HCZ and IS: (16 g mL-1 of AML,
16 g mL-1 of HCZ, 160 g mL-1 of VAL and 100 g mL-1 of IS)

Peak Area

Peak Area Ratio to IS

Wavelength (nm)
AML

HCZ

VAL

IS

AML

HCZ

VAL

203

66265 146077 1841391 365774 0.181

0.399

5.034

210

52578 109062 1825075 363935 0.144

0.300

5.015

220

32218 134227 1489437 258277 0.125

0.520

5.767

230

27050 148232 1048758 124057 0.218

1.195

8.454

240

27816

82551

769974

65863

0.422

1.253

11.691

250

25836

26766

621544

76513

0.388

0.350

8.123

260

17552

35390

562031

170272 0.103

0.208

3.301
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Table 2.2.4 Performance data for the determination of the studied drugs by the proposed CZE
method
Parameter

VAL

AML

HCZ

Linearity range (µg mL-1)

10-200

2-20

2-20

Intercept (a)

-0.0837

-0.0047

0.0154

Slope (b)

0.0637

0.0123

0.0453

Correlation coefficient (r)

0.9999

0.9998

0.9995

S.D. of residuals (Sy/x)

0.052

0.002

0.0114

S.D. of intercept (Sa)

0.035

0.001

0.0089

S.D. of slope (Sb)

0.0004

0.0001

0.0007

% RSD

3.362

3.357

3.164

% Error

1.368

1.380

1.304

LOD (µg mL-1)

1.819

0.385

0.647

LOQ (µg mL-1)

5.513

1.166

1.960
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Table 2.2.5 Assay results for the determination of the studied drugs in pure form by the CZE and
reference methods

Compound

VAL

Mean ± S.D.
Student t test
F
AML

Mean ± S.D.
Student t test
F
HCZ

Reference
method

Proposed method
Amount taken
(g mL-1)
32.00
64.00
96.00
128.00
160.00

Amount found
(g mL-1)
31.942
64.124
95.129
128.190
158.834

2.75
5.50
8.25
11.00
13.75

2.740
5.585
8.309
11.033
13.902

2.50
5.00
7.50
10.00
12.50

2.552
4.936
7.519
9.815
12.442

Recovery %

Recovery %

99.82
100.19
99.09
100.15
99.27
99.70± 0.50
1.17 (2.31)
2.56 (6.39)
99.63
101.55
100.71
100.30
101.11
100.66± 0.74
0.97 (2.31)
4.61 (6.39)
102.08
98.72
100.25
98.15
99.53
99.74± 1.53
1.02 (2.31)
1.57 (6.39)

99.78
100.47
99.98
99.68
100.16
100.01± 0.32

Mean ± S.D.
Student t test
F
Each result is the average of three separate determinations.
The values between parentheses are the tabulated t and F values at P = 0.05.

100.07
97.69
102.13
100.11
99.52
99.90± 1.59

99.48
102.02
101.44
100.99
99.25
100.64± 1.22
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Figure 2.2.1 The structural formulae for the studied drugs; (a) valsartan (VAL), (b) amlodipine
besylate (AML), (c) hydrochlorothiazide (HCZ) and (d) Pyrazinoic acid (IS)

148

Figure 2.2.2 Typical electropherogram for a laboratory prepared mixture; (a) 11 µg mL-1 AML,
(b) 10 µg mL-1 HCZ, (c) 128 µg mL-1 VAL and (d) 100 µg mL-1 IS under the described
electrophoretic conditions
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Figure 2.2.3 Application of the proposed method for the simultaneous determination of VAL,
AML and HCZ in their co-formulated tablets; (a) 11 µg mL-1 AML, (b) 10 µg mL-1 HCZ, (c) 128
µg mL-1 VAL and (d) 100 µg mL-1 IS under the described electrophoretic conditions
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Figure 2.2.4 Effect of phosphate buffer pH; operating conditions: 40mM phosphate buffer,
injection (3 s), 15 kV, 25 ◦C, 210 nm (bandwidth 20 nm). (12 g mL-1 AML, 30 g mL-1 HCZ,
192 g mL-1 VAL and 100 g mL-1 IS)
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Figure 2.2.5 Effect of phosphate buffer concentration.
Operating conditions: pH 7.5 phosphate buffer, injection (3 s), 15 kV, 25 ◦C, 210 nm (bandwidth
20 nm). (12 g mL-1 AML, 30 g mL-1 HCZ, 192 g mL-1 VAL and 100 g mL-1 IS)
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Figure 2.2.6 Effect of injection time.
Operating conditions: pH 7.5 phosphate buffer, injection (3 s), 15 kV, 25 ◦C, 210 nm (bandwidth
20 nm). (12 g mL-1 AML, 30 g mL-1 HCZ, 192 g mL-1 VAL and 100 g mL-1 IS)
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Figure 2.2.7 Selection of the detection wavelength.
Operating conditions: 40mM phosphate buffer, pH 7.5, injection (3 s), 15 kV, 25 ◦C. (16 g mL-1
AML, 16 g mL-1 HCZ, 160 g mL-1 VAL and 100 g mL-1 IS)
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2.3

Simultaneous determination of aliskiren hemifumarate, amlodipine besylate, and
hydrochlorothiazide in their triple mixture dosage form by capillary zone
electrophoresis

Copyright © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Journal of Separation Science (2014) 37(9-10):1206-1213
DOI 10.1002/jssc.201301140

A novel, specific, reliable and accurate capillary zone electrophoresis (CZE) method was
developed and validated for the simultaneous determination of aliskiren hemifumarate (ALS),
amlodipine besylate (AML) and hydrochlorothiazide (HCZ) in their triple mixture dosage form
AMTURNIDE®. Separation was carried out in fused silica capillary (57.0 cm total length and
50.0 cm effective length, 75.6 µm i.d.) by applying a potential of 17 KV (positive polarity) and a
running buffer consisting of 40 mM phosphate buffer at pH 6.0 with UV detection at 245 nm.
The samples were injected hydrodynamically for 2 s at 0.5 psi and the temperature of the
capillary cartridge was kept at 25 °C. Meoxipril (MXP) was used as internal standard (IS). The
method was suitably validated with respect to specificity, linearity, limit of detection and
quantitation, accuracy, precision, and robustness. The method showed good linearity in the
ranges of 1-10, 2.5-25 and 30-300 µg/mL with limits of detection of 0.11, 0.33 and 5.83 µg/mL
and limits of quantification of 0.33, 1.01 and 17.65µg/mL for AML, HCZ and ALS, respectively.
The proposed method was successfully applied for the analysis of the studied drugs in their
laboratory prepared mixtures and co-formulated tablets without any interfering peaks. The
estimated amounts of AML, HCZ and ALS were almost identical with the certified values, and
their percentage relative standard deviation values (%R.S.D.) were found to be ≤ 1.80% (n = 3).
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The results were compared to reference methods and no significant difference was found
statistically.
2.3.1. Introduction
Aliskiren hemifumarate (ALS), (2(S), 4(S), 5(S), 7(S)-N- (2-carbamoyl- 2- methylpropyl)
-5-amino-4-hydroxy2,7diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)

phenyl]

octanamide

hemifumarate) (Fig 2.3.1a) is the first direct renin inhibitor (DRI) suitable for oral administration
62

. ALS reduces baseline systolic and diastolic blood pressure (BP) by directly inhibiting the

catalytic activity of renin system at its rate-limiting step

62

. Therefore, ALS is used as a new

effective treatment for hypertension alone and extra antihypertensive activity can be achieved
when it is used in combination therapy

63

. Amlodipine besylate (AML), 2-[(2-

Aminoethoxy)methyl]-4-(2–chlorophenyl)-1,4–dihydro–6–methyl–3,5–pyridinedicarboxylic
acid 3–ethyl 5–methyl ester

64

(Fig 2.3.1b) is an oral dihydropyridine calcium channel blocker,

which acts only on the L-type channel to produce its pharmacological effect 65. Like most of the
second generation dihydropyridine derivatives, AML has greater selectivity for the vascular
smooth muscle than myocardial tissue and therefore their main effect is vasodilatation

66

. AML

is used alone or in combination with other medicines for the treatment of chronic stable angina
and in the management of mild-to-moderate essential hypertension

65

. Hydrochlorothiazide

(HCZ), 6-chloro-1, 1-dichloro-3, 4, dihydro -2H-1, 2, 4-benzoliadiazine-7-sulphanomide1, 1dioxide

64

(Fig 2.3.1c) is a potent oral thiazide diuretic and antihypertensive agent. HCZ affects

the renal tubular mechanisms of electrolytes reabsorption, directly increasing excretion of
sodium salt and chloride in approximately equivalent amount

67

. The ALS/AML/HCZ triple

combination therapy in patients with moderate to severe hypertension was well tolerated and
provided clinically significant BP reductions and effective BP control 68.
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Literature survey revealed several reported methods for the determination of ALS in
pharmaceutical preparation or biological fluids alone or in combination with other antihypertensive agents. These methods include HPLC
spectroflourimetry

77, 78

69-73

, CE 74, UV-spectrophotometry 75, 76 and

. Several methods have also been reported for the estimation of AML

alone or in combination with other anti-hypertensive agents such as HPLC
83

, UV-spectrophotometric41, 84, 85 and spectroflourimetric

86, 87

79-81

82

, CE

. For HCZ determination alone or

in combination with other anti-hypertensive agents, several methods like HPLC
97

, LC-MS

88-93

, LC-MS

94-

, UPLC 98 and UV- spectrophotometric 99 have been described.
Regarding ALS, AML and HCZ simultaneous analysis, only two RP-HPLC methods

101

100,

have been reported for the simultaneous determination of the triple mixture either in pure

form or in their co-formulated dosage form. Rao et al

100

described a RP-HPLC method for

determination of the drugs in their dosage form using C18 column and a complex mobile phase
consisting of acetonitrile: methanol: 50mM phosphate buffer( pH 3) in the ratio of 20:50:30%
v/v. Moreover, the linearity range of ALS practically will not allow proper simultaneous
determination of the three drugs in their co-formulated tablets. However, Selvakumar et al

101

reported a RP-HPLC method using 20 mM potassium dihydrogen phosphate buffer ( pH 6.5 ):
methanol: acetonitrile (55:10:35 v/v) as mobile phase for determination of the triple mixture in
pure form only. The samples were separated with poor sensitivity on C8 column within a long
run time of 16 min.
To the best of our knowledge, no CZE method has been yet described for the
simultaneous determination of ALS, AML and HCZ in their triple co-formulated dosage form.
The use of capillary electrophoresis (CE) methods for pharmaceutical analysis has
become increasingly popular in recent years. The wide range of pharmaceutical applications for
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which its use has proved successful, include assay of drugs, determination of drug-related
impurities, physicochemical measurements of drug molecules, chiral separation, and the analysis
of vitamins and pharmaceutical excipients. The advantages of using CE for pharmaceutical
analysis include its speed and low cost of analysis, reductions in solvent consumption and
disposal, and the possibility of rapid method development. CE also offers the possibility that a
single set of separation conditions can be applied for a wide range of analyses, giving efficiency
savings

6, 102

. Recently, CE techniques have been applied to the simultaneous determination of

co-formulated drugs in dosage form 3, 103.
The goal of this study is to develop and validate a reliable, accurate, inexpensive,
selective and sensitive method using capillary electrophoresis that could be applied to the routine
quality control analysis of ALS, AML and HCZ simultaneously in bulk drug samples and in
combined dosage formulation. The studied drugs; ALS, AML and HCZ, are co-formulated in a
medicinally recommended ratio of 23.9:1.0:1.8, respectively. Analysis of such mixture with
strong spectral overlapping is challenging. The proposed CZE method allowed the separation
and quantitation of the three drugs with satisfied accuracy and precision. The developed CZE
method has the advantages of being more simple, sensitive, accurate and faster for quality
control and routine analysis of ALS, HCZ and AML triple mixture in comparison with the
reported methods

100, 101

. Moreover, this method consumes no organic solvent so it can be

considered a green method.
2.3.2. Experimental
2.3.2.1. Instruments
The assay was developed and validated using a Beckman P/ACE 5510 system (Fullerton,
CA, U.S.A) equipped with an autosampler, a photodiode array (PDA) detector, a temperature
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controlling system (4 oC - 40 oC) and power supply able to deliver up to 30 KV. Beckman
P/ACETM station software (version 1.2) was used for the instrument control, data acquisition and
analysis. Electrophoretic analyses were performed in a fused silica capillary (Polymicro
Technologies, Phoenix, AZ, U.S.A) of 57.0-cm-long (50.0-cm effective length) and 75.6 µm i.d.
in normal mode, applying a voltage of 17 KV. The wavelength for analysis was 245 nm,
hydrodynamic injection of samples for 2 s under a pressure of 0.5 psi and the temperature of the
capillary cartridge was kept at 25 oC. The background running buffer (BRB) was filtered using
0.2 µm Anatop 25 Whatman inorganic membrane filter (Maidstone, England) and degassed
using Branson Ultrasonic 5510 degasser (Danbury, CT, U.S.A). A SympHonly (SB20) pH-meter
(Thermo Orion Beverly, MA, U.S.A) was used for pH measurements. Deionized water was
prepared using a Barnstead NANO pure DIamond Analytical (USA) ultrapure water system.
2.3.2.2. Materials and reagents
All the chemicals used were of Analytical Reagent grade, and the solvents were of HPLC
grade. Aliskiren hemifumarate (certified to contain 99.51%) was supplied by Novartis
Pharmaceuticals Corporation East, New Jersey, USA. Amlodipine besylate (certified to contain
99.75%) was kindly supplied by Global Nabi Co., Giza, Egypt. Hydrochlorotiazide (certified to
contain 99.93%) was supplied by AstraZeneca - Cairo, Egypt. Moexipril hydrochloride was
purchased from Sigma-Aldrich (Saint Louis, MO, USA) with labeled purity > 98%. Amturnide ®
300-10-25 mg tablets; batch # NDC 0078-0614-15 (Novartis Pharmaceuticals Corporation East,
New Jersey, USA 07936) were purchased from commercial sources in the USA market. Each
labeled to contain 331.5 mg aliskiren hemifumarate (equivalent to 300 mg aliskiren as a free
base), 13.87 mg amlodipine besylate (equivalent to 10 mg amlodipine as a free base) and 25 mg
hydrochlorothiazide, sodium hydroxide, acetic acid and sodium dihydrogen phosphate (J.T.
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Baker,NJ, U.S.A), orthophosphoric acid 85%, sodium acetate and boric acid (Fisher Scientific,
NJ, U.S.A), acetonitrile, methanol and ethanol (Sigma-Aldrich, MO, U.S.A) were used.
2.3.2.3. Standard and sample solutions
2.3.2.3.1. Standard solutions
Stock solutions 1.0 mg/mL of AML, HCZ, MXP and 4.0 mg/mL of ALS were prepared
by dissolving 25 mg of AML, HCZ, MXP and 100 mg of ALS separately in 25 mL of solvent
composed of methanol and water (10:90 v/v). Working solutions were prepared by further
dilution of the stock solutions with the same solvent to give a final desired concentration. The
solutions were stable for one week when kept in the refrigerator at 2 oC.
2.3.2.3.2. Background electrolyte (BGE)
Optimized BGE solution was 40 mM sodium dihydrogen phosphate buffer adjusted to pH
6 with 1 M NaOH 104 and filtered through a 0.2 µm membrane filter.
2.3.2.4. Electrophoretic procedure
Before the first use, the capillary was conditioned by flushing with 1.0 M NaOH for 60
min, then with water for 30 min and BGE for 30 min at 0.5 psi pressure. At the beginning of
each working day, the capillary was rinsed with 0.1 M NaOH for 10 min, water for 5 min and
then with BGE for 5 min at 20 psi pressure. Before each injection, the capillary was
preconditioned with 0.1 M NaOH (5 min), water (5 min) and BGE (5 min) at 20 psi pressure to
maintain proper repeatability of run-to-run injections. Injection was carried out under
hydrodynamic pressure at 0.5 psi for 2 s. PDA detector was set at 245 nm with a bandwidth of 20
nm. The capillary temperature was kept constant at 25 ◦C and a voltage of 17 kV was applied
(positive polarity).
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2.3.2.5. Procedures
2.3.2.5.1. Construction of calibration graphs
Aliquots of the suitable drug stock or working standard solutions were transferred into a
series of 4-mL vials so that the final concentrations were in the range of 1-10 µg/mL for AML,
2.5-25 µg/mL for HCZ and 30-300 µg/mL for ALS. A constant 100 µL MXP stock solution was
added (final concentration of 25 µg/mL) and the volumes were diluted to 4 mL with a solvent
composed of methanol and water (10:90 v/v). The peak area ratio (peak area of the studied drug/
peak area of MXP) was plotted versus the final concentration of each drug in µg/mL to get the
calibration graph. Alternatively, the corresponding regression equations were derived.
2.3.2.5.2. Analysis of the cited drugs separately
Aliquots of ALS, AML and HCZ standard solutions covering the working concentration
ranges were transferred into a series of 4-mL vials, diluted with a solvent composed of methanol
and water (10:90 v/v) after addition of 100 µL MXP and mixed well. The above procedure
described under "Construction of calibration graphs" was then applied. The percentages found
were calculated by referring to the calibration graphs, or using the corresponding regression
equations.
2.3.2.5.3. Analysis of ALS/AML/HCZ laboratory prepared mixtures
Aliquots of ALS, AML and HCZ standard solutions keeping the pharmaceutical ratio of
23.9:1.0: 1.8 m/m/m were transferred into a series of 4-mL vials, diluted with a solvent
composed of methanol and water (10:90 v/v) after addition of 100 µL MXP and mixed well. The
above procedure described under "Construction of calibration graphs" was then applied. The
percentages found were calculated by referring to the calibration graphs, or using the

161

corresponding regression equations.
2.3.2.5.4. Analysis of the studied drugs in Amturnide® co-formulated tablets
Ten tablets were weighed and finely pulverized after decoating by careful rubbing with a
clean tissue wetted with methanol. An accurately weighed amount of the fine powder (0.2748
gm) equivalent to 4.000 mg ALS, 0.167 mg AML and 0.301 mg HCZ was transferred to 10mL volumetric flask and 6 mL of a solvent composed of methanol and water (10:90 v/v) was
added. The flask was sonicated for 30 min and vortex mixing for 15 min by Fisher vortex
(Fisher Scientific), and then diluted to the mark with the same solvent. The solution was
filtered through Whatmann filter paper and then filtered again using 0.2 µm Whatmann
inorganic membrane filter. For analysis, appropriate aliquots from the prepared sample solution,
spiked with 100 µL MXP stock solution, was diluted to 4 mL using the same solvent. The above
procedure described under "Construction of calibration graphs" was then applied. The
percentages found were calculated by referring to the calibration graphs, or using the
corresponding regression equations. All solutions were filtered through a 0.2 µm membrane filter
and degassed for 5 min before injection to the CE system.
2.3.3. Results and discussion
The proposed method offered the separation and quantification of the studied drugs in
their co-formulated tablets in a single run (less than 7 min) with good resolution. Figure 2.3.2
shows a typical electropherogram for a synthetic mixture of the studied drugs under the
described electrophoretic conditions. The retention times for AML, ALS, HCZ and MXP were
4.2, 4.4, 5.4 and 6.8 min., respectively. A large peak width of HCZ and MXP compared to AML
and ALS was observed. The contributors to the peak width may be analyte wall interactions
(wall adsorption) and/or electromigration dispersion

105-107

. The proposed method offers good
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sensitivity as about 0.11 µg/mL of AML, 0.33 of HCZ and 5.83 µg/mL of ALS could be
detected.
2.3.3.1. Optimization of CE conditions
In CZE, the buffer type, pH and concentration is the key strategy for optimizing the
separation of ionizable analytes as it determines the degree of the analyte ionization, its
electrophoretic mobility and the magnitude of EOF. Several running buffers such as phosphate,
acetate and borate at different pHs and molarities were tested for CZE analysis and the best
results were obtained in phosphate buffer taking into consideration different parameters
(migration time, resolution, peak shape, height, baseline noise and the electric current produced).
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Figure 2.3.1 Typical electropherogram of synthetic mixture of 8 µg/mL of AML (4.2 min), 240
µg/mL ALS (4.4 min), 20 µg/mL HCZ (5.4 min) and 25 µg/mL MXP (6.8 min).
Operating conditions: 40 mM phosphate buffer (pH 6), injection (2 s at 0.5 psi), 17 kV, 25
◦

C, 245 nm (bandwidth 20 nm)
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2.3.3.1.1. Effect of phosphate buffer pH
The effect of the buffer pH was investigated within the range of 5.0–7.0 at a 40 mM
phosphate buffer concentration. The results demonstrated that the studied compounds were easily
separated in this pH range and both resolution and migration times decreased with increasing pH. At
pH less than 5, the separation of the sample matrix will take long time. At pH more than 7
overlapping of ALS peak with AML peak was noticed. pH 6.0 was selected as optimum pH as it
gave a good compromise regarding resolution, peak symmetry and migration time (Fig. 2.3.3). As
ALS has pKa value of 9.49 108, AML has pKa value of 8.6 109 and HCZ has pKa values 7.0 and 9.09 110,
111

, ALS and AML are positively charged at pH 6.0 and can be analyzed and separated from the

unionized HCZ by CZE. In fact, at this pH value HCZ neither underwent protonation nor deprotonation
and as such remained a neutral compound thus migrated with the EOF.
2.3.3.1.2. Effect of phosphate buffer concentration
Buffer concentration has also a significant effect on the separation performance through
its influence on the EOF and the current produced in the capillary. The effect of phosphate
concentration of running buffer was examined by varying the concentration from 10 to 50 mM.
As shown in Figure 2.3.4, with an increasing in phosphate concentration, both resolution and
migration times increased. A 40 mM concentration of phosphate buffer was chosen in order to
reduce the analysis time while maintaining good resolution (≈ 2.9, 8.8, 3.4, respectively) and
acceptable current (≈ 41µA).
2.3.3.1.3. Effect of organic modifiers
The addition of organic modifiers to the running buffer was considered because they
affect several parameters such as viscosity, dielectric constant and Zeta potential. In order to
investigate the effect of organic modifiers, methanol, ethanol and acetonitrile were added at
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various concentrations (5, 10 and 15% v/v) to the running background electrolyte of 40 mM
phosphate buffer pH 6.0. No appreciable improvements were observed, but migration times
increased significantly with the addition of organic modifiers. Therefore, no organic modifiers
were incorporated in the proposed analysis method (Fig. 2.3.5).
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Figure 2.3.2 Effect of phosphate buffer pH on separation of the studied drugs.
Operating conditions: 40 mM phosphate buffer, injection (2 s, 0.5 psi), 17 kV, 25 ◦C, 245 nm
(bandwidth 20 nm). Peak names and drugs conc.: are as given in Figure 2.3.1.
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Figure 2.3.3 Effect of phosphate buffer conc. on separation of the studied drugs.
Operating conditions: phosphate buffer (pH 6), injection (2 s, 0.5 psi), 17 kV, 25 ◦C, 245 nm
(bandwidth 20 nm). Peak names and drugs conc.: are as given in figure 2 and the produced
current (µA) is written.

(
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Figure 2.3.4 Effect of organic modifiers on separation of the studied drugs (A) methanol, (B)
ethanol, and (C) acetonitrile.
Operating conditions: 40 mM phosphate buffer (pH 6), injection (2 s, 0.5 psi), 17 kV, 25 ◦C, 245
nm (bandwidth 20 nm). Peak names and drugs conc.: are as given in figure 2.3.2.
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2.3.3.1.4. Effect of applied voltage
The applied voltage effect was investigated under the optimized conditions selected
above from 5 to 20 kV. As expected, increasing the applied voltage increases the EOF, leading to
shorter analysis time and higher efficiencies as shown in Figure 2.3.6. However, lowering the
applied voltage to less than 10 kV decreases the EOF so the time for separation was more than
20 min and increasing applied voltage to more than 20 kV exhibited higher currents and
produced Joule’s heating. To limit this heating inside the capillary, the maximum applied voltage
was chosen from an Ohm’s plot (current vs voltage). The selected voltage was 17 kV (current (≈
41 µA).
2.3.3.1.5. Effect of injection time
Injection time affects the peak width and peak height. Sample solutions were
hydrodynamically injected at 0.5 psi while the injection time was varied from 1.0 to 5.0 s. After
3.0 s, the peak widths of the studied compounds were increased and the peak shapes were
deformed, so 2.0 s was selected as the optimum injection time (Fig. 2.3.7).
2.3.3.1.6. Effect of capillary cartridge temperature
Controlling the temperature of the capillary cartridge is important in capillary
electrophoresis. The viscosity of the running buffer is dependent on capillary temperature, so
changes in temperature cause changes in EOF, electrophoretic mobilities and injection volume.
The influence of the temperature on analysis was investigated at 20, 25 and 30 ◦C. As shown in
Figure 2.3.8, the selected temperature was 25 ◦C because it provided the best resolution and the
generated current was not more than 42 µA.
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Figure 2.3.5 Effect of applied voltage (kV) on separation of the studied drugs.
Operating conditions: 40 mM phosphate buffer (pH 6), injection (2 s, 0.5 psi), 25 ◦C, 245 nm
(bandwidth 20 nm). Peak names and drugs conc.: are as given in figure 2.3.2.
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Figure 2.3.6 Effect of injection time (sec.) on separation of the studied drugs.
Operating conditions: 40 mM phosphate buffer (pH 6), 17 kV, 25 ◦C, 0.5 psi, 245 nm (bandwidth
20 nm). Peak names and drugs conc.: are as given in figure 2.32.
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Figure 2.3.7 Effect of capillary cartridge temperature (◦C) on separation of the studied drugs.
Operating conditions: 40 mM phosphate buffer (pH 6), 17 kV, 2 sec, 0.5 psi, 245 nm (bandwidth
20 nm). Peak names and drugs conc.: are as given in figure 2.3.2.
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2.3.3.1.7. Selection of internal standard (IS)
The use of IS is recommended to compensate for injection errors, minor fluctuations
effect of the migration time and improve the quantitative analysis. Then MXP was chosen as it
possesses pka value of 5.4

112

and its molar mass is high (535.03 g/mol) so it will be negatively

charged under the optimized condition and as expected it eluted after HCZ 11.
2.3.3.1.8. Selection of the detection wavelength
In order to optimize sensitivity and detection limit of the method, a multi wavelength
detection system (190–300 nm) was used in the CE system. For the simultaneous determination
of the triple mixture, the maximum detection sensitivities were obtained at 245 nm (bandwidth
20 nm). Figure 2.3.9 shows the effect of detection wavelength on the proposed CZE method.
Optimum electrophoretic conditions for the CZE determination of the studied drugs are
summarized in Table 2.3.1. At 5.4 minutes on the electropherogram (Fig. 2.3.2), this distinct
wide CE peak corresponds to the migration time of HCZ (neutral analyte at pH 6.0) which also
corresponds to the EOF. The electroosmotic mobility (μeof), apparent mobility (μa) and effective
mobility (μe) was calculated and the data were abridged in Table 2.3.2. The subsequent apparent
mobility (μap) of HCZ is determined to be 5.2 × 10-4 cm2/Vs (the electroosmotic mobility (μeof))
and its effective mobility (μe) is equal to zero as it is neutral compound under the optimized
conditions.

On the other hand, AML retained overall positive charge under the operating

conditions and thus is first to be eluted in the CZE process (the small positive ion migrated the
fastest). ALS also retained overall positive charge and migrate with different mobility rate than
AML according to charge-to-size ratio. MXP (IS) at pH 6.0 becomes negatively charged and
migrated eventually towards the cathode due to the higher force of EOF. Negatively charged
species exhibit higher migration time and consequently negative effective mobilities.
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Figure 2.3.8 Selection of the detection wavelength.
Operating conditions: Operating conditions: 40mM phosphate buffer (pH 6), injection (2 s, 0.5
psi), 17 kV, 25 ◦C. Peak names and drugs conc.: are as given in figure 2.3.2.
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Table 2.3.1 Typical electrophoretic conditions for the CZE determination of the studied drugs
Fused silica capillary
Capillary

(57.0 cm total length and 50.0 cm effective length, 75.6 µm id)

BGE

40 mM phosphate buffer at pH 6.0

Applied Voltage

Normal (positive) polarity, + 17 kV

Detector

DAD at 245 nm

Bandwidth

20 nm

Sample Injection

Hydrodynamic injection for 2 s under a pressure of 0.5 psi

capillary Cartridge Temperature

25 oC

Sample Solvent

Methanol and water (10:90 v/v).
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Table 2.3.2 Mobilities and migration times of the studied compounds using CZE
Analyte

Average
Migration time
(s)

Electroosmotic
mobility (μeof)

Apparent
mobility (μa)

Effective
mobility (μe)

(× 10-4 cm2/ Vs)

(× 10-4 m2/Vs)

(× 10-4 cm2/ Vs)

EOF

324

5.2

AML

252

6.7

1.5

ALS

264

6.4

1.2

HCZ

324

5.2

0

MXP

408

4.1

-1.1
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2.3.3.2. Validation
Validation of the proposed CZE method was performed with respect to linearity and
range, specificity, limit of detection, limit of quantitation, accuracy, precision and robustness
according to the ICH Guidelines 113
2.3.3.2.1. Linearity and Range
A linear relationship was established by plotting the peak area ratio (the studied drug
peak area / IS peak area) against the drug concentration in µg/mL as shown in Figures 2.3.102.3.12. The concentration ranges were found to be linear in the range of 1-10 µg/mL, 2.5-25
µg/mL and 30-300 µg/mL for AML, HCZ and ALS, respectively. Linear regression analysis of
the data gave the following equations:
P = 0.0110 C - 0.0009

(r=0.9999)

for AML

P = 0.0203 C + 0.1298

(r=0.9999)

for HCZ

P = 0.0122 C + 0.0846

(r=0.9998)

for ALS

Where: P is the peak area, C is the concentration of the drug in µg/mL and r is the
correlation coefficient.
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Figure 2.3.9 Calibration curve for the CZE determination of ALS
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Figure 2.3.10 Calibration curve for the CZE determination of AML.
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Figure 2.3.11 Calibration curve for the CZE determination of HCZ.
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The statistical analysis of the data 114 gave high values of the correlation coefficient (r) of
the regression equations, small values of the standard deviation of residuals (Sy/x),
of intercept (Sa), and of slope (Sb), and small values of the percentage relative standard deviation
and the percentage relative error (Table 2.3.3). These data proved the linearity of the calibration
graphs and indicated the high accuracy and precision of the proposed method.
2.3.3.2.2. Limit of Detection (LOD) and Limit of Quantitation (LOQ)
LOQ and LOD were calculated according to ICH Q2R1 recommendations using the
following equations 113:
LOQ = 10 Sa /b and LOD = 3.3 Sa /b
Where Sa = standard deviation of the intercept and b = slope of the calibration curve.

The limit of quantitation (LOQ) was determined by establishing the lowest concentration
that can be measured and below which the calibration graph is nonlinear. The limit of detection
(LOD) 115 115 115 [238] [225] was determined by establishing the minimum level at which the
analyte can be reliably detected. LOQ values were found to be 0.33, 1.01 and 17.65 µg/mL
while, LOD values were found to be 0.11, 0.33 and 5.83 µg/mL for AML, HCZ and ALS,
respectively. The results are shown in Table 2.3.3.
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Table 2.3.3 Performance data for the determination of the studied drugs by the proposed CZE
method
AML

HCZ

ALS

1-10

2.5-25

30-300

Intercept (a)

-0.0009

0.1298

0.0846

Slope (b)

0.0110

0.0203

0.0122

Correlation coefficient (r)

0.9999

0.9999

0.9998

S.D. of residuals (Sy/x)

0.0005

0.0026

0.0277

S.D. of intercept (Sa)

0.0004

0.0021

0.0215

S.D. of slope (Sb)

0.0001

0.0002

0.0001

Percentage relative standard deviation, % RSD

0.79

0.67

0.80

Limit of detection, LOD (µg/mL)

0.11

0.33

5.83

Limit of quantitation, LOQ (µg/mL)

0.33

1.01

17.65

Parameter

Linearity and range (µg/mL)
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2.3.3.2.3. Accuracy
To prove the accuracy of the proposed method, the results of the assay of ALS, AML and
HCZ, both in pure form and in pharmaceutical preparations were compared with those of the
comparison method

116

. Statistical analysis

114

of the results using Student's t-test and variance

ratio F-test revealed no significant difference between the performance of the two methods
regarding the accuracy (Tables 2.3.4 - 2.3.6). The comparison method 116 depends on the analysis
of ALS, AML and HCZ triple mixture by ion-pair LC using C18 column, acetonitrile: 25 mM
octane sulphonic acid sodium salt monohydrate (60: 40 v/v) as the mobile phase and UV
detection at 232 nm.
2.3.3.2.4. Precision
2.3.3.2.4.1. Repeatability
Intra-day precision (repeatability) was performed through replicate analysis of three
concentrations of the studied drugs in pure forms on three successive times (Table 2.3.7).
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Table 2.3.4 Assay results for the determination of the studied drugs in pure forms by the CZE
and comparison methods
Comparison method
(HPLC) 116

Proposed method
Compound
AML

Amount taken
(g/mL)
1.00
2.00
4.00
6.00

Amount found
(g/mL)

% Found

% Found

0.990
1.990
3.990
6.080

99.00
99.55
99.78
101.4

100.7
99.78
99.34
100.4

8.00
10.0

7.990
9.990

99.89
99.91
99.92± 0.79
Mean ± S.D.
0.28 (2.31)
t
1.73 (9.01)
F
HCZ
2.50
2.490
99.68
5.00
4.950
99.00
10.0
10.10
100.7
15.0
15.10
100.6
20.0
20.10
100.4
25.0
24.90
99.64
100.0± 0.67
Mean ± S.D.
0.04(2.31)
t
1.50 (5.41)
F
ALS
30.0
30.00
100.1
60.0
60.20
100.3
120
120.5
100.5
180
181.8
101.1
240
237.1
98.79
300
302.7
100.9
100.3± 0.81
Mean ± S.D.
0.26(2.31)
t
1.27 (5.41)
F
N.B. Each result is the average of three separate determinations.
The values between parentheses are the tabulated t and F values at P = 0.05 114.

100.1± 0.60

100.0
99.22
101.1
99.57

99.98± 0.82

101.2
99.14
99.66
100.5

100.1± 0.91
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Table 2.3.5 Assay results for the determination of the studied drugs in their laboratory prepared
mixture and comparison methods

Ratio

Proposed method

Compound
Amount taken
(g/mL)
3.14
7.50
10.0

Amount found
(g/mL)
3.150
7.500
10.01

% Found

% Found

100.29
99.97
100.06

100.52
99.35
100.24

Mean ±
S.D.
% RSD

100.11± 0.17

100.04± 0.61

t
F
HCZ

0.22 (2.36)
1.68 (19.29)
99.26
101.58
100.27

99.18
100.84
99.71

Mean ±
S.D.
% RSD

100.37± 1.17

99.91± 0.85

t
F
ALS

0.18(2.36)
1.62 (5.79)
98.59
99.27
99.61

98.63
101.05
99.82

99.16± 0.52

99.83± 2.21

AML

AML: HCZ: ALS
1.0 : 1.8: 23.9 m/m/m

Comparison
method 116

Mean ±
S.D.
% RSD

0.17

5.65
13.5
18.0

5.610
13.71
18.05

1.16

75.0
179
239

73.94
177.9
238.0

0.52

0.65(2.36)
t
2.27 (5.79)
F
N.B. Each result is the average of three separate determinations.
The values between parentheses are the tabulated t and F values at P = 0.05 114.
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Table 2.3.6 Assay results for the determination of the studied drugs in their co-formulated tablets
and comparison methods.

Dosage
Form

Proposed method

116

Compound

AML

Amount
taken
(g/mL)
3.14
7.50
10.0

Amount
found
(g/mL)
3.180
7.500
10.10

Mean ±
S.D.
% RSD

AMTURNIDE® 300-10-25 mg tabletsb

Comparison
method (HPLC)

t
F
HCZ

5.65
13.5
18.0

5.720
13.60
17.70

Mean ±
S.D.
% RSD
t
F
ALS

Mean ±
S.D.
% RSD

75.0
179
239

75.10
182.0
242.0

% Founda

% Founda

101.2
99.98
101.1
100.75±
0.67
0.67

98.88
100.86
99.85

0.09 (2.36)
1.56 (5.79)
101.3
100. 9
98.4
100.2±
1.59
1.58
0.05(2.36)
15.29
(19.29)
100.1
101.8
101.2
101.1±
0.85
0.84

99.86± 0.99

99.82
100.2
99.97
99.98± 0.17

99.28
101.6
99.32
100.1± 1.32

t
0.29(2.36)
F
2.68 (5.79)
a
Each result is the average of three separate determinations.
b

Labeled to contain 331.5 mg aliskiren hemifumarate (equivalent to 300 mg aliskiren as a free

base), 13.87 mg amlodipine besylate (equivalent to 10 mg amlodipine as a free base) and 25 mg
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hydrochlorothiazide; manufactured by Novartis Pharmaceuticals Corporation East, NJ, USA;
batch # NDC 0078-0614-15. Nominal contents of AML = 10.07 mg as free base, of HCZ =
25.05 mg as free base and of ALS = 303.30 mg as free base per tablet.The values between
parentheses are the tabulated t and F values at P = 0.05 114.
2.3.3.2.4.2. Intermediate Precision
Inter-day precision (Intermediate precision) was assessed using three concentrations of
the studied drugs in pure forms and three replicates of each concentration on three successive
days. The results are summarized in Table 2.3.7. The relative standard deviations and percentage
relative errors were found to be very small indicating excellent repeatability and intermediate
precision of the proposed method.
2.3.3.2.5. Robustness
The robustness of the proposed method was evaluated by the constancy of the peak area
ratio with the deliberated changes in the experimental parameters; these parameters include
(phosphate buffer pH 6.0 ± 0.2, Phosphate buffer concentration 40 ± 5 mM, applied voltage 17 ±
2 kV and capillary cartridge temperature 25 ± 2 ◦C). Analyses were carried out in triplicate and
only one parameter was changed in the experiments at a time. These changes didn’t greatly affect
the peak area ratio and migration times of the studied drugs (Table 2.3.8).
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Table 2.3.7 Precision data for the determination the studied drugs by the proposed CZE method
AML concentration

HCZ concentration

ALS concentration

(g/mL)

(g/mL)

(g/mL)

Parameters

Amount
founda

3.14

7.50

10.00

5.65

13.50

18.00

75.00

179.25 239.00

3.17

7.41

9.96

5.72

13.51

17.87

75.02

178.68 239.60

3.11

7.57

10.21

5.65

13.63

17.97

75.72

179.36 242.08

3.16

7.63

10.14

5.62

13.72

17.67

74.92

180.95 243.71

100.90

99.10

100.29 100.23 101.17

Inter-day

Intra-day

(g/mL)

a

(x )

100.18

±S.D.

1.05

1.50

1.29

0.87

0.79

0.85

0.59

0.65

0.87

%RSD

1.05

1.49

1.28

0.87

0.78

0.86

0.58

0.65

0.86

3.21

7.42

10.09

5.66

13.85

18.12

75.97

181.56 239.60

Amount
founda

3.11

7.49

9.81

5.74

13.65

18.25

76.56

180.49 244.64

(g/mL)

3.18

7.68

9.97

5.62

13.63

17.98

75.22

177.58 243.73

(x )

100.83

100.40

99.57

100.43

101.54

100.64 101.22 100.35 101.53

±S.D.

1.48

1.80

1.41

1.14

0.88

0.76

0.89

1.15

1.13

%RSD

1.47

1.80

1.41

1.13

0.87

0.75

0.88

1.14

1.11

100.47 101.03 100.26

Each result is the average of three separate determinations

189

Table 2.3.8 Robustness data for the determination the studied drugs by the proposed CZE
method
Migration times

Peak area ratios

(min.)

Parameters
AML

ALS

HCZ

AML

ALS

HCZ

Optimized condition

4.20

4.40

5.40

0.066

2.976

0.538

5.82

4.33

4.51

5.59

0.065

2.961

0.534

6.21

4.05

4.25

5.15

0.067

2.979

0.538

35

4.10

4.25

5.20

0.064

2.969

0.537

45

4.25

4.80

5.55

0.069

2.994

0.528

15

4.76

4.98

6.13

0.076

2.606

0.524

20

3.46

3.62

4.43

0.076

2.645

0.561

23

4.40

4.65

5.83

0.068

2.805

0.537

27

4.08

4.25

4.95

0.066

2.928

0.585

Buffer pH

Buffer
concocentration (mM)

Applied
voltage (kV)

Capillary
temp. (oC)

N.B. Each result is the average of three separate determinations.
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2.3.3.2.6. Specificity
The specificity of the method was investigated by observing any interference encountered
from common tablet excipients and it was confirmed that the signals measured was caused only
by the analytes. Each film-coated tablet of Amturnide® contains the following inactive
ingredients: colloidal silicon dioxide, crospovidone, hypromellose, iron oxide red, iron oxide
yellow, iron oxide black, magnesium stearate, microcrystalline cellulose, polyethylene glycol,
povidone, talc, and titanium dioxide. It was found that these compounds did not interfere with
the results of the proposed method. As shown in Figures 2.3.13, 2.3.14 the tablets did not show
any additional peak when compared to the synthetic mixture electropherogram which confirm
the specificity of the method (Table 2.3.6).
2.3.3.3. Analysis of AML, HCZ and ALS in laboratory prepared mixtures and co-formulated
tablets
The proposed CZE method was applied to the simultaneous determination of AML,
HCZ and ALS in laboratory prepared mixtures in the medicinally recommended ratio of 1.0:
1.8: 23.9 m/m/m, respectively (Fig. 2.3.13). Furthermore, the proposed method was successfully
applied to their determination in co-formulated tablets (Fig. 2.3.14). The average percent found
of different concentrations were based on the average of three replicate determinations. The
results shown in Tables 2.3.5,2.3.6 are in good agreement with those obtained using a
. Statistical analysis of the results obtained using Student’s t-test and

comparison method

116

variance ratio F-test

114

revealed no significant difference between the performance of the two

methods regarding the accuracy and precision, respectively.
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Figure 2.3.12 Application of the proposed method for the simultaneous determination of a
laboratory prepared mixture of 8 g/mL of AML, 240 g/mL ALS, 20 g/mL HCZ and 25
g/mL MXP (IS).
Operating conditions: 40mM phosphate buffer (pH 6), injection (2 s, 0.5 psi), 17 kV, 25 ◦C and
DAD at 245 nm (bandwidth 20)

192

mAU
12000

ALS

11000
10000
9000
8000
7000
6000
5000

AML

4000

HCZ

3000

IS

2000
1000
0
0

0.5

1

1.5

2

2.5

3

3.5

4

4.5

5

5.5

6

6.5

7

7.5

8

8.5

9

9.5 10

Time, min

Figure 2.3.13 Application of the proposed method for the simultaneous determination of the
studied drugs in Amturnide® tablets (7.5 g/mL of AML, 179.25 g/mL ALS, 13.5 g/mL HCZ
and 25 g/mL MXP; IS).
Operating conditions: 40 mM phosphate buffer (pH 6), injection (2 s, 0.5 psi), 17 kV, 25 ◦C and
DAD at 245 nm (bandwidth 20)
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2.4 Conclusions
In section 2.2, a new, simple, accurate, selective and validated CZE method was
developed for the simultaneous determination of VAL, AML and HCZ in ternary mixture. The
proposed method has distinct advantages regarding reliability, selectivity and operation cost.
LOD of 1.82, 0.39, 0.65 µg mL-1 and LOQ of 5.51, 1.17, 1.96 µg mL-1 for VAL, AML and HCZ,
respectively were obtained. Moreover, this method was successfully applied for the analysis of
the three medications in their laboratory prepared mixtures and co-formulated tablets.
In section 2.3, a novel, simple, accurate and precise CZE method was explored for the
simultaneous determination of AML, HCZ and ALS in triple mixture. The developed method has
distinct advantages regarding analysis time, sensitivity and cost compared with those of the
previously reported methods. Limits of detection of 0.11, 0.33 and 5.83 g/mL and limits of
quantitation of 0.33, 1.01 and 17.65 g/mL for AML, HCZ and ALS, respectively were obtained.
The good validation criteria of the proposed method allow its utilization for quality control
laboratories. In addition, it is a good analytical tool for the simultaneous analysis of the studied
drugs in their co-formulated tablets. Moreover, the analysis of the same therapeutic class drugs in
a single run has the advantage of a unique sample extraction procedure and a shorter analytical
run, thus reducing the overall turnaround time. In addition, this method consumes no organic
solvents and thus it can be classified as green chemistry.
Finally, the proposed methods can be used for the quality control of the cited drugs in
ordinary laboratories.
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3 SPECTROMETRIC DETERMINATION OF SOME SELECTED
PHARMACEUTICAL COMPOUNDS
3.1 Introduction
Fluorescence spectrometry, by virtue of its great inherent sensitivity, finds wide applications
in quantitative studies of rates of degradation, metabolism and excretion of drugs where other
analytical techniques are not sufficiently sensitive 1. The two main advantages of fluorimetric
analysis are that, it is capable of measuring much lower concentrations than spectrophotometric
analysis, and that it is potentially more selective because both the excitation and emission
wavelengths can be varied and because not every compound fluoresce. Moreover, measuring the
synchronous fluorescence spectra of analytes with overlapping emission spectra can help also to
increase the selectivity of the spectrfluorimetric technique 2. Fluorimetric analysis is typically
sensitive down to 10-8 to 10-9 M concentration, depending on the intensity of the excitation
source, the quantum efficiency and molar absorptivity of the analyte 3.
Different compounds can be assayed fluorimetrically by procedures utilizing, either their
inherent fluorescence or the fluorescence of suitable derivatives of them. The most important
application of fluorimetry is in the analysis of pharmaceuticals, clinical samples, food products,
and natural products. The sensitivity and selectivity of the method make it a particularly valuable
tool in these fields. Moreover, several inorganic species can be determined fluorometrically
based on either direct formation of fluorescent chelates or the measurement of the decrease in
fluorescence intensity due to the quenching action of the substance being determined 4.
Fluorescence techniques are based on the measurement of emitted photons of an excited
analyte. Fluorescence can be enhanced by increasing the radiative rate of a molecule. In
particular, shielding the fluorescent molecule from quenching impurities and/or solvent
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molecules can be used to achieve this enhancement. Surfactant organized assemblies such as
micelles, reversed micelles, and microemulsions have been used extensively to enhance the
fluorescence. It is well known that the addition of a surfactant at a concentration above its critical
micellar concentration to a given fluorophore solution increases the molar absorptivity and/or the
fluorescence quantum yield of the fluorophore 5, 6.
The enhanced fluorescence in micellar media may be attributed to stabilization and/or
protection of the excited singlet state, which hinders decay by quenching, and other non‐radiative
deactivation processes. The radiative relaxation process of the analyte is modified when it is
solubilized in the micellar system because the micelle not only protects the analyte from
quenching molecules but also modifies the physical properties of the environment around it, i.e.,
viscosity, polarity, etc. The enhancement was found to be dependent on the structure of the
surfactant and the analyte 7, 8.
This enhancement facilitates the use of this technique as a complementary means for the
detection and identification of fluorescent compounds. This general observation has been used to
improve the performance of spectrofluorimetric methods of various analytes and active drugs 9-20.
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3.2

Steady-state and synchronous spectrofluorimetric methods for simultaneous
determination of aliskiren hemifumarate and amlodipine besylate in dosage forms

Copyright © 2014 John Wiley & Sons, Ltd
Luminescence (2014) 29(7): 878-83
DOI 10.1002/bio.2636

Aliskiren hemifumarate (ALS) and amlodipine besylate (AML) were simultaneously
determined by two different spectrofluorimetric techniques. The first technique depends on
direct measuring of the steady state fluorescence intensities of ALS and AML at 313 nm and 452
nm upon excitation at 290 and 375 nm, respectively, in a solvent composed of methanol and
water (10:90 v/v). The second technique utilizes synchronous fluorimetric quantitative screening
of the emission spectra of ALS and AML at 272 and 366 nm, respectively using Δλ of 97 nm.
Effects of different solvents and surfactants on relative fluorescence intensity were studied. The
method was validated according to ICH guidelines. Linearity, accuracy and precision were found
to be satisfactory in both techniques over the concentration ranges of 1 – 15 and 0.4 – 4 µg ml-1
for ALS and AML, respectively. In the first technique, LOD and LOQ were estimated and found
to be 0.256 and 0.776 g ml-1 for ALS as well as 0.067 and 0.204 g ml-1 for AML, respectively.
Also, LOD and LOQ were calculated in the synchronous method and found to be 0.293 and
0.887 g ml-1 for ALS as well as 0.034 and 0.103 g ml-1 for AML, respectively. The methods
were successfully applied for the determination of the two drugs in their co-formulated tablets.
The results were compared statistically with reference methods and no significant difference was
found. The developed methods are rapid, sensitive, cheap and accurate for the quality control and
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routine analysis of the cited drugs in bulk and in pharmaceutical preparations without preseparation.

3.2.1. Introduction

Aliskiren hemifumarate, (2(S), 4(S), 5(S), 7(S)-N- (2-carbamoyl- 2- methylpropyl) -5amino-4-hydroxy2,7

diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]

octanamide

hemifumarate) (Fig. 1.3.1f), is the first orally active direct renin inhibitor. It may provide higher
protection from hypertension

21

. Also, its efficacy to decrease systolic and diastolic blood

pressure could be compared to other first-line antihypertensive agents. Additional advantages can
be achieved when it is used in combination with other antihypertensive drugs

21

. Amlodipine

besylate (AML), (3-Ethyl 5-methyl (4RS)-2-[(2-aminoethoxy) methyl]-4-(2-chlorophenyl)-6methyl-1,4-dihydropyridine-3,5-dicarboxylate benzenesulphonate) (Fig. 1.3.1g), is a long-acting
dihydropyridine calcium channel blocker that inhibits the influx of calcium ions into vascular
and cardiac muscles

22

. Amlodipine acts directly on vascular smooth and reduces peripheral

vascular resistance and blood pressure

23

. Combination therapy of ALS and AML proved to be

effective and well tolerated in treating hypertensive patients 24.
Literature survey revealed LC

25-28

, CE

29

, UV-spectrophotometric

30,

31

and

spectrofluorimetric 32, 33 methods reported for the estimation of aliskiren hemifumarate alone or
in combination with other anti-hypertensive agents. Also, LC
spectrophotometric

38-40

and spectrofluorimetric

41, 42

34-36

, LC/MS/MS

22

, CE

37

, UV-

methods are reported for estimation of

amlodipine alone or in combination with other agents. To the best of our knowledge, there are no
reported direct or synchronous spectrofluorimetric methods for determination of ALS either
alone or in combination with AML without the need for derivatization methodologies. Thus, the
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aim of the present study was to develop validated, sensitive, simple, rapid, cheap and precise
spectrofluorimetric procedures for analysis of ALS and AML in bulk drug samples and in their
combined dosage formulations. The developed methods are suitable for quality control and
routine analysis of ALS in its commercial dosage forms either alone or co-formulated with
AML.

3.2.2. Experimental
3.2.2.1. Materials and Reagents
All the chemicals used in the present studies were of analytical reagent grade and the solvents
were of HPLC grade.
Working standard of ALS (certified to contain 99.51%) was kindly supplied by Novartis
Pharmaceuticals Corporation (East, New Jersey- USA 07936). AML (certified to contain 99.75%)
was kindly supplied by Global Nabi Co., (Giza- Egypt). Hydrochlorothiazide (HCZ) (certified to
contain 99.93%) was supplied by AstraZeneca (Cairo- Egypt) (Under license of AstraZeneca,
Sweden). Tekamlo® 150/10 mg tablets labeled to contain 165.8 mg ALS and 13.9 mg AML per each
tablet were purchased from commercial sources in the local market. Methanol, Sodium dodecyl
sulphate (SDS), cetyl trimethyl ammonium bromide (CTAB), hydroxymethyl cellulose (HMC) and
Triton® X-100 were obtained from Sigma-Aldrich, MO, USA. β-Cyclodextrin (β-CD) (TCI, Tokyo
Kasei, Japan). Orthophosphoric acid 85% and hydrochloric acid (Fisher Scientific, NJ, USA) were
used. Sodium hydroxide and sodium dihydrogen phosphate were purchased from J.T. Barker, NJ,
USA. Phosphate buffer (0.2 M, pH 4) solution was freshly prepared. SDS, CTAB, β-CD, HMC and
Triton® X-100 were prepared as 1% w/v aqueous solutions. Also, 0.1N NaOH and 0.1N HCl were
prepared.
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3.2.2.2. Instruments
A LS 55 Fluorescence Spectrometer, 120 V (PerkinElmer, Waltham, MA, USA),
equipped with a high energy pulsed xenon source for excitation, variable slit and holographic
gratings was used. Fluorescence spectra and measurements were recorded using PekinElmer FL
WinLab™ software. A 1 cm quartz cell was used. A VWR SympHoly (SB20) pH meter (Thermo
Orion, Beverly, MA, USA) was used for pH measurements. Deionized water was prepared using
a Barnstead NANO pure Dlamond Analytical ultrapure water system (Thermo Fischer Scientific,
Waltham, MA, USA).
3.2.2.3. Standard solutions
Ten mg of ALS, AML and HCZ were accurately weighed and transferred separately into
10 mL volumetric flasks. Then, they were dissolved and made up to volume with methanol to
give concentrations of 1000 g mL-1 for each. Further dilutions were made separately using the
same solvent to prepare 100 g mL-1 of AML and HCZ.
3.2.2.4. Procedures
3.2.2.4.1. Linearity and construction of calibration graphs
Aliquots of ALS and AML standard stock solutions were separately transferred into two
series of 10 ml Fisherbrand disposable tubes to give final concentrations of 1–15 and 0.4–4 µg
mL-1 for ALS and AML, respectively, then completed to 500 µL with methanol. Finally, 4.5 mL
deionized water were added to each tube to reach final volume of 5 mL, the contents were mixed
well. Relative fluorescence intensity (RFI) was measured in two ways. In the first technique, it
was measured directly against a solvent blank at 313 and 452 nm upon excitation at 290 and 375
nm for ALS and AML, respectively. Excitation and emission slit width of 4.5 were used in the
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case of ALS as well as 8 in the case of AML, (Fig. 3.2.1). In the second technique, RFI of the
synchronous spectrofluorimetric spectra were measured against a solvent blank using Δλ of 97 at
272 and 366 nm for ALS and AML, respectively, (Fig. 3.2.2). The excitation and emission slit
width were 8. RFI was plotted versus the corresponding final drug concentration of ALS and
AML (µg mL-1) to obtain the calibration graphs and regression equations. Figures (3.2.3 – 3.2.6)
show linear relationships which were established by plotting the RFI against ALS and AML
concentrations in µg mL-1. Linear regression analysis of the data gave the following equations:
RFIALS = 063.679C + 7.138

(r=0.9999); (Conventional method)

eq. (1)

RFIAML= 241.398C + 0.417

(r=0.9998); (Conventional method)

eq. (2)

RFIALS = 060.459C + 28.911

(r=0.9999); (Synchronous method)

eq. (3)

RFIAML= 233.118C – 0.214

(r=0.9999); (Synchronous method)

eq. (4)

Where: RFI is the relative fluorescence intensity, C is the concentration of ALS or AML
in µg mL-1 and r is the correlation coefficient.
3.2.2.4.2. Analysis of ALS and AML laboratory prepared mixtures
Aliquots of ALS and AML standard stock solutions were accurately transferred into a
series of 10 mL Fisherbrand disposable tubes to give final concentrations of 4.8 – 14.4 and 0.4 –
1.2 µg mL-1 for ALS and AML, respectively. The procedure described under "Linearity and
construction of calibration graphs" was then applied. The recovery percentage was calculated
using the corresponding regression equation. Tables 3.2.1 and 3.2.2 show the mean percentage
recoveries ± S.D. of ALS and AML using the proposed methods.
3.2.2.4.3. Sample preparation and application to Dosage Form
Twenty tablets of Tekamlo were weighed and finely powdered. A portion of the powder
equivalent to ALS (50 mg) and AML (4.192 mg) was introduced into a 50 mL volumetric and
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sonicated with 30 mL methanol for 15 minutes, and then diluted to the mark with methanol. The
solution was filtered through Whatman filter paper. The procedure described under "Linearity
and construction of calibration graphs" was then applied. The recovery percentage was
calculated using the corresponding regression equations. Standard addition technique was
applied and the concentrations of the examined drugs were calculated using the corresponding
regression equation. Tables (3.2.3 – 3.2.6) show the mean percentage recoveries ± S.D. of ALS
and AML using the proposed methods.
3.2.2.5. Validation

The suggested analytical method was validated according to ICH guidelines with respect
to certain parameters such as linearity, LOD and LOQ, accuracy, precision, specificity and
stability.

3.2.2.5.1. Linearity

The linearity of the method was established by spiking a series of standard mixtures in
the range 1–15 and 0.4–4 µg mL-1 of ALS and AML, respectively. The procedure described
under "Linearity and construction of calibration graphs" was applied. Linear regression was
applied and standard deviation of slope (Sb), standard deviation of intercept (Sa), correlation
coefficient (r) and standard error (Es) were determined.

3.2.2.5.2. Limit of detection & Limit of quantification

Detection and quantification limits were determined through dilution method using S/N
approach. LOD was considered as the minimum concentration with a signal to noise ratio of at
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least three (S/N˜3), while LOQ was taken as a minimum concentration with a signal to noise
ratio of at least ten (S/N˜10).

3.2.2.5.3. Accuracy

Accuracy was determined in terms of percent recovery. A set of standard mixtures at six
different concentration levels 4.8, 7.2, 9.6, 12, 13.2, 14.4 µg mL-1 of ALS and 0.4, 0.6, 0.8, 1,
1.1, 1.2 µg mL-1 of AML were prepared. The procedure described under "Linearity and
construction of calibration graphs" was then applied. The percentage recoveries of ALS and
AML were calculated.

3.2.2.5.4. Precision

Method precision was determined both in terms of repeatability (intra-day
reproducibility) and intermediate precision (inter-day reproducibility) using three different
concentration levels 2, 6, 12 µg mL-1 of ALS and 0.6, 1.8, 3.4 µg mL-1 of AML.

3.2.2.5.5. Specificity

Specificity was examined by analyzing ALS and AML in their laboratory prepared
mixtures and pharmaceutical dosage forms to detect any interference caused by the combined
drugs present in dosage formulations or the co-formulated excipients. Also, specificity was
checked by analyzing 12 µg mL-1 ALS and 0.5 µg mL-1 AML in their triple mixture with 0.5, 1
and 2 µg mL-1 of HCZ. The percentage recovery and standard deviation were calculated.
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3.2.2.5.6. Stability

The stability studies of ALS and AML samples were carried out over a period of 72h at
2–80 °C (refrigerator) and standard stock solutions for one month at 2–80 °C.

Figure 3.2.1 Excitation (A, C) and direct fluorescence spectra of (B, D) of ALS and AML
respectively (ALS: 12 µg mL-1 and AML: 3 µg mL-1) in a solvent composed of methanol and
water (10:90, v/v) and (A`, B`, C`, D`) for blank solvent composed of methanol and water
(10:90, v/v). Where (A, C, A`, C`) are the excitation spectra and (B, D, B`, D`) are the emission
spectra
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Figure 3.2.2 Synchronous fluorescence spectra of (A) ALS (12 µg mL-1), (B) AML (3 µg mL-1)
in a solvent composed of methanol and water (10:90, v/v) and (A, B`) solvent composed of
methanol and water (10:90, v/v)
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Figure 3.2.3 Standard calibration curve for determination of ALS by the proposed conventional
spectrofluorimetric method

Figure 3.2.4 Standard calibration curve for determination of AML by the proposed conventional
spectrofluorimetric method
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Figure 3.2.5 Standard calibration curve for determination of ALS by the proposed synchronous
spectrofluorimetric method

Figure 3.2.6 Standard calibration curve for determination of AML by the proposed synchronous
spectrofluorimetric method
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Table 3.2.1 Determination of ALS and AML using the conventional spectrofluorimetric method
RFIALS = 063.679C + 7.138
RFIAML= 241.398C + 0.417

Amount taken
Mixture

ALS

[μg/ml]

No
ALS

AML

AML

RFI of

Found

Recovery

RFI of

Found

Recovery

ALS

[μg/ml]

%

AML

[μg/ml]

%

1

4.8

0.4

303

96

4.870

0.396

101.47

98.99

2

7.2

0.6

456

148

7.273

0.611

101.01

101.89

3

9.6

0.8

593

196

9.424

0.810

98.17

101.28

4

12.0

1.0

747

241

11.843

0.997

98.69

99.66

5

13.2

1.1

822

264

13.021

1.092

98.64

99.26

6

14.4

1.2

936

295

14.811

1.220

102.85

101.69

Mean

100.14

100.46

± S.D.

1.90

1.30

± S.E.

0.78

0.53
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Table 3.2.2 Determination of ALS and AML using the synchronous spectrofluorimetric method
RFIALS = 060.459C + 28.911
RFIAML= 233.118C – 0.214

Amount taken
Mixture

ALS

[μg/ml]

No
ALS

AML

AML

RFI of

Found

Recovery

RFI of

Found

Recovery

ALS

[μg/ml]

%

AML

[μg/ml]

%

1

4.8

0.4

317

92

4.765

0.396

99.27

98.89

2

7.2

0.6

459

139

7.114

0.597

98.80

99.53

3

9.6

0.8

599

187

9.429

0.803

98.22

100.39

4

12.0

1.0

757

231

12.043

0.992

100.36

99.18

5

13.2

1.1

832

254

13.283

1.090

100.63

99.14

6

14.4

1.2

906

279

14.507

1.198

100.74

99.81

Mean

99.67

99.49

± S.D.

1.05

0.54

± S.E.

0.43

0.22
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Table 3.2.3 Determination of ALS using the conventional spectrofluorimetric method
RFIALS = 063.679C + 7.138

Amount of ALS
(μg/ml)

Mixture

RFI of ALS

No

Tablet &

Amount of ALS found
(μg/ml)
Tablet &

Tablet

Added

Tablet

1

6

4

363

616

5.813

9.786

3.973

96.88

99.33

2

6

6

363

748

5.813

11.859

6.046

96.88

100.77

3

6

9

363

939

5.813

14.858

9.045

96.88

100.50

4

9

4

551

806

8.767

12.769

4.002

97.41

100.06

5

9

5

551

876

8.767

13.869

5.102

97.41

102.03

6

9

6

551

940

8.767

14.874

6.107

97.41

101.78

Mean

97.14

100.74

± S.D.

0.29

1.03

± S.E.

0.12

0.42

added

Tablet

Recovery %

added

Added Tablet Added
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Table 3.2.4 Determination of AML using the conventional spectrofluorimetric method
RFIAML= 241.398C + 0.417

Amount of AML
Mixture

(μg/ml)

Amount of AML found
RFI of AML

Recovery %
(μg/ml)

No

Tablet &

Added

Tablet

1

0.503

0.4

115

213

0.475

0.881

0.406

94.38

101.49

2

0.503

1.0

115

355

0.475

1.469

0.994

94.38

99.42

3

0.503

2.0

115

602

0.475

2.492

2.017

94.38

100.87

4

0.754

0.6

179

323

0.740

1.336

0.597

98.06

99.42

5

0.754

1.0

179

422

0.740

1.746

1.007

98.06

100.66

6

0.754

2.0

179

671

0.740

2.778

2.038

98.06

101.91

Mean

96.22

100.63

± S.D.

2.02

1.03

± S.E.

0.82

0.42

added

Tablet

Tablet &

Tablet

added

Added Tablet Added
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Table 3.2.5 Determination of ALS using the synchronous spectrofluorimetric method.
RFIALS = 060.459C + 28.911

Amount of ALS
(μg/ml)

Mixture

Amount of ALS found
RFI of ALS

Recovery %
(μg/ml)

No

Tablet &

Added

Tablet

1

6

4

376

621

5.749

9.793

4.045

95.81

101.11

2

6

6

376

738

5.749

11.728

5.980

95.81

99.66

3

6

9

376

925

5.749

14.821

9.073

95.81

100.81

4

9

4

563

801

8.834

12.770

3.937

98.15

98.41

5

9

5

563

869

8.834

13.895

5.061

98.15

101.23

6

9

6

563

928

8.834

14.871

6.037

98.15

100.62

Mean

96.98

100.31

± S.D.

1.28

1.08

± S.E.

0.52

0.44

added

Tablet

Tablet &

Tablet

added

Added Tablet Added
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Table 3.2.6 Determination of AML using the synchronous spectrofluorimetric method
RFIAML= 233.118C – 0.214

Amount of AML
Mixture

(μg/ml)

Amount of AML found
RFI of AML

Recovery %
(μg/ml)

No

Tablet &

Added

Tablet

1

0.503

0.4

113

205

0.486

0.880

0.395

96.56

98.66

2

0.503

1.0

113

351

0.486

1.507

1.021

96.56

102.09

3

0.503

2.0

113

588

0.486

2.523

2.038

96.56

101.88

4

0.754

0.6

174

313

0.747

1.344

0.596

99.06

99.38

5

0.754

1.0

174

409

0.747

1.755

1.008

99.06

100.81

6

0.754

2.0

174

649

0.747

2.785

2.038

99.06

101.88

Mean

97.81

100.78

± S.D.

1.37

1.46

± S.E.

0.56

0.59

added

Tablet

Tablet &

Tablet

added

Added Tablet Added
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3.2.3. Results and Discussion:

The goal of the present investigation was to develop validated, sensitive, simple and rapid
specrofluorimetric analytical methods for simultaneous determination and quantification of ALS
and AML in pharmaceutical preparations. Also, many trials were attempted to enhance the
intensity of the emission bands and increase molar absorptivity and quantum yield through
selection of proper solvent and addition of surfactants at concentrations above their critical
micellar concentration in order to perform micelles or reversed micelles able to stabilize the
exited singlet states and delay the decay process. The fluorescence performance of ALS was
studied in various solvents and micellar media and a solvent composed of methanol and water
(10:90 v/v) was chosen as no one of the studied media caused significant enhancement in RFI of
ALS (Fig. 3.2.1 and 3.2.2).

3.2.3.1. Optimization of the experimental conditions
3.2.3.1.1. Effect of different organized media
The fluorescence properties of ALS in various micellar media were studied using anionic
surfactant (SDS), cationic surfactant (CTAB) and non-ionic surfactant (Triton® X-100) and
different macromolecules, like β-Cyclodextrin (β-CD) and hydroxyl methyl cellulose (HMC).
ALS has pKa above 9 so it will be positively charged under acidic conditions obtained by adding
phosphate buffer (pH 4). No one of the examined surfactants showed significant enhancement in
RFI of ALS, (Fig. 3.2.7).
3.2.3.1.2. Effect of the diluting solvent
For the steady state spectrofluorimetric procedure, the influence of different diluting
solvents on RFI of ALS was investigated using water, methanol, phosphate buffer solution at pH
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4, 0.1N HCl and 0.1N NaOH to give final solutions containing 10% v/v methanol for each.
Water was chosen as diluting solvent as it showed a good RFI compared with methanol but it is
friendlier to the environment and with much less blank readings, (Fig. 3.2.8).
3.2.3.1.3. Selection of Δλ in the synchronous spectrofluorimetric method
To separate entirely synchronous fluorescence peaks of ALS and AML, the synchronous
fluorescence spectra of the mixtures were recorded using different Δλ. It was found that Δλ of 97
nm is suitable for simultaneous determination of ALS and AML in their medicinally
recommended ratio of (12: 1), respectively. The result was showed in (Fig. 3.2.2), where the
maximum synchronous fluorescence peaks of ALS and AML were at 272 and 366 nm,
respectively. Obviously, no significant interference would occur in their combined formulation`s
ratio.
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Figure 3.2.7 Effect of type of surfactant (1mL of 1% solution for each) on the RFI of ALS (8 µg
mL-1)

Figure 3.2.8 Effect of different diluting solvents on the RFI of ALS (8 µg mL-1)
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3.2.3.2. Validation
3.2.3.2.1. Linearity and Range

The linearity of the calibration curves was validated by the high value of correlation
coefficients (r) of the regression equation, small values of the standard deviation of residuals
(Sy/x) and small value of the percentage relative error (Table 3.2.7). The analytical data of the
calibration curves including standard deviations for the slope and intercept (Sb, Sa) are
summarized in (Table 3.2.7). These data proved the linearity of the calibration graphs.

3.2.3.2.2. Limit of Detection (LOD) and Limit of Quantitation (LOQ)
LOQ and LOD were calculated according to ICH Q2R1 recommendations using the
following equations:
LOQ = 10 Sa /b and LOD = 3.3 Sa /b
Where: Sa = standard deviation of the intercept and b = slope of the calibration curve.

LOQ was determined by establishing the lowest concentration that can be measured and below
which the calibration graph is nonlinear. LOD was determined by establishing the minimum level at
which the analyte can be reliably detected. LOD and LOQ were estimated and found to be 0.256 and
0.776 g mL-1 for ALS as well as 0.067 and 0.204 g mL-1 for AML, respectively. Also, LOD and
LOQ were calculated in the synchronous method and found to be 0.293 and 0.887 g mL-1 for ALS as
well as 0.034 and 0.103 g mL-1 for AML, respectively. The results are shown in Table 3.2.7.
3.2.3.2.3. Accuracy
Accuracy of the results was calculated by % recovery of 6 different concentrations of the
two drugs analyzed by the proposed spectrofluorimetric methods. The results obtained including
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the mean of the recovery and standard deviations are displayed in (Table 3.2.7). To prove the
accuracy and utility of the proposed method, the results of the assay of ALS and AML with the
proposed spectrofluorimetric methods were compared with those of the reference methods

26, 43

.

Statistical analysis of the results using Student's t-test and variance ratio F-test revealed no
significant difference between the performance of the developed methods and reference methods
regarding the accuracy and precision, respectively (Table 3.2.8). The reference method

26

and

pharmacopeal method 43 depend on the analysis of ALS and AML, respectively, using RP-HPLC.
3.2.3.2.4. Precision
Repeatability (intra-day, n=3) and intermediate precision (inter-day, n=3) were checked
using three different concentrations at low, medium and high level of the standard curve. Relative
standard deviations were calculated to check the precision of the method, (Table 3.2.9).
The relative standard deviations and percentage relative errors were found to be very small
indicating reasonable repeatability and intermediate precision of the proposed method.
3.2.3.2.5. Specificity

The specificity of the methods was investigated by observing any interference
encountered from the excipients of the tablets. It was shown that these compounds do not
interfere with the proposed method (Table 3.2.7). It was also found that ALS and AML do not
interfere with each other either in their laboratory prepared mixtures or in their co-formulated
tablets (Table 3.2.7). Moreover, the steady state method showed better results and higher
tolerance in presence of 1 µg mL-1 HCZ for the determination of ALS and AML than the
synchronous method (Table 3.2.7). So, the steady state method is more reliable to be used for
simultaneous determination of ALS and AML in presence of HCZ specifically in the medicinally
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recommended ratio of (12:0.5:1), respectively, in their co-formulated tablets, Amturnide® (Table
3.2.7).

3.2.3.2.6. Stability
Results from the stability studies of standard stock solutions indicated that they were
stable for one month at 2–8 °C with satisfactory recovery percentage of about 98%. These
solutions can therefore be used during this interval of time without the results being affected.
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Table 3.2.7 Performance data and results of the proposed spectrofluorimetric methods for the
simultaneous determination of ALS and AML
Conventional fluorescence

Synchronous fluorescence

Item
ALS

AML

ALS

AML

Linearity range (g mL-1)

1 – 15

0.4 – 4

1 – 15

0.4 – 4

LOD (g mL-1)

0.256

0.067

0.293

0.034

LOQ (g mL-1)

0.776

0.204

0.887

0.103

Regression equation (Y) a: Slope (b)

63.679

241.398

60.459

233.118

Standard deviation of slope (Sb)

0.548

2.114

0.595

1.031

Intercept (a)

7.1382

0.4170

28.9113

- 0.2143

Standard deviation of intercept (Sa)

4.942

4.928

5.362

2.403

Regression coefficient (r)

0.9999

0.9998

0.9999

0.9999

Standard deviation of residuals (Sy/x)

5.937

6.480

6.442

3.159

%Error

1.292

0.448

1.378

0.467

Results

a
b

(Recovery ± S.D.)

Drug in bulk

101.33 + 0.91

99.81 ± 0.84

100.74 ± 0.88

100.68 + 0.72

Drugs in lab. mixture

100.14 + 1.90

100.46 ± 1.30

99.67 ± 1.05

99.49 + 0.54

Drugs in lab. Mixture with HCZ

100.72 + 1.58

100.02 ± 0.35

95.68 ± 1.39

99.86 + 0.77

Tekamlo® 150/10 mg tablets

97.14 + 0.29

96.22 + 2.02

96.98 ± 1.28

97.81 + 1.37

Drug spiked to dosage form

100.74 + 1.03

100.63 + 1.03

100.31 ± 1.08

100.78 + 1.46

Y=a+bC, where C is the concentration in g mL-1 and Y is the peak area.
95% confidence limit.
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Table 3.2.8 Statistical comparison between analysis results of pure samples of the studied drugs
using spectrofluorimetric methods and those of the reference methods
ALS

AML

Statistical
Reported

Conventional

Synchronous

method [6]

fluorescence

fluorescence

Mean

101.10

101.33

100.74

±S.D.

1.64

0.91

±S.E.

0.73

%RSD

Term

Reported
method

Conventional Synchronous
fluorescence

fluorescence

99.90

99.81

100.68

0.88

1.59

0.84

0.72

0.37

0.36

0.71

0.34

0.29

1.62

0.90

0.87

1.59

0.84

0.72

n

5

6

6

5

6

6

V

2.69

0.83

0.77

2.53

0.71

0.52

Student`s t

0.783

1.003

0.180

1.312

test

(1.833*)

(1.833*)

(1.833*)

(1.833*)

3.241

3.494

3.563

4.865

(6.260*)

(6.260*)

(6.260*)

(6.260*)

[24]

F-test

* Figures in parentheses are the theoretical t and F values at (p= 0.05) and n is the number of
experiments.
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Table 3.2.9 Intra-and inter-day validation for the spectrofluorimetric determination of ALS and
AML
Intra-day assay
Concentration of

Direct

Synchronous

Direct

Synchronous

ALS (g mL-1)

fluorescence

fluoresence

fluorescence

fluoresence

Found ± RSDa

Found ± RSDa

Found ± RSDa

Found ± RSDa

2

1.997 ± 0.79

1.959 ± 2.97

2.004 ± 1.18

1.967 ± 1.90

6

5.975 ± 1.35

6.006 ± 1.26

5.996 ± 1.32

5.942 ± 1.74

12

12.021 ± 0.72

12.092 ± 1.54

11.955 ± 1.13

12.056 ± 1.20

Intra-day assay

a

Inter-day assay

Inter-day assay

Concentration of

Direct

Synchronous

Direct

Synchronous

AML (g mL-1)

fluorescence

fluoresence

fluorescence

fluoresence

Found ± RSDa

Found ± RSDa

Found ± RSDa

Found ± RSDa

0.6

0.609 ± 1.42

0.591 ± 1.51

0.604 ± 1.55

0.601 ± 2.09

1.8

1.797 ± 0.96

1.813 ± 0.90

1.814 ± 1.13

1.835 ± 1.26

3.4

3.397 ± 0.46

3.394 ± 0.58

3.419 ± 0.97

3.396 ± 0.41

Mean and standard deviation of three determinations
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3.3

Spectrophotometric and Spectrofluorimetric Studies on Azilsartan Medoxomil and
Chlorthalidone to be Utilized in their Determination in Pharmaceuticals

Copyright © 2014 the author(s), publisher and licensee Libertas Academica Ltd.
Analytical Chemistry Insights (2014) 7; 9:33-40
DOI: 10.4137/ACI.S13768

The angiotensin II receptor blocker, Azilsartan medoxomil (AZL) was determined
spectrophotometrically and spectrfluorimetrically in its combination with chlorthalidone (CLT).
The UV-spectrophotometric technique depends on simultaneous measurement of the first
derivative spectra for AZL and CLT at 286 nm and 257 nm, respectively, in methanol. The
spectrofluorimetric technique depends on measurement of the fourth derivative of the
synchronous spectra intensities of AZL in presence of CLT at 298 nm in methanol. Effects of
different solvents on spectrophotometric and spectrfluorimetric responses were studied. For, the
spectrofluorimetric study, the effect of pH and micelle assisted fluorescence enhancement were
also studied. The method was validated according to ICH guidelines. Linearity, accuracy and
precision were found to be satisfactory over the concentration ranges of 8 – 50 and 2 – 20 µg
mL-1 for AZL and CLT, respectively, in the spectrophotometric method as well as 0.01 - 0.08 µg
mL-1 for AZL in the spectrofluorimetric method. The methods were successfully applied for the
determination of the studied drugs in their co-formulated tablets. The developed methods are
inexpensive and simple for the quality control and routine analysis of the cited drugs in bulk and
in pharmaceuticals.
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3.3.1 Introduction

Azilsartan medoxomil (AZL), (5-Methyl-2-oxo-1,3-dioxol-4yl) methyl 2-ethoxy-1-{[2`(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7carboxylate, (Fig. 1.2.1a). AZL is practically insoluble in water, freely soluble in methanol,
dimethylsulfoxide, soluble in acetic acid, slightly soluble in acetone, and acetonitrile and
sparingly soluble in tetrahydrofuran and 1-octanol 44. Azilsartan, the active metabolite of AZL, is
a novel non-peptide angiotensin II type 1 (AT1) receptor blocker (ARB), was recently approved
for treatment of hypertension

45

. It has a superior ability to control systolic blood pressure (BP)

relative to other widely used ARBs. Greater antihypertensive effects of AZL might be due in part
to its unusually potent and persistent ability to inhibit binding of angiotensin II to AT1 receptors
46

. Preclinical studies have indicated that AZL may also beneficially affect cellular mechanisms

of cardio-metabolic disease and insulin sensitizing activity 47. There is only one reported method
44

for determination of AZL alone and it was applied to analysis in plasma. Chlorthalidone

(CLT), (2-chloro-5- (1-hydroxy-3-oxoiso-indolin-1-yl) benzenesulfonamide), (Fig. 1.2.1b), is an
orally taken thiazide-like diuretic for controlling hypertension and edema, including that
associated with heart failure 48. CLT has been determined in different matrices either alone or in
combination with other medications using LC

49,

50

, LC/MS/MS

51

, HPTLC

52,

53

,

chemiluminometry 54, spectrophotometry 55 and CE 56 techniques. Binary combination therapies
of AZL and CLT proved to induce significant reductions in systolic and diastolic BP in patients
with mild to severe hypertension

57

. Accordingly, it is desirable to develop validated simple

analytical methods for assay of AZL in its combination with CLT either in their synthetic
mixtures or in their combined pharmaceutical preparations. Regarding simultaneous
determination of CLT and AZL, there is only one LC reported method

58

, done on a symmetry
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C18 column with a mobile phase consisting of methanol: Water: Acetonitrile : 0.1% Ortho
phosphoric acid (30:35:15:5, v/v/v/v) at λ of 251 nm. To the best of our knowledge there is no
spectrophotometric or spectrofluorimetric methods developed for determination of AZL either
alone or in its combination with CLT. Hence, the aim of these studies was to develop and
validate simple, rapid and inexpensive analytical methods using spectrophotometric and
spectrofluorimetric techniques for determination of AZL in its combination with CLT to be
applied to their determination in pharmaceuticals. These newly developed and validated methods
can be used for routine analysis and quality control of the cited medications either separately or
in combinations without pre-separation.

3.3.2 Experimental
3.2.2.1 Materials and reagents

All the chemicals used in the present studies were of analytical reagent grade and the solvents
were of HPLC grade.
CLT (certified to contain 98%) was supplied by Ark Pharm. Inc., IL 60048 USA. AZL
(certified to contain 98%) was supplied by D-L Chiral Chemicals, LLC., NJ 08540 USA.
Edarbcyclor® 40-25 mg tablets; batch # NDC 64764-0994-30 (Takeda Pharmaceutical Company
Limited, Tokyo, Japan) each labeled to contain 42.68 mg of azilsartan kamedoxomil (equivalent to
40 mg AZL) and 25 mg CLT were purchased from commercial sources in local market. Methanol,
Sodium dodecyl sulphate (SDS), cetyl trimethyl ammonium bromide (CTAB), and hydroxymethyl
cellulose (HMC) were obtained from Sigma-Aldrich, MO, USA. β-Cyclodextrin (β-CD) (TCI,
Tokyo Kasei, Japan). O-phosphoric acid 85% and hydrochloric acid (Fisher Scientific, NJ, USA)
were used. Sodium hydroxide and sodium dihydrogen phosphate were purchased from J.T. Baker,
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NJ, USA. Phosphate buffer solutions (PBS) (0.02 M) were freshly prepared. SDS, CTAB, β-CD and
HMC were prepared as 1% w/v aqueous solutions. Also, 0.1N NaOH and 0.1N HCl were prepared.

3.3.2.2 Instruments
A Lambda 20 UV/VIS spectrometer (Perkin Elmer, Massachusetts, USA) was used for
the spectrophotometric measurements whereas a LS 55 Fluorescence spectrometer, 120V (Perkin
Elmer,

Massachusetts,

USA)

was

used

for

the

spectrofluorimetric

measurements.

Spectrophotometric measurements and data handling were performed using UV WinLab 1.22
software whereas fluorescence spectra measurements and data handling were performed using
FL WinLab™ software. Quartz cells (1 cm) were used. A VRW SympHoly (SB20) pH-meter
(Thermo Orion. Beverly, MA, USA) was used for pH measurements. Deionized water was
prepared using a Barnstead NANO pure Dlamond Analytical ultrapure water system (Thermo
Fischer Scientific, Waltham, MA, USA).
3.3.2.3 Standard solutions
10 mg of AZL and CLT were accurately weighed and transferred separately into 10 mL
volumetric flasks. Then, they were dissolved and made up to volume with methanol to give
concentrations of 1000 g mL-1 for each. Further dilutions were made separately using the same
solvent to prepare 1 g mL-1 solutions for each.
3.3.2.4 Procedures
3.3.2.4.1 Linearity and construction of calibration graphs for the spectrophotometric technique
Aliquots of AZL and CLT standard stock solutions (1000 g mL-1) were separately
transferred into two series of 10 mL Fisherbrand disposable tubes to give final concentrations of
8–50 and 2–20 µg mL-1 for AZL and CLT, respectively, then completed to 5 mL with methanol
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and the contents were mixed well. The absorbance spectra were recorded against a methanol
blank and then the first derivative spectra were obtained (number of points = 18), (Fig. 3.3.1).
The amplitudes at 286 nm and 257 nm for AZL and CLT, respectively, were measured then
plotted versus the corresponding final drug concentration of AZL and CLT (µg mL-1) to obtain
the calibration graphs and the regression equations. Figures (3.3.2 & 3.3.3) show linear
relationships which were established by plotting first derivative of the spectra for AZL or CLT at
286 nm and 257 nm against AZL and CLT concentrations in µg mL-1. Linear regression analysis
of the data gave the following equations:
1DAZL = 0.0075C + 0.0064

(r=0.9998);

eq. (1)

1DCLT = 0.0224C - 0.0154

(r=0.9999);

eq. (2)

Where: 1D is the first derivative of the spectra for AZL or CLT at 286 nm and 257 nm,
respectively. C is the concentration of AZL or CLT in µg mL-1 and r is the correlation
coefficient.
3.3.2.4.2 Linearity and construction of calibration graphs for the spectrofluorimetric technique
Aliquots of AZL standard stock solution (1 g mL-1) were transferred into a series of 10
ml Fisherbrand disposable tubes to give final concentrations in the range of 0.01-0.08 µg mL-1.
Then, completed to 5 mL with methanol and the contents were mixed well. Relative fluorescence
intensity (RFI) of the synchronous spectrofluorimetric spectra were recorded against a solvent
blank using (Δλ= 110 nm, slit width for excitation and emission= 10 nm) and then the fourth
derivatives were obtained (number of points = 90), (Fig. 3.3.4). The amplitudes of the fourth
derivative of the synchronous spectra at 298 nm were measured and plotted versus the
corresponding final drug concentration of AZL (µg mL-1) to obtain the calibration graphs and
regression equations. Figures (3.3.5 – 3.3.7) show linear relationships which were established by
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plotting the RFI of AZL or CLT against their concentrations in µg mL-1. Linear regression
analysis of the data gave the following equations:
4DAZL = 789.1C + 0.7876

(r=0.9998); (Synchronous method)

eq. (3)

RFIAZL = 6289.8C+ 41.996

(r=0.9991); (Conventional method)

eq. (4)

RFIAML = 3922.4C + 3.534

(r=0.9996); (Conventional method)

eq. (5)

Where: 4D is the fourth derivative of the synchronous fluorescence for AZL, RFI is the
relative fluorescence intensity, C is the concentration of AZL or CLT in µg mL-1 and r is the
correlation coefficient.
3.3.2.4.3 Preparation of AZL and CLT laboratory prepared mixtures
For the spectrophotometric method, aliquots of AZL and CLT standard stock solutions
(1000 g mL-1) were accurately transferred into a series of 10 ml Fisherbrand disposable tubes to
give final concentrations of 9.6, 16.0, 24.0 g mL-1 for AZL and 6.0, 10.0, 15.0 g mL-1 for
CLT. The procedure described under "section 2.2.4.2" was then applied. For the
spectrofluorimetric method, aliquots of AZL and CLT standard stock solutions (1 g mL-1) were
accurately transferred into a series of 10 ml Fisherbrand disposable tubes to give final
concentrations of 0.0384, 0.0576, 0.0768 g mL-1 for AZL and 0.0240, 0.0360, 0.0480 g mL-1
for CLT. The procedure described under "section 2.2.4.3" was then applied. For both methods,
the percentage recoveries were calculated using the corresponding regression equation. Table
(3.3.1) shows the mean percentage recoveries ± S.D. of AZL and CLT using the proposed
methods.
3.3.2.4.4 Sample preparation and application to dosage form
Ten tablets of Edarbcyclor were weighed and finely powdered after removal of the coat
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using a tissue moistened with methanol. A portion of the powder equivalent to AZL (40 mg) and
CLT (25 mg) was introduced into a 25 mL volumetric flask and completed to volume with
methanol. The solutions were sonicated for 30 min then filtered through a Whatman filter paper
and then filtered again using 0.2 µm a Whatman inorganic membrane filter. For
spectrophotometric analyses, different aliquots from the prepared sample solutions were scanned
and manipulated using the same procedure described under section “2.2.4.2”. For the
spectrofluorimetric analyses, further dilutions were prepared and different aliquots from the
prepared sample solutions were scanned and manipulated using the same procedure described
under section “2.2.4.3”. The percentage recoveries were calculated by referring to the
corresponding regression equations. Table (3.3.1) shows that the mean percentage recoveries ±
S.D. of ALS and AML using the proposed methods.
3.3.2.5 Validation

The suggested analytical methods were validated according to ICH guidelines with
respect to certain parameters such as linearity, LOD and LOQ, accuracy, precision, specificity
and stability.

3.3.3 Results and discussion
The goal of the present investigations was to perform spectrophotometric and
spectrophotometric studies on AZL and CLT in order to develop validated, rapid, sensitive,
simple, inexpensive and selective spectrophotometric and specrofluorimetric methods for
quantification of AZL in its combination with CLT. These studies focused on factors that
enhance the absorbance or the intensities of the emission bands of each analyte separately and in
their combination.
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3.3.3.1 Optimization of experimental conditions for the spectrophotometric technique
For the spectrophotometric technique, the effect of different diluting solvents such as
methanol, 0.1N HCl and 0.1N NaOH on absorbance was studied. 0.1N NaOH showed a slightly
higher response for both drugs, (Fig. 3.3.8). This solvent can be used for ordinary UV
measurements of AZL or CLT separately at 260 nm and 232 nm, respectively. Methanol was
used as a convenient diluting solvent with satisfactory linearities in the range 8-50 and 2-20 µg
mL-1 for AZL and CLT at 242 nm and 266 nm, respectively, (Fig. 3.3.1). The spectra of AZL
and CLT in all the studied solvents showed severe overlap, (Fig. 3.3.1). Obtaining the first
derivative for the absorbance spectra of the analyzed drugs was able to resolve such overlapping
between AZL and CLT, only in methanol, to be utilized for their simultaneous quantitative
determination at 286 nm and 257 nm, respectively, (Fig.3.3.9).
3.3.3.2 Optimization of experimental conditions for the spectrofluorimetric technique
3.3.3.2.1. Effect of diluting solvent
AZL is freely soluble in methanol so it was added to the solvent media in at least 10% of
the final volume then either methanol, 0.1N HCl, 0.1N NaOH or PBS was added to complete the
volume. The influence of these different diluting solvents on the relative fluorescence intensity
(RFI) of AZL and CLT was studied and methanol was chosen as it showed the highest RFI, (Fig.
3.3.10).
3.3.3.2.2 Effect of pH
The effect of pH on RFI of AZL and CLT was investigated and pH 7.5 was found to give
slightly higher RFI for AZL as its pKa values is 6.1 and it will have higher ionization percentage

247

at that pH, (Fig. 3.3.11). For CLT (pKa = 9.4), it is highly ionized at all the studied pHs so the
effect of the studied pH values was not significant, (Fig. 3.3.11).
3.3.3.2.3 Effect of different organized media
The fluorescence properties of AZL and CLT in various micellar media were studied
using anionic surfactant (SDS), cationic surfactant (CTAB) and different macromolecules; (βCD) and (HMC). Micelles or reversed micelles are able to stabilize the exited singlet state and
delay the decay process and thus may enhance the intensity of the emission bands 59. PBS of pH
7.5 was used in this study to allow proper ionization of both analytes. None of the examined
surfactants showed significant enhancement in RFI of AZL and CLT, (Fig. 3.3.12).
3.3.3.2.4 Techniques and parameters settings
Satisfactory linearities were obtained for AZL and CLT in methanol at 381 nm and 330
nm, upon excitation at 260 nm, respectively, at slit width of excitation and emission of 10 nm,
(Fig. 3.3.13), (Table 3.3.1). However, the spectra of AZL and CLT in all of the studied solvents
showed severe overlap so they cannot be used for their simultaneous determination, (Fig. 3.3.13).
Also, synchronous fluorescence was not able to resolve such overlap at (λ= 10 – 300 nm, slit
width for excitation and emission= 5 - 10 nm), (Fig. 3.3.4). Obtaining the fourth derivative for
the synchronous fluorescence spectra (λ=110 nm, slit width for excitation and emission= 10 nm)
of the analyzed drugs was able to resolve such overlap between AZL and CLT, only in methanol,
to be utilized for quantitative determination of AZL in presence of CLT at 298 nm in their
medicinally recommended ratio of (1.6: 1), respectively, (Fig. 3.3.14).
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3.3.3.3 Validation of the proposed methods
3.3.3.3.1 Linearity and range
Linear relationships between the responses of AZL or CLT and their corresponding
concentrations were obtained. The regression equation y = bC ± a for each drug was also
computed. In these studies, five concentrations for AZL or CLT were used. The linearity of the
calibration curves was validated by the high value of correlation coefficients (r) of the regression
equation, small values of the standard deviation of residuals (Sy/x) and small value of the
percentage relative error (Table 3.3.1). The analytical data of the calibration curves including
standard deviations for the slope and intercept (Sb, Sa) are summarized in (Table 3.3.1). These
data indicate the linearity of the calibration graphs.
3.3.3.3.2 Limit of detection and limit of quantification
LOQ and LOD were calculated according to ICH recommendations

51

. LOD was

considered as the minimum concentration with a signal to noise ratio of at least three (S/N˜3),
while LOQ was taken as a minimum concentration with a signal to noise ratio of at least ten
(S/N˜10). Results are given in (Table 3.3.1).
3.3.3.3.3 Accuracy and precision
The satisfactory recovery results for the assay of AZL and/with CLT in their synthetic
mixtures indicate the accuracy of the method, (Table, 3.3.2). Repeatability (intra-day) and
intermediate precision (inter-day) were assessed using three concentrations and three replicates
of each concentration. The relative standard deviations were found to be very small indicating
reasonable repeatability and intermediate precision of the proposed method (Table 3.3.3).
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3.3.3.3.4 Specificity
The specificity of the method was investigated by observing any interference encountered
from common tablet excipients and it was confirmed that the signals measured was caused only
by the analytes. The inactive ingredients in Edarbcylor® are: mannitol, microcrystalline cellulose,
fumaric acid, sodium hydroxide, hydroxypropyl cellulose, crospovidone, magnesium stearate,
hypromellose 2910, talc, titanium dioxide, ferric oxide red, polyethylene glycol 8000, and
printing ink gray F1. It was found that the excipients did not interfere with the results, (Table
3.3.2). For the spectrophotometric method, it was found that AZL and CLT can be determined
simultaneously either in their laboratory prepared mixtures or in their co-formulated tablets,
(Table 3.3.2). On the other hand, the spectrofluorimetric method was only able to determine AZL
in presence of CLT in methanol, (Table 3.3.2).
3.3.3.3.5 Stability
Stabilities of the standard stock solutions of AZL and CLT, stored at 2 – 8 °C, were
evaluated at various time points over 1 month. The concentrations of freshly prepared solutions
and those aged for 1 month were calculated by the methods developed and the difference
between them was found to be less than 2%. Also, the prepared solutions for analysis were found
to be stable for at least 3 days at 2 – 8 °C and for a day at room temperature. These solutions can
therefore be used during this interval of time without the results being affected.
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Figure 3.3.1 Zero order UV-absorbance spectra of (a) 8, 12, 20, 30, 50 µg mL-1 AZL and (b) 2,
4, 8, 12, 20 µg mL-1 CLT against (c) methanol blank
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Figure 3.3.2 Standard calibration curve for determination of AZL by the proposed
spectrophotometric method

Figure 3.3.3 Standard calibration curve for determination of CLT by the proposed
spectrophotometric method
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Figure 3.3.4 Synchronous fluorescence spectra for 0.06 µg mL-1 of (a) AZL and (b) CLT upon
excitation at 260 nm against (c) methanol blank using the described parameters
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Figure 3.3.5 Standard calibration curve for determination of AZL by the proposed synchronous
spectrofluorimetric method

Figure 3.3.6 Standard calibration curve for determination of AZL by the proposed Conventional
spectrofluorimetric method
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Figure 3.3.7 Standard calibration curve for determination of CLT by the proposed Conventional
spectrofluorimetric method

Figure 3.3.8 Effect of different diluting solvents on the Zero order UV-absorbance spectra of (a)
20 µg mL-1 of AZL at 260 nm and (b) 8 µg mL-1 of CLT at 232 nm
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Figure 3.3.9 First derivative for the spectra of (a) 8, 12, 20, 30, 50 µg mL-1 of AZL and (b) 2, 4,
8, 12, 20 µg mL-1 CLT against (c) methanol blank
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Figure 3.3.10 Effect of different diluting solvents on the relative conventional fluorescence
intensities for 0.02 µg mL-1 of AZL and CLT at 381 nm upon excitation at 260 nm using the
described parameters
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Figure 3.3.11 Effect of pH of PBS on the relative conventional fluorescence intensities for 0.02
µg mL-1 of AZL and CLT at 381 nm upon excitation at 260 nm using the described parameters

Figure 3.3.12 Effect of different surfactants (1 mL of 1% solution for each) on the relative
conventional fluorescence intensities for 0.02 µg mL-1 of AZL and CLT at 381 nm upon
excitation at 260 nm using the described parameters

258

Figure 3.3.13 Conventional emission spectra for 0.06 µg mL-1 of (a) AZL and (b) CLT upon
excitation at 260 nm against (c) methanol blank using the described parameters
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Table 3.3.1 Performance data and results of the proposed spectroscopic methods
Spectrophotometric

Spectrofluorimetric

technique

technique

Item
AZL

CLT

AZL

AZL

CLT

(1D)

(1D)

(4D)

(381 nm)

(330 nm)

0.977

0.296

0.001

0.001

0.002

2.960

0.897

0.003

0.004

0.005

Intercept (a)

0.0064

-0.0154

0.7876

41.996

3.5339

Slope (b)

0.0075

0.0224

789.1

6289.8

3922.4

Correlation coefficient (r)

0.9998

0.9999

0.9998

0.9991

0.9996

S.D. of residuals (Sy/x)

0.003

0.003

0.478

4.396

2.576

S.D. of intercept (Sa)

0.002

0.002

0.267

2.469

2.043

S.D. of slope (Sb)

0.001

0.001

8.048

74.453

61.598

0.75

0.55

0.76

0.94

1.23

8.00-50.00

2.00-20.00

0.01-0.08

0.01-0.08

0.01-0.06

99.55±

100.62±

99.94±

99.54±

100.61±

1.69

1.24

0.80

2.09

2.75

Limit of detection, LOD
(µg mL-1)
Limit of quantitation, LOQ
-1

(µg mL )

Percentage relative error, %
Error
Linearity range (µg mL-1)
Mean recovery ± %R.S.D.
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Table 3.3.2 Intra-and inter-day validation for the spectroscopic methods

Medication

AZL

Intra-day assay

Inter-day assay

Found ±

Found ±

%R.S.D a

%R.S.D a

12.000

12.619 ± 0.63

12.124 ± 1.68

20.000

20.124 ± 2.02

20.258 ± 1.01

30.000

29.813 ± 1.23

29.457 ± 1.19

4.000

4.028 ± 0.32

4.051 ± 0.64

8.000

7.905 ± 1.63

8.054 ± 1.66

12.000

11.923 ± 1.08

11.789 ± 1.58

0.015

0.015 ± 2.09

0.015 ± 2.92

0.030

0.030 ± 2.22

0.030 ± 2.77

0.050

0.050 ± 1.36

0.050 ± 2.88

Concentration
(µg mL-1)

Spectrophotometric
Technique
CLT

Spectrofluorimetric
Technique

a

AZL

Mean and standard deviation of three determinations
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Figure 3.3.14 Fourth derivative of the synchronous fluorescence spectra for (a) 0.01, 0.02, 0.04,
0.06, 0.08 µg mL-1 of AZL and (b) 0.01, 0.02, 0.03 0.04, 0.06 µg mL-1 of CLT against (c)
methanol blank using the described parameters
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Table 3.3.3 Assay results for the determination of the studied drugs in their laboratory prepared
mixtures and dosage form
Synthetic mixtures (CLT:

Dosage form

AZL) (1.0: 1.6)

(Edarbcyclor® tablets)

Compound

CLT

Amount

Amount

%

taken

found

Found

(g mL-1)

(g mL-1)

6.000

6.045

10.000
18.000

Amount

Amount

taken

found

(g mL-1)

(g mL-1)

100.74

6.000

6.045

97.95

9.839

98.39

10.000

10.286

99.10

17.875

99.31

18.000

17.875

101.71

recovery%

technique

Spectrophotometric

Mean

± %R.S.D.

AZL

technique

Spectrofluorimetric

± %R.S.D.

99.59

1.19

1.93

102.22

9.600

9.813

100.45

16.000

15.813

98.83

16.000

16.480

101.17

28.800

28.480

98.89

28.800

28.480

100.48

± %R.S.D.

recovery%

99.48

9.813

recovery%

Mean

Found

9.600

Mean

AZL

%

99.98

100.70

1.94

0.40

0.0384

0.039

101.26

0.0384

0.037

97.40

0.0576

0.058

100.12

0.0576

0.057

99.30

0.0768

0.077

100.47

0.0768

0.076

98.80

100.62

98.50

0.58

1.00

Each result is the average of three separate determinations.
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3.4 Conclusions
In section 3.2, rapid, sensitive, and simple spectrofluorimetric methods were developed
and validated for simultaneous determination of ALS and AML in bulk and in dosage forms. The
proposed methods have many advantages regarding analysis time, sensitivity and cost compared
with those of the previously reported methods. Also, the proposed methods are less pollutant to
far extent as no harmful reagents are used. Moreover, lower values for LOD and LOQ could be
obtained easily by controlling the slit width of excitation and emission which could allow
determination of these drugs separately in plasma using the steady state spectrofluorimetric
method. Moreover, the direct steady state method showed good tolerance and could be applied
for the determination of ALS and AML in their co-formulated tablets with HCZ.
In section 3.3, rapid, sensitive, inexpensive and simple spectrophotometric and
spectrofluorimetric methods were developed and validated for determination of AZL in its
combination with CLT either in their laboratory prepared mixtures or in their combined
pharmaceutical formulation. The proposed methods have many advantages regarding analysis
time, sensitivity and cost.
Finally, the proposed methods can be used for the quality control of the cited drugs in
ordinary laboratories.
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4 FUNCTIONALIZED SILICA NANOPARTICLES FOR ENHANCED
ELECTROPHORETIC SEPARARTION OF SOME ACIDIC AND BASIC DRUGS

This chapter provides a systematic comparison of five functionalized silica nanoparticles
(SNPs) that can be used as pseudo-stationary phases (PSPs) in capillary electrochromatography.
Monoamine-modified SNPs (MA-SNPs), L-lysine-modified SNPs (L-SNPs), and linear poly Llysine (LPL-SNPs) were prepared using the proper organosilane coupling agents to render a
positive charge on the surface of the SNPs, whereas, cysteine-modified SNPs (CYS-SNPs) and
Glutamic acid-modified SNPs (GLU-SNPs) were prepared using amino acids-based organosilane
conjugate moieties to render a zwitter ionic nature and a negative charge on the surface of the
SNPs at the proper pH, respectively. The SNPs were prepared using the reverse microemulsion
approach with mean diameters in the range of 53.4 ± 5.9 nm to 82.7 ± 4.7 nm as shown by the
TEM measurements. The differences in the electrophoretic behavior, and the ability to separate
mixtures of acidic and basic drugs using these PSPs were evaluated by analyzing a mixture of
ibuprofen, ketoprofen, and valsartan as well as a mixture of atenolol and propranolol as examples
of acidic and basic compounds, respectively. An enhanced separation of the acidic or basic drug
mixtures was achieved using LPL-SNPs. Also, MA-SNPs resulted in fast and enhanced
separation of the acidic drugs mixture using the reversed polarity mode. Both CYS-SNPs and
GLU-SNPs did not show any significant change in the electroosmotic flow with non-negligible
improvement in the separation of the acidic drugs mixture at pH 4 using the reversed polarity
mode. These amino acids or peptides-modified SNPs can significantly help in achieving fast and
efficient separation of challenging mixtures of compounds of different charges.
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4.1 Introduction

The use of silica nanoparticles (SNPs) with surface modifications in different
applications is a topic of growing interest. Nanochemistry has been widely used in recent years
in various fields, including chemistry, physics, biology, material science, etc., because of their
advantageous features 1. The interest in nanoparticles (NPs) comes from their unique mechanical,
magnetic, catalytic, electronic, optical, and biological characteristics. Size of NPs can range from
1 to 1,000 nm and can consist of biodegradable polymers, metals, inorganic, or lipid constituents
2

. The applications of NPs include catalysis, electronics, biosensors, medicines, cosmetics,

imaging, bioanalysis and bio-related applications 3.

For instance, NP-based drug delivery

systems have been utilized to improve human health by illuminating tumors, brain, and other
cellular functions while using medical imaging 4.
Breakthroughs in the synthesis of SNPs are beneficial when designing and developing
nanosized probes.

SNPs can be modified with various organic groups and conjugated to

molecules, which include monoclonal antibodies, DNA, or other moieties 5.
The SNPs usually consist of a polymeric structure consisting of siloxan (-Si-O-Si-O-) and
high concentrations of silanol (Si-OH) groups on the outer surface and are a type of colloidal
metal oxide, which can be easily modified. There are two major classes of SNPs: solid SNPs
(SSNPs) and mesoporous SNPs (MSNPs). The MSNPs have many pores with a silica matrix,
and SSNPs have no pores. The MSNPs, with its empty pores and channels, can be filled with
various amounts of biomolecules and drugs as well as filling the gaps of molecules 6. Controlled
release of drugs from MSNPs pores is an excellent feature and can also prolong drug efficiency
6

.
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Functionalized SNPs also have some useful applications in the field of separation of
organic molecules either by using liquid chromatography or capillary electrophoresis (CE) as
they can be used as pseudostationary phases (PSP) or as additives to the mobile phase to enhance
the separation performance and get better resolutions 7.
NP capillary electrophoresis is the combination of NPs and CE technology in which NPs
are used as stationary or PSP to alter the electroosmotic flow (EOF), increase column capacity,
and improve separation selectivity and column efficiency. The technique combines the high
efficiency of CE with the high selectivity of HPLC that can be used for the separation of
different types of analytes. The use of NPs-based PSPs in capillary electrochromatography
(CEC)

8

has attracted the interest of many researchers because of its several merits, such as no

packing or frits, fast regeneration of the column, and the absence of stationary phase carry-over
effects. When NPs are used as PSPs, they are suspended in the background electrolyte and are
continuously pumped through the capillary. Compared with other CEC types, NPs are much
smaller than the particles used in packed columns, and improved separation efficiency is
expected due to their high surface-to-volume ratio 9. And compared with traditional micelles,
NPs have higher stability and larger surface area, which make them powerful buffer additives for
achieving more efficient separations 7.
NPs used in CEC usually include polymer nanoparticles, gold nanoparticles, molecularly
imprinted polymer NPs, dendrimers, and SNPs. Nilsson 7 and Palmer 4 reviewed the research in
the field of NPs in detail, including SNPs as well. SNPs own many advantages over other types
of NPs, such as good biocompatibility, no swelling in aqueous and organic solvents, and easy
post-modifications with different functional groups, etc. 10
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In the past decade, functionalized SNPs have received considerable attention and had
been successfully used as PSPs for the enhanced separation of organic acids and bases, drugs and
proteins

11

. SNPs used in CEC, contain hydroxyl functional groups with different binding sites

on the surface. In many cases, the SNPs have to be surface coated or are derived using specific
functional groups to provide additional interaction sites

12

. Achieving controlled localization of

two or more different molecular functionalities on the surface of NPs would offer several
profound advantages. For example, Bachmann and Gottlicher covalently modified commercially
available SNPs with a combination of reversed-phase groups and negatively charged groups

13

.

Also, Neiman et al. prepared one neutrally charged and two positively charged modified silica
solutions for the CEC separation of aromatic acids and their structural isomers

14

. Accordingly,

the development of synthetically tailored SNPs is of great significance in separation science.
EOF is a very important factor in CEC separation because analytes move through the
capillary by EOF drive, as well as self-electrophoretic mobility if they are charged

15

. Knowing

the direction and magnitude of the EOF will be helpful to understand the separation behavior.
Since the structures of amino acids can be easily modified, amino acids and their
derivatives would be candidates to act as precursors for modifying the surface of SNPs. Also,
due to their weak UV absorption and low cost, it is meaningful to use native amino acids functionalized SNPs as additives for enhanced electrophoretic separation of chiral and achiral
drugs

16

. Therefore, the design and synthesis of amino acid-functionalized SNPs could prove

useful for separation and determination of pharmaceutical compounds especially for
enantiomeric drugs and metabolites either alone or in combination with other chiral selectors
such as cyclodextrins, antibiotics or carbohydrates.

Synthesis of SNPs is usually carried out through two sol–gel methods: the Stöber method
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17

and the water in oil reverse microemulsion (WORM) method

18

. The particles prepared by

Stöber methods usually are not uniform. To overcome these shortcomings, WORM method is
preferred as it results in SNPs with better monodispersity. However, a high amount of surfactants
is needed in the synthesis process which necessitates extensive subsequent cleaning steps 19. This
article provides a systematic comparison of five functionalized SNPs using the WORM method;
Monoamine-modified SNPs (MA-SNPs), L-lysine-modified SNPs (L-SNPs), and linear poly Llysine (LPL-SNPs) were prepared using the proper organosilane coupling agents to render a
positive charge on the surface of the SNPs, whereas, cysteine-modified SNPs (CYS-SNPs) and
Glutamic acid-modified SNPs (GLU-SNPs) were prepared using amino acids-based organosilane
conjugate moieties to render a zwitterionic nature and a negative charge on the surface of the
SNPs at the proper pH, respectively, Fig. 4.1.
The separation of acidic compounds in unmodified capillaries is often unsatisfactory and
requires higher pH buffer solutions (∼neutral or alkaline) in order to produce higher cathodic
EOF to surpass the anodic electrophoretic mobility of analytes. The poor separation of the acidic
analytes in bare capillary can be caused by the migration of the acidic compounds in reverse
direction with the EOF. Hence, the five proposed modified SNPs were explored as background
electrolyte additive to investigate their effect on the EOF, and hence on the separation of two
separate mixtures of acidic and basic drugs. The mixture of acidic drugs consisted of ibuprofen
(IBU), Ketoprofen (KET), and Valsartan (VAL) whereas the mixture of basic drugs consisted of
propranolol (PRP) and atenolol (ATN), Fig. 4.2.
These amino acids or peptides-modified SNPs can significantly help in achieving fast and
efficient separation of challenging mixtures of achiral and chiral compounds of different charges.
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Figure 4.1 The structural formulae of the proposed amino acid-based functionalized SNPs; (a)
MA-SNPs, (b) L-SNPs, (c) LPL-SNPs, (d) CYS-SNPs, and (c) GLU-SNPs
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Figure 4.2 The structure formulae for (a) ibuprofen, (b) ketoprofen, (c) valsartan, (d) atenolol,
and (e) propranolol

4.2 Experimental
4.2.1 Reagents and materials

All chemicals were analytical-grade unless noted otherwise. All the following chemicals
were produced by Sigma-Aldrich, MO, USA: 1-heptanol (anhydrous, ≥99%), 3-aminopropyl
triethoxysilane (APTES) (≥98%), tetraethyl orthosilicate (TEOS) (99.99% trace metal basis), 3(Triethoxysilyl)propyl isocyanate (95%), Ethyl acetate, anhydrous (99.8%), tert-butyl alcohol
(99.5%), (±)-propranolol hydrochloride (99%), (±)-atenolol (98%), (±)-ketoprofen (98%),
sodium hydroxide (pellets, 97+%, A.C.S. reagent), cyclohexane (anhydrous, 99.5%), di-tertbutyl dicarbonate (98%), L-cysteine (97%), poly-L-lysine hydrobromide (P2636), ethanol
(99.7%), dichloromethane, sodium phosphate, dibasic (98+%), potassium phosphate monobasic
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(>95%), TRIS-HCl buffer, magnesium sulfate anhydrous (99.5%), potassium hydrogen sulfate
(99%), sodium bicarbonate, trifluoroacetic acid (TFA), hydrochloric acid (37%), and Triton™ X100 (laboratory grade). Fisher Scientific, Fair Lawn, NJ, produced ammonium hydroxide
solution (28%). Alfa Aesar, Ward Hill, MA, produced L-glutamic acid, 99+%. Aldrich
Pharmaceutical

Company

Inc.,

Milwaukee,

WI,

USA

produced

DMAP

(4-

Dimethylaminopyridine) (99%), 1,3-dicyclohexyl-carbodiimide (DCC) (99%), sodium hydrogen
carbonate (99%), and glutaric dialdehyde (50 wt.%) solution in water. AK Scientific, Inc., Union
City, CA, USA produced ±ibuprofen (98%), and L(+)-glutamic acid (99%). Pharmaceutical
grade VAL USP was supplied by Zydus, batch No.: VSK1MK A02B (certified to contain
99.4%).

4.2.2 Instrumentation
Regarding instrumentation, separations were performed using a Beckman Coulter P/ACE
MDQ (144001) Capillary Electrophoresis System (Fullerton, CA, USA) equipped with an
autosampler and a UV detector for the CE technique. Beckman Coulter's 32 Karat™ Software
3.0 was used for the instrument control, data acquisition, and analysis. Electrophoretic analyses
were performed in a fused silica capillary (Polymicro Technologies, Phoenix, AZ, USA) of 53.2
cm long (42.5 cm effective length) and 50 μm id. Prior to the first use, the capillary was
successively rinsed with methanol, DI water, 1 M NaOH, DI water, 1 M NaOH, DI water, 0.1 M
HCl, DI water, and 25 mM phosphate buffer (pH 5) for 20 min each. Afterwards, the capillaries
were flushed with a 5 mg/mL SNPs suspension for 5 min and left to stand for 10 min, and this
step was repeated three times. Nano pure water was prepared using a Barnstead NANO pure
DIamond Analytical ultrapure water system (Fischer Scientific, NJ, USA). A SympHonly
(SB20) pH-meter (Thermo Orion, MA, USA) was used for pH adjustment. Transmission
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electron microscopy micrographs were conducted by the Zeiss LEO 912AB (Zeiss, Thornwood,
NY). Scanning electron microscopy micrographs were conducted by the Tescan Vega3 LMU
scanning electron microscope (TESCAN, Kohoutovice, Czech Republic) and Denton Desk II
sputter coated with a gold target (Denton Vacuum, NJ, USA). 0.2 mg/mL SNPs suspensions
dispersed in ethanol or water were subjected to particle size determination analysis using a
Malvern Mastersizer (Malvern Instruments Ltd., Malvern, UK. The polydispersity index (PDI),
and standard deviation were obtained from three independent measurements of the dispersions of
SNPs. The zeta potential of particles dispersions in water was measured. NPs separation required
an Allegra 64R Centrifuge (Beckman Coulter Inc., Brea, CA).
4.2.3 Synthesis of the amino acid-based conjugate moieties (ACM)
The reaction progress was monitored using silica gel 60 F254 thin layer chromatography
plates (Merck EMD Millipore, Darmstadt, Germany). Open column chromatography was
utilized for the purification of all final compounds using 60−200 μm, 60A classic column silica
gel (Dynamic Adsorbents, Norcross, GA). The nuclear magnetic resonance spectra were
obtained using high quality Kontes NMR tubes (Kimble Chase, Vineland, NJ) rated to 500 MHz
and were recorded on a Bruker Avance 400 MHz spectrometer interfaced to a PC using Topspin
3.1. High-resolution accurate mass spectra were obtained at the Georgia State University Mass
Spectrometry Facility using a Waters Q-TOF micro (ESI-Q-TOF) mass spectrometer.
4.2.3.1 Synthesis of L-ACM
The synthesis included three steps, (Scheme 4.1). In the first step, a 50 mL flask was
charged with a solution of NaOH (0.454 g, 0.011 moles) in water (12.5 mL). Then, L-lysine
(1.503 g, 0.010 moles) was added followed by tert-butyl alcohol (10 mL). The solution was
cooled in an ice bath, and subsequently, di-tert-butyl dicarbonate (5.462 g, 0.025 moles) was

282

added in three portions over a one hour period. After the addition was completed, the reaction
mixture was stirred for another hour. Then, the ice bath was removed and the reaction mixture
was stirred overnight at room temperature. After that, the reaction mixture was diluted with an
equal volume of ethyl acetate and acidified by the addition of a solution of KHSO 4 (2.3 g, 0.017
mole) in water (15 mL). The ethyl acetate layer was separated, and the aqueous phase was
extracted once more with ethyl acetate. The combined ethyl acetate fractions were washed with
water, separated, dried over MgSO4, filtered, and evaporated under reduced pressure. Upon
drying under vacuum, the resulting yellow oil turned into yellowish white foam (di-BOC-lysine).
Yield was 2.88 g (81%). In the second step, 4 0.533 g (488 μL, 1.54 mmoles) of di-BOC-lysine
free acid, 167 μl (0.77 mmoles) of APTES, 36.6 mg (0.324 mmoles) of DMAP (4Dimethylaminopyridine), and 0.32 g (1.53 mmoles) of DCC were dissolved in 15 mL of
methylene chloride and stirred for 20 h at room temperature. The reaction mixture was filtered to
remove N,N'-dicyclohexyl urea (DCU), washed four times with 15 mL 0.5 M sodium
bicarbonate, 15 mL 0.2 N HCl, and 15 mL saturated NaCl solution, and dried over MgSO4. The
solution was then concentrated under reduced pressure to obtain di-BOC-L-ACM. In the third
step, the precipitate then obtained (0.5 g) was collected and was subjected for further reaction
preceded by its deprotection with 1:1 trifluoroacetic acid (TFA): dichloromethane (DCM) (2 mL)
and stirred for 8 hours at room temperature. The solution was then concentrated overnight under
reduced pressure. Materials were recrystallized in a 3:1 acetone/methanol mixture and dried to
obtain yellowish white crystals of L-ACM. Yield was 0.122 g (34% yield). MS (ESI): 478 (M+).
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Scheme 4.1 Synthesis of L-ACM

4.2.3.2 Synthesis of the zwitter ionic L-cysteine-based conjugate moieties (CYS-ACM)
A 50-mL flask was charged with L-Cysteine (0.315 g, 2.0 mmole) in DMF (4.0 mL).
Then, 3-(Triethoxysilyl)propyl isocyanate (0.519 mL, 2.10 mmole) was added. After the addition
was completed, the reaction mixture was stirred for three days at room temperature. The product
was filtered and washed several times with DMF. The solid was dried under reduced pressure to
obtain CYS-ACM. Yield was 0.681 g (92% yield), Scheme 4.2.

Scheme 4.2 Synthesis of CYS-ACM
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4.2.4 Preparation of the functionalized SNPs
To obtain spherical SNPs with small size and narrow size distribution patterns, modified
Stöber methods were used in the beginning for the synthesis of bare SNPs, MA-SNPs, L-SNPs,
and CYS-SNPs then a WORM method was used for the preparation of bare SNPs, MA-SNPs, LSNPs, LPL-SNPs, CYS-SNPs, and GLU-SNPs, (Fig. 4.3). The amounts of all reagents for each
preparation method were adjusted carefully.
4.2.4.1 Preparation of bare SNPs and MA-SNPs by a modified Stöber method
MA-SNPs were prepared by modifying the Stöber method, Fig. 4.3. The first solution
was a mixture of 0.930 mL TEOS and 7.50 mL ethanol, and the second solution was a mixture of
0.230 mL 28% (w/w) ammonia, 2.30 mL DI water, and 5.870 mL ethanol. With stirring, the first
solution was added to the second solution. After reaction for 24 h at room temperature, APTES
acting as surface functionality was added with TEOS, with the volume ratio of APTES to TEOS
equals 1:1 for particle co-condensation. The total amount of functionalized trialkoxysilane
reagents added corresponds to 5% of the initial amount of TEOS. The mixture was further
reacted for 24 h, and the particles thus formed were centrifuged and washed with ethanol and DI
water for several times, then vacuum-dried at 80 °C for 6 h. If no functionalization was intended,
the reaction mixture of TEOS, ethanol, and ammonia was stirred overnight at room temperature
in a similar way, and the bare SNPs thus formed were centrifuged and washed with ethanol and
DI water for several times and then vacuum-dried at 80 °C for 6 h.
4.2.4.2 Synthesis of L-SNPs by a modified Stöber method
L-SNPs were prepared by modifying the Stöber method

20

, Fig. 4.3. A total amount of 1

mL of TEOS (∼4.5 mmol) was added to a conical flask in the presence of 12.5 mL of ethanol
and 1 mL DI water. The solution was sonicated for 10 minutes, and then 0.4 mL of ammonia was
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added gradually. After 24 h of reaction under stirring at room temperature (200 rpm), 0.23
mmoles (107 mg) of L-ACM was dissolved in 0.5 mL ethanol and added with extra TEOS (0.23
mmoles, 50 μL) gradually. The reaction of the obtained mixture continued for another 24 h (120
rpm), and the particles thus formed were centrifuged and washed with ethanol and DI water
repeatedly, then the residue was left to dry completely at 80 °C.
4.2.4.3 Synthesis of CYS-SNPs by a modified Stöber method
CYS-SNPs were prepared by modifying the Stöber method 20, Fig. 4.3. A total amount of
0.625 mL of TEOS (∼2.8 mmol) was added to a conical flask in the presence of 1 mL of
methanol, 0.36 mL DI water, and 0.08 mL NH4OH. The solution was stirred at room temperature
for 24 h, and then 0.09 mmol CYS-ACM were added, and stirred for another 24 h at room
temperature, and the particles thus formed were centrifuged and washed with methanol and DI
water repeatedly, then the residue was left to dry completely at 80 °C.
4.2.4.4 Synthesis of bare SNPs and MA-SNPs by WORM method
Bare SNPs were prepared by modifying the WORM method. The micelles were prepared
using 15.0 mL cyclohexane, 2.60 mL 1-heptanol, 3.55 mL Triton™ X-100, and 1.13 mL DI H2O
which were stirred for 10 min to generate the microemulsion. After time elapsed, 3.0 mL TEOS,
and 0.12 mL ammonium hydroxide were added and the solution was stirred at low speed for 24
h. In order to modify the surface of the SNPs to prepare MA-SNPs, 0.075 mL from each of
TEOS and APTES were added gradually to the reaction mixture and stirred at low speed for
another 24 h at room temperature. Afterward, 5.0 mL acetone were added, and the NPs were
collected by centrifugation and washed 5 times with absolute ethanol and two times with water
to remove any unreacted chemicals, Fig. 4.3, then the residue was left to dry completely at 80 °C.
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4.2.4.5 Synthesis of L-SNPs, and CYS-SNPs by WORM method
75.0 mg bare SNPs prepared as described in the previous section were added to a conical
flask, and suspended in 7.5 mL 50 mM TRIS-HCl buffer (pH 8.0) with stirring at low speed.
Afterwards, 7.5 mg L-ACM in the case of L-SNPs or 7.5 mg CYS-ACM in the case of CYSSNPs were dissolved in 2.0 mL 90% ethanol, and added dropwise to the reaction mixture. Then,
15.0 μL TEOS and 40.0 μL ammonium hydroxide were added, and the reaction mixture was
stirred for 18 h at room temperature. The NPs were collected by centrifugation and washed 3
times with each of 50 mM TRIS-HCl buffer (pH 8.0), ethanol and water to remove any unreacted
chemicals, Fig. 4.3, then the residue was left to dry completely at 80 °C.

Figure 4.3 Modifying the surface of bare SNPs to prepare MA-SNPs, L-SNPs, and CYS-SNPs
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4.2.4.6 Immobilization of linear poly-L-lysine or glutamic acid on the surface of MA-SNPs
The primary amino groups on the MA-SNPs carrier were modified with glutaric acid
dialdehyde molecules to effectively combine with the linear poly-L-lysine (LPL) or L-glutamic
acid (GLU), Fig. 4.4. In detail, 60 mg of MA-SNPs prepared by WORM method were dispersed
in 5.0 mL 50 mM ammonium acetate buffer solution of pH 7.0, and then 1 mL of 50 (Wt.%)
glutaric acid dialdehyde solution in water was then added to the dispersion solution, which was
stirred overnight at room temperature. Samples were then centrifuged and washed with DI water
four times to remove the excess reagent. Finally, the solid was dried at 60 °C in a vacuum drying
oven. For the immobilizing procedure, 50 mg of carrier (Glut-MA-SNPs) were added into 2 mL
of 10.0 mg/mL LPL or 7.5 mg/mL L-glutamic acid solutions prepared in 50 mM ammonium
acetate buffer, pH 5. Afterwards, the mixtures were stirred gently for 12 h in an ice bath,
followed by centrifugation. The collected NPs were rinsed alternately three times with the same
buffer and DI water, then the residue was left to dry completely at 60 °C.
4.2.5 Characterization of the functionalized SNPs

The developed functionalized SNPs were characterized in detail by one or more of the
following techniques: TEM, SEM, dynamic light scattering (DLS), zeta potential measurements,
and FT-IR.

288

Figure 4.4 Immobilization of linear poly-L-lysine or L-glutamic acid on the surface of MASNPs

4.2.6 Standard and working solutions
72 mM of IBU, KET, 48 mM of ATN, PRP and 24 mM of VAL stock solutions were
prepared separately in methanol. The mixture of the acidic drugs consisted of 3.6 mM IBU, 3.6
mM KET, and 1.2 mM VAL whereas the mixture of the basic drugs consisted of 2.4 mM PRP
and 3.6 mM ATN which were prepared by transferring the proper aliquots from the
corresponding stock solutions, and completing the volume with methanol and water to reach a
final ratio of 25% methanol in DI water. The solutions were stable for one month when kept in
the refrigerator at 2 oC.
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4.3 Results and discussion
4.3.1 Characterization of the functionalized SNPs
The physical nature and dimensions of the particles were derived from the SEM, TEM,
and DLS scans. Two sol-gel methods were used in preparing the functionalized SNPs. The NP
diameter obtained from TEM images, the mean hydrodynamic particle sizes by DLS, PDI, and
zeta potential values are summarized in Table 4.1 and 4.2. The NPs prepared by Stöber method
had relatively larger diameters with a poor control on the monodispersity of the size and shape as
shown in Fig. 4.5 and Table 4.1. SEM and TEM micrographs showed that the SNPs prepared by
WORM method had a spherical shape and a narrow size distribution as can be seen in Fig.4.6
and Table 4.2. Although having different surface functional groups, the five functionalized SNPs
had nearly the same shape and size morphology. The five materials were sphere-like and uniform
in shape, with an average size of approximately 79 nm.
As shown in Table 4.2, the zeta potential of both the bare SNPs

21

and GLU-SNPs

colloidal SNPs showed a highly negative charge of about -44 mV whereas CYS-SNPs and LSNPs showed a relatively lower negative charge of about -37 and -35 mM, respectively. MASNPs showed a positive charge of +14.7 ± 4.37 mV while LPL-SNPs showed a wide range of
charge deviation between -48.0 to + 60.0 mV which can be attributed to the ionization nature of
the poly L-lysine protein at the neutral pH of the used dispersant.
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Figure 4.5 TEM photographs for SNPs prepared by Stöber method for (a) bare SNPs, (b) MASNPs, (c) L-SNPs, and (d) CYS-SNPs

Figure 4.6 SEM and TEM photographs for SNPs prepared by WORM method. (a) SEM
photographs of bare SNPs, TEM photographs for: (b) bare SNPs, (c) LPL-SNPs, (d) MA-SNPs,
(e) L-SNPs, (f) CYS-SNPs, and (g) GLU-SNPs
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Table 4.1 Diameter determined by TEM and DLS, polydispersity index (PDI), zeta potential of
0.1 mg/ml SNPs in ethanol (prepared by Stӧber method)
SNPs

Diameter (TEM)
(nm)

Diameter (DLS)
(nm)

PDI

Zeta potential
(mV)

Bare SNPs

343.2 ± 40.4

145.3 ± 36.45

0.402

-25.0 ± 14.9

MA-SNPs

119.8 ± 9.9

299.6 ± 119.3

0.217

+6.7 ± 5.2

L-SNPs

123.3 ± 6.3

275.4 ± 105.8

0.190

-12.3 ± 9.1

CYS-SNPs

347.7 ± 38.3

387.5 ± 41.2

0.285

-32.0 ± 5.6

Table 4.2 Diameter determined by TEM and DLS, polydispersity index (PDI), zeta potential of
0.1 mg/ml SNPs in DI water (prepared by WORM method).
SNPs

Diameter (TEM)
(nm)

Diameter (DLS)
(nm)

PDI

Zeta potential
(mV)

Bare SNPs

58.8 ± 6.6

189.8 ± 81.7

0.242

-44.1.0 ± 11.3

MA-SNPs

77.1 ± 4.6

384.2 ± 126.6

0.254

+14.7 ± 4.37

LPL-SNPs

79.9 ± 6.3

164.2 ± 0.01

0.974

-0.36 ± 31.5

L-SNPs

77.9 ± 4.9

342.4 ± 78.1

0.656

-35.7 ± 6.31

CYS-SNPs

82.7 ± 4.7

328.3 ± 180.8

0.531

-37.2 ± 3.78

GLU-SNPs

78.1 ± 5.0

439.3 ± 51.9

0.542

-44.3 ± 3.46
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FT-IR spectra of bare SNPs and amine-modified SNPs (Fig. 4.7) showed the presence of
organic groups. In comparison with pure SNPs, several new absorption bands appeared in the
spectrum of MA-SNPs. The peak between 3,300 and 3,500 cm-1 are assigned to the stretching
vibration of the amino group (m-NH2), and the peaks at 1,650 and 624 cm-1 are the bending
vibrations of the amino group (d-NH2 and s-NH2). These results confirmed the presence of
functional groups on the surface of SNPs.

3600

3100

2600

Bare SNPs-S

2100

1600

1100

600

MA-SNPs-S

Figure 4.7 The IR spectra of bare SNPs (a), and MA-SNPs (b)

4.3.2 EOF Characteristics
EOF is a very important factor in CE separation because analytes are driven through the
capillary both by the EOF and as a result of self-electrophoretic mobility if they are charged.
When the amine-functionalized NPs such as MA-SNPs, L-SNPs, and LPL-SNPs are suspended
in the acidic background electrolyte, they are positively charged, because of the amino groups on
their surface. Thus they were adsorbed on the inner wall of the negatively charged capillary to
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form a dynamic coating under acidic buffer solutions. As a result, reversed anodic EOF was
obtained. Fig. 4.8 depicts the dependence of the EOF mobility of the used SNPs-based PSPs on
buffer solution pH. Considering that the silica-based materials tend to dissolve in strongly
alkaline solutions, the pH range of 3–8 was selected for this investigation.
From Fig. 4.8 it can be observed that only cathodic EOF can be detected by varying the
pH of the running electrolyte because no suitable functional groups exist on the surface of the
bare SNPs and GLU-SNPs to reverse the EOF. Moreover, bare SNPs, CYS-SNPs, L-SNPs, and
GLU-SNPs did not show in significant difference in EOF from the unmodified capillary
columns. With MA-SNPs and LPL-SNPs the anodic EOF velocity decreased when the buffer pH
increased from 3 to 5 whereas the cathodic EOF velocity increased when the buffer pH increased
from 6.5 to 8. At pH 3, the amine groups of the functionalized SNPs were protonated strongly
and residual silanol groups on the capillary were partly suppressed. With increasing pH, the
anodic EOF velocity decreased as the ionization of the amine groups became weaker. At pH 6.0,
no EOF was observed because the net charge between the positively charged functionalized
SNPs and the negatively charged capillary wall was nearly zero. Moreover, from this plot, it can
be observed that an increased reversed anodic EOF can be obtained from LPL-SNPs compared
with MA-SNPs at very low pH values. The amine-modified SNPs that can generate a reversed
EOF should have a positive effect on the separation of charged analytes especially the acidic
compounds.
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Figure 4.8 Effect of buffer pH on EOF. Experimental conditions: capillary, total length 53.2 cm,
effective length 42.5 cm; buffer, 25 mmol/L KH2PO4 buffer without additives (a), with 0.5
mg/mL bare SNPs (b), with 0.5 mg/mL functionalized SNPs (c-g); detection wavelength, 214
nm; separation voltage, 20 kV or – 20 kV; hydrodynamic injection for 6 s

4.3.3 Electrophoretic Separation
4.3.3.1 Effect of modified SNPs
The separation of acidic compounds in unmodified capillary columns is often
unsatisfactory because acidic compounds migrate in the reverse direction to the EOF, resulting in
longer separation time

22

. For fast and efficient separation of acidic compounds, it is preferred

that the analytes migrate in the same direction as the EOF (co-EOF). Because the direction of the
EOF is from cathode to anode under low pH conditions in the case of MA-SNPs and LPL-SNPs
(Fig. 4.8), it is expected that fast separation can be obtained for acidic compounds. Taking into
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account all those aspects, three acidic drugs IBU, KET, and VAL and two basic drugs PRP and
ATN were chosen as target analytes to evaluate the performance of five functionalized SNPs as
buffer additives in CE. First, no NPs were added to the running buffer. However, it was difficult
to observe resolved peaks of the three acidic drugs or the two basic drugs using normal polarity
mode over the pH range 3.0 to 8.0 as can be seen in Fig. 4.9 and 4.10, respectively. Hence, the
organically functionalized SNPs were evaluated as buffer additives to improve the separation
where five different functionalized SNPs were separately added to the running buffer as PSP in
the concentration of 0.5 mg/mL. A background electrolyte of pH 4 and negative polarity were
used in the case of analyzing the acidic drugs, Fig. 4.11, whereas pH 3 and positive polarity were
used in the case of analyzing the basic drugs, Fig. 4.12. As it can be observed in Fig. 4.11 and
Table 4.3, only MA-SNPs and LPL- SNPs additives were able to resolve the three acidic
analytes in less than 15 min with acceptable peak shapes. Also, only LPL-SNPs were able to
resolve the two analyzed basic drugs but with a prolonged run time and poor peak shapes, Fig.
4.12, Table 4.3.
The fast and successful separation of the acidic analytes is based on the fact that the
direction of EOF is from cathode to anode under lower pH conditions in the tested separation
system, that is, to say that the analytes migrate in the same direction with the EOF (co-EOF).
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Figure 4.9 The effect of pH on the separation of the three acidic drugs without SNPs.
Experimental conditions: Applied voltage 20 kV at pH 3, 4, 5, 6.5 or 8. The other conditions are
the same as given in Fig. 4.8. Peak identities: 1 VAL; 2 KET; 3 IBU.
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Figure 4.10 The effect of pH on the separation of the two basic drugs without SNPs.
Experimental conditions: Applied voltage 20 kV at pH 3, 4, 5, 6.5 or 8. The other conditions are
the same as given in Fig. 4.8. Peak identities: 1 PRP; 2 ATN
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Figure 4.11 Electropherograms obtained from the three acidic drugs in the absence of SNPs (a),
in the presence of MA-SNPs (b), LPL-SNPs (c), L-SNPs (d), GLU-SNPs (e), and CYS-SNPs (f).
Experimental conditions: buffer, 25 mM phosphate buffer (pH 4) with (or without) 0.5 mg/mL
SNPs added; applied voltage -20 kV; injection, 1psi for 6 s. The other conditions are the same as
for Fig. 4.8.
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Figure 4.12 Electropherograms obtained from the three acidic drugs in the absence of SNPs (a),
in the presence of MA-SNPs (b), LPL-SNPs (c), L-SNPs (d), GLU-SNPs (e), and CYS-SNPs (f).
Experimental conditions: buffer, 25 mM phosphate buffer (pH 3) with (or without) 0.5 mg/mL
SNPs added; applied voltage 20 kV; injection, 1psi for 6 s. The other conditions are the same as
for Fig. 4.8.
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Table 4.3 Comparison of migration times and resolution using the proposed modified SNPs as
PSPs

Unmodified capillary

Migration time (min)

VAL

KET

IBU

ATN PRP

14.4

19.5

32.6

7.2

Resolution
MA-SNPs

Migration time (min)

1.07
9.5

Resolution
LPL-SNPs

Migration time (min)
Resolution

L-SNPs

GLU-SNPs

CYS-SNPs

11.2
1.43

8.5
0.91
14.6

Resolution

10.9

Migration time (min)

15.1

Migration time (min)
Resolution

0.95

10.6
1.0

------

25.7

---11.4 13.1
----23.5 29.1
1.55
9.6

11.1

----19.2

15.9
0.97

----16.8

13.0
1.18

9.5

Migration time (min)

Resolution

1.68

7.6

21.3

24.2
0.78

7.4

8.2

----6.7
-----

7.3
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4.3.3.2 Effect of pH
Running buffer pH is often important in achieving separations with high resolution in CE
[26]. In this investigation, MA-SNPs and LPL-SNPs were used as PSPs and added to the running
buffer using a pH ranging from 3 to 8 to evaluate any enhancement in the separation of the
selected mixtures of the acidic and basic drugs. It is clear that separation efficiency can be
readily tuned by adjusting the running buffer pH. For MA-SNPs (Fig. 4.13) and LPL-SNPs (Fig.
4.14), it was observed that at pH 3 the three acidic analytes were not resolved and at pH 8 only
VAL appeared. The pH range of 4 to 6.5 was suitable for the separation of the three acidic
analytes within a reasonable time where pH 4 showed the best separation efficiency for the three
analytes using both amine-based PSPs as presented in Table 4.3. Regarding the separation of the
two basic analytes, MA-SNPs did not show any obvious resolution of the two peaks over the
tested pH range (Fig. 4.15) whereas LPL-SNPs at pH 3 showed separation of the two peaks but
with poor peak shapes and prolonged migration times, (Fig. 4.16).
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Figure 4.13 The effect of pH on the separation of the three acidic drugs using 0.5 mg/mL MASNPs. Experimental conditions: 25 mM phosphate buffer at pH 3, 4, 5, 6.5 or 8. The other
conditions are the same as given in Fig. 4.11.
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Figure 4.14 The effect of pH on the separation of the three acidic drugs using 0.5 mg/mL LPLSNPs. Experimental conditions: 25 mM phosphate buffer at pH 3, 4, 5, 6.5 or 8. The other
conditions are the same as given in Fig. 4.11.

304

Figure 4.15 The effect of pH on the separation of the two basic drugs using 0.5 mg/mL MASNPs. Experimental conditions: 25 mM phosphate buffer at pH 3, 4, 5, 6.5 or 8. The other
conditions are the same as given in Fig. 4.12.
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Figure 4.16 The effect of pH on the separation of the two basic drugs using 0.5 mg/mL MASNPs. Experimental conditions: 25 mM phosphate buffer at pH 3, 4, 5, 6.5 or 8. The other
conditions are the same as given in Fig. 4.12.

4.3.3.3 Effect of applied voltage and SNPs concentration
In order to enhance the peak shapes, optimize the separation efficiency, and shorten the
run time while separating PRP and ATN using LPL-SNPs as PSPs, the effect of the applied
voltage was investigated. As can be observed in Fig. 4.17, increasing the voltage to +25 KV did
not show a significant enhancement in the separation efficiency of the two basic analytes. On the
other hand, the effect of changing the concentration of LPL-SNPs on the separation of the
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selected analytes was also investigated. As shown in Fig. 4.18, decreasing the concentration of
LPL-SNPs from 0.5 mg/mL to 0.2 mg/mL decreased the resolution and the migration times in
the case of the basic drugs and increased the migration times with a better resolution and poor
peak shapes in the case of the acidic drugs.

Figure 4.17 The effect of voltage on the separation of the two basic drugs without SNPs.
Experimental conditions: 25 mM phosphate buffer at pH 3. The other conditions are the same as
given in Fig. 4.12.
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Figure 4.18 The effect of LPL-SNPs concentration on the separation of the two basic drugs
using 0.5 mg/mL LPL-SNPs (a) and 0.2 mg/mL LPL-SNPs (b), and on the three acidic analytes
using 0.5 mg/mL LPL-SNPs (c) and 0.2 mg/mL LPL-SNPs (d). The other conditions are the
same as given in Fig. 4.11 and 4.12.
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4.4 Conclusions
Five functionalized-SNPs were successfully prepared by using Stöber or reverse
microemulsion methods. Under optimum experimental conditions, the obtained functionalized
SNPs were tested as PSPs which can be used to enhance the electrophoretic separation of
challenging mixtures of acidic or basic drugs. Four of these modifications were based on amino
acids to form suitable conjugate moieties to be copolymerized and grafted on the surface of
SNPs and render them different charges and ionization patterns based on the nature of the added
functional groups and the pH of the used background electrolyte. Furthermore, the
electrophoretic properties of bare SNPs and the functionalized SNPs, determined by their
different surface properties, were systematically investigated. The effects of running buffer pH,
applied voltage and concentrations of the PSPs on separation efficiency were also evaluated. It
was found that bare SNPs, L-SNPs, CYS-SNPs, and GLU-SNPs did not result in any significant
enhancement in the separation of the selected acidic or basic drugs` mixtures. However, MASNPs and LPL-SNPs showed obvious enhancement in the separation of the acidic drugs VAL,
KET, and IBU in the pH range of 4-6.5 in terms of migration times, peak shapes, and separation
efficiency especially at pH 4. The fast and successful separation of the acidic analytes can be
attributed to the anodic co-EOF caused by the positive charge of the amino groups on the surface
of these modified SNPs at low pH. Regarding PRP and ATN binary mixtures, LPL-SNPs at pH 3
provided the most suitable conditions to resolve these two analytes but with prolonged migration
times and poor peak shapes. Finally, the introduced functionalized SNPs could be tested either
alone or in combination with other chiral selectors for their ability to enhance the separation of
some enantiomeric drug mixtures using the CE technique.
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5 FLUORESCENTLY LABELED SILICA NANOPARTICLES FOR SOME
FORENSIC AND BIO-RELATED APPLICATIONS
5.1 Introduction
Silica nanoparticles (SNPs) have proven to be useful in many applications in the areas of
chemistry, forensics, nanomedicine and related technologies. Combining the properties of SNPs
and fluorescent dyes that can serve as chemical probes is relatively easy by synthesizing
fluorophore-encapsulated core-shell silica nanoparticles (FLSNPs), a process that results in the
fluorescent dye covalently or non-covalently attached to the structure of the silica matrix.
Moreover, this platform can enhance both the brightness and photostability of the dyes,
compared to the free dye 1.
Several approaches have been reported for the encapsulation of organic fluorophores into
SNPs 2, 3. To meet certain applications` requirements, FLSNPs must possess high quantum yield,
good photostability, size uniformity as well as minimized dye leakage. Synthesis of FLSNPs is
usually carried out through two sol–gel methods: the Stöber method 4 and the water in oil reverse
microemulsion (WORM) method 5. The particles prepared by Stöber methods usually are not
uniform. To overcome these shortcomings, WORM method is preferred as it results in SNPs
with better monodispersity. However, a high amount of surfactants is needed in the synthesis
process which necessitates extensive subsequent cleaning steps 6. Recently, an approach via an
amino acid-catalyzed seeds regrowth technique (ACSRT) using L-arginine as a catalyst to
prepare nanoparticles of tunable sizes as well as minimized dye leakage without covalent
copolymerization has been developed 7. The new technique can overcome the limitations of the
other two methods by obtaining less polydisperse SNPs without the use of surfactants.
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The formation mechanism of SNPs affects the rate of dye leaching. Toshiyuki Yokoi et
al. 8, reported that silica nanoparticles were synthesized under weakly basic conditions where the
basic amino acid, L-arginine was used as a catalyst. The pH of the reaction medium during the
seeds formation step is about 9-10 in the basic amino acids based approach whereas the
hydrolysis reaction of TEOS in the other methods is conducted under much more basic
conditions (pH 12-13). Moreover, a slight change in the pH was observed in the ACSRT system.
This is probably due to consumption of the hydroxyl species as well as the formation of a large
number of weakly acidic silanol groups. The presence of arginine with a buffering action might
cause the slight reduction in the pH during the synthesis to achieve a slow hydrolysis of TEOS
which allows particle growth through complete hydrolysis. Thus, the FLSNPs synthesized with
the amino acid approach are less vulnerable to dissolution and dye leakage 8, 9.
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5.2

A Comparative Study of Fluorescein Isothiocyanate-Encapsulated Silica
Nanoparticles Prepared in Seven Different Routes for Developing Fingerprints

Preparation of fluorescein isothiocyanate (FITC)-encapsulated silica nanoparticles (FSNPs) with seven different approaches to be used as developing agents for fingerprints detection
is presented in this report. In this study, the suitability of each synthesis route toward
incorporation of the selected fluorophore into silica matrix and its efficiency in fingerprints
detection were systematically studied. The composition of the particles was designed to examine
the hydrophobic and/or ionic interactions between the silicate backbone and both of the
fluorescent reporter molecule and the fingerprint residues. F-SNPs were prepared using two
conventional approaches; Stöber method and water in oil reverse microemulsion (WORM)
method. The alkoxysilane precursor, tetraethoxyorthosilicate (TEOS) and its binary mixtures
with phenyltriethoxysilane (PTEOS) or 3-aminopropyl triethoxysilane (APTES) have been used
in preparing the F-SNPs to study the effect of nanoparticles composition on fingerprints
development. In addition, FITC was conjugated with APTES so it can be covalently bonded to
the silica matrix and to be compared with the non-covalently FITC-doped SNPs. Moreover, the
enhancement effect of introducing polyvinylpyrrolidone (PVP) onto the surface of the less
hydrophobic F-SNPs on fingerprints detection was also investigated. The mean diameters of the
F-SNPs were between 4.1±0.6 and 110.4±31.1 nm as shown by TEM size analysis for the
nanoparticles prepared by WORM and Stöber methods, respectively. The obtained results clearly
highlight the advantages of using a mixture of TEOS and PTEOS alkoxysilane precursors in
preparing F-SNPs with remarkable encapsulation efficiency and clear detection of fingerprints
due to the efficient embedding of the fluorophore inside the silica network even without
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conjugation. It was also observed that both Stöber and WORM methods gave comparable results
and that PVP coated particles did not show any significant enhancement in fingerprints
visualization. This systematic investigation can be followed to determine the appropriate
preparation route of silica nanoparticles loaded with any other small molecules to be utilized in
forensic or biomedical applications.
5.2.1 Introduction
Detection of fingerprints at a crime scene is of great interest in forensic investigation
mainly for collecting physical evidences. Fingerprints visualization requires a specific reaction of
the developing agent with the fingerprint residue to obtain a clear contrast from the underlying
substrate. This residue is a complex mixture of organic compounds such as proteins, amino
acids, and lipids and some inorganic substances. Development of fingerprint can be achieved
either through a chemical interaction between the reagent and the components found in the
fingerprint deposit or via physical adhesion of a developing agent to the sticky fingerprint
residue 10, 11.
Various methods such as powder dusting, cyanoacrylate fuming, and ninhydrin have been
developed for fingerprint visualization. However, there is still a need for selective and sensitive
reagents for fingerprint development. Recently, there have been increased interests in using
nanoparticles (NPs) for fingerprints detection due to their unique properties. First, their small
particle size enhances detection of fingerprints due to increased resolution because small
particles have the ability to adhere with high affinity to the fingerprint residue

12

. Second, the

optical properties of fluorescent NPs allow detecting fingerprints with improved overall
sensitivity

13

. Finally, surface modification can be achieved by the incorporation of functional

groups possessing the potential interactions with certain components in the fingerprint residue,
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and thus increase the selectivity. Leggett et al. reported the use of antibody-functionalized gold
NPs to detect specifically cotinine, a metabolite of nicotine, only present in fingerprints left by
smokers 14. Many types of NPs such as gold NPs 15, quantum dots 16, 17, nanostructured powders
18

, and silica nanoparticles (SNPs)

19-21

, have been used as developing agents for fingerprints.

Despite all advantages of nanoparticles for fingerprint detection, there are still concerns
regarding their toxicity, cost, and laborious procedures. SNPs are a favorable candidate for
fingerprints detection due to their great surface-to-volume ratio, biocompatibility and high
photochemical stability 19. Furthermore, modification of SNPs surface can be easily achieved by
introducing several types of silicate monomer to target various compounds in the fingerprint
residue. For example, amphiphilic SNPs were synthetized and used as a developing agent where
the hydrophobic and hydrophilic nature of the used monomers made the surface of these particles
sensitive to the amino acids present in the fingerprint residue 20. Moreover, fluorophores such as
organic dye molecules can be incorporated within the silica matrix during the synthesis process,
providing superior optical properties and low background interference as presented in Theaker et
al. work where they developed hydrophobic silica micro- and NPs encapsulating fluorescent
dyes as developing agents for fingerprints detection 21.
Synthesis of SNPs is typically carried out through two commonly used sol–gel methods:
the Stöber method

4

and the water in oil reverse microemulsion (WORM) method 5. The

modified Stöber process is used in synthesizing silica colloids by means of hydrolysis and
condensation of the organosilicate monomers such as tetraethyl orthosilicate (TEOS), 3aminopropyl triethoxysilane (APTES) and phenyltriethoxysilane (PTEOS) in alcoholic alkaline
solutions (pH 11–12) where ammonia acts as a catalyst. On the other hand, the NPs prepared by
WORM show less polydispersity with better control of particle size allowed

5, 22

. However, a
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high amount of surfactants and co-surfactants are needed in the synthesis process making tedious
subsequent washing steps necessary

23

. Regardless of the synthesis route, several approaches

have been suggested for coupling of organic fluorophores into the SNPs platform

2, 3

. The

simplest approach is the non-covalent encapsulation of dyes into the silica matrix. Nevertheless,
the absence of a stable covalent attachment between the fluorophores and the silica matrix
implies that the dye molecules can leak out of the NPs over time, resulting in decrease in the
brightness of the NPs, increase in the background signal and exposition of the fluorophores to the
surrounding environment making them less suitable for fingerprints detection 24. On the contrary,
the dye leakage can be effectively avoided by covalent dye encapsulation. The covalent
incorporation of dyes into silica can be achieved by using an amine-containing organosilane as
the crosslinker such as APTES which can form a covalent binding between its amine group and
cyanate of the dye leading to the formation of thiourea linkage 25. It is obvious that the covalent
bonding approach is the best method for incorporation of a dye into SNPs. However, the dye
should have the necessary functional groups towards modification and conjugation with the
silicate precursors. This concept might increase considerably the difficulty of dye selection and
pre-modification.
To the best of our knowledge, most of the reports dealing with the application of
fluorescent SNPs in fingerprints development concentrated on the incorporation of fluorophores
into the colloidal silica spheres and on the nature of these fluorophores

26-28

. Nevertheless, very

few studies have been carried out that focus on the core and surface properties of the NPs used
for fluorophore encapsulation and their effects on the efficiency of fingerprints detection in a
systematic manner. It was suggested that for effective dye doping and fingerprints visualization,
mixtures of TEOS and PTEOS have to be used in synthesizing the NPs, hence it was concluded
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that analogous hydrophobic and electrostatic interactions occur within these hydrophobic NPs
between compatible groups within the fluorescein isothiocyanate (FITC) dye molecules or any
other dye of a related structure and the silica matrix 21. Moreover, it was reported that the dye is
not subject to photo-bleaching under exposure to high intensity UV illumination. Hence, these
NPs can be utilized as agents for developing fingerprints, including aged prints where the
residues mainly consist of hydrophobic endogenous chemicals secreted by the donor, due to the
hydrophobic nature of some of the proposed FITC-encapsulated silica nanoparticles (F-SNPs) 21.
It should also be noted that as the proportion of PTEOS increases, the hydrophobicity of the
resulting sol–gel also increases 29.
In this study, a systematic investigation of several factors that may influence the
efficiency of developing fingerprints is presented. These factors include (i) method of SNPs
preparation, (ii) the method of fluorophore encapsulation into the NPs matrix, and (iii) nature of
the used organosilicate precursors and (iv) surface modification of the dye encapsulated SNPs
using adhesive agents such as polyvinylpyrrolidone (PVP) and its enhancing effect on the
binding affinity to fingerprints. In order to study these factors, F-SNPs were prepared using
seven different approaches and tested as developing agents for some forensic applications such
as fingerprints detection.
5.2.2 Experimental
5.2.2.1 Materials and reagents
All the chemicals used were of Analytical Reagent grade, and the solvents were of HPLC
grade. All the following chemicals were produced by Sigma-Aldrich, MO, USA: fluorescein
isothiocyanate (FITC) (isomer I, 90%), 1-hexanol (anhydrous, ≥99%), 3-aminopropyl
triethoxysilane (APTES) (≥98%), tetraethyl orthosilicate (TEOS) (99.99% trace metal basis),
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sodium hydroxide (pellets, 97+%, A.C.S. reagent), cyclohexane (anhydrous, 99.5%), Ethanol
(99.7%), and Triton™ X-100 (laboratory grade). Fisher Scientific, Fair Lawn, NJ, produced
ammonium hydroxide solution (28%). Phenyltriethoxysilane (PTEOS) was supplied by ChemImpex Int`l Inc., IL, USA whereas polyvinylpyrrolidone (PVP) was supplied by Alfa Aesar, MA,
USA.
5.2.2.2 Pre-modification of FITC
In order to covalently incorporate FITC in the silica matrix, it was modified by inducing a
reaction between the isothiocyanate group of FITC and the amine group of APTES and forming
a thiourea linkage. A known amount of FITC was added to 1-hexanol to make a 1.0 mM
solution. 10 molar equivalents of APTES were added and allowed to stir for 24 h in a roundbottom flask to get the FITC conjugated with APTES (FCA), (Scheme 5.2.1). The reagents are
air sensitive and the reaction needs to be completed in a closed container in the dark.
5.2.2.3 Preparation of F-SNPs
To obtain F-SNPs with narrow size distribution patterns, the amounts of all reagents for
each preparation method were adjusted carefully in preliminary experiments. Seven synthesis
routes are schematically illustrated in Scheme 5.2.1.
5.2.2.3.1 Preparation of FITC doped (non-covalently) into the TEOS/PTEOS-based SNPs
(FDTPS)
FDTPS were prepared using the Stöber method where 0.30 mL 10 mM solution of FITC
in ethanol was transferred into a 25 mL round flask containing 2.7 mL ethanol and mixed with
0.25 mL PTEOS. 0.20 mL ammonium hydroxide was added to the resulting solution to start the
hydrolysis of the alkoxysilane precursor. The solution was stirred at low speed for 24 hours at
room temperature. 0.5 mL TEOS and 0.25 mL PTEOS, dissolved in 5.0 mL ethanol were added

320

to the hydrolyzed solution and further reacted with 0.10 mL ammonium hydroxide solution via
the Stöber process. The reaction was carried out for an hour at 0°C with continuous sonication
and frequent vortexing then stirred for another 24 hours at room temperature. The formed
particles were centrifuged and washed 3 times with a solution composed of ethanol and DI water
(1:1, v/v), then the residue was left to dry completely.
5.2.2.3.2 Preparation of FITC three covalently bonded-SNPs (FCTS, FCTPS, and FCTAS)
FCTS, FCTPS, and FCTAS were also prepared by the Stöber method where 0.50 mL of
the FCA conjugate solution were dissolved in 20.0 mL ethanol, followed by the sequential
addition of the proper volume of the alkoxysilane precursor(s), 1.60 mL DI H2O, and 1.60 mL
ammonium hydroxide solution. 1.00 mL TEOS was used in the case of FCTS preparation while
0.5 mL TEOS and 0.5 mL PTEOS were used in the case of FCTPS preparation. Similarly, 0.5
mL TEOS and 0.5 mL APTES were used in the case of FCTAS. The mixture was stirred at 400
rpm for 24 hours at room temperature. The formed particles were centrifuged and washed 3
times with ethanol and water, then the residue was left to dry completely, (Scheme 5.2.1).
5.2.2.3.3 Preparation of FITC covalently encapsulated SNPs using WORM method (FCTPSRM)
The micelles were prepared using 15.0 mL cyclohexane, 2.60 mL 1-hexanol, 3.55 mL
Triton™ X-100, and 1.13 mL DI H2O which were stirred for 10 min to generate the
microemulsion. After time elapsed, 0.50 mL of the FCA conjugate solution was slowly added to
the microemulsion and stirred for 30 min at 120 rpm. Finally, 0.50 mL TEOS, 0.50 mL PTEOS,
and 0.12 mL ammonium hydroxide were added and the solution was stirred for 24 h. Afterward,
5.0 mL acetone were added and the NPs were collected by centrifugation and washed 5 times
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with absolute ethanol and two times with water to remove any unreacted chemicals and free dye
conjugates, (Scheme 5.2.1).
5.2.2.3.4 Surface Modification of F-SNPs with PVP
60 mg PVP were dissolved in a solution containing 30 mg of either FCTS or FCTAS in
5.0 mL ethanol, and the mixture was stirred for 24 hours at room temperature and then
centrifuged for 20 min at 3800 rpm. The precipitate was re-dispersed in ethanol, and the
dispersion was centrifuged again then the residue was left to dry completely to obtain the
corresponding PVP coated F-SNPs, FCTS-PVP and FCTAS-PVP, respectively (Scheme 5.2.1).
5.2.2.4 Instruments and particles characterization
0.1 mg/mL F-SNPs suspensions dispersed in ethanol were subjected to particle size
determination analysis using a Malvern Mastersizer (Malvern Instruments Ltd., Malvern, UK.
Polydispersity index (PDI), and standard deviation were obtained from three independent
measurements of the dispersions of NPs. Zeta potential of NPs dispersions in ethanol was also
measured. Transmission electron microscopy micrographs were conducted by the Zeiss LEO
912AB (Zeiss, Thornwood, NY). NPs separation required an Allegra 64R Centrifuge (Beckman
Coulter Inc., Brea, CA). A SympHonly (SB20) pH-meter (Thermo Orion, MA, USA) was used
for pH adjustment. Nano pure water was prepared using a Barnstead NANO pure DIamond
Analytical ultrapure water system (Fischer Scientific, NJ, USA). All fluorescence spectra were
performed on ISS K2 multifrequency cross-correlation phase and modulation fluorimeter (ISS™
Focus and Discover, Champaign, IL, USA), equipped with a 300W xenon arc lamp. A 1.0 cm
disposable plastic was used for all fluorescence measurements. To investigate the fluorescence
properties of the F-SNPs, they were dispersed in a 1:1 (v/v) water/ethanol solvent and their
emission spectra were recorded.
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5.2.2.5 Use of F-SNPs as developing agents for fingerprints:
Fingerprints were collected from a 26-year-old male donor and then developed after 24
hours of deposition. Fingerprints were obtained by requesting the donor to rub his finger with his
nose immediately prior to fingerprints deposition. The donor was instructed not to wash his
hands within the last two hours. Fingerprints were deposited onto glass microscope slides (Fisher
Scientific, Fair Lawn, NJ) which were used as received. A specific concentration of 5.0 mg/mL
suspensions for each of the F-SNPs in a solvent composed of 1:1 (v/v) DI water: ethanol were
prepared, then the they were sonicated for 10 min to ensure sufficient particles dispersion. About
0.5-1.0 mL of the suspension was pipetted onto the sample using a transfer pipette. After 5
minutes, the excess solution was removed, and the sample was gently washed with a mixture of
1:1 (v/v) DI water: ethanol. After that the developed fingerprint sample was left to dry at room
temperature. The photographs were recorded with luminescence mode using the forensic light
source (FLS), Mini-CrimeScope 400 MCS-400 (Spex Forensics, Edison, NJ) at excitation
wavelength of 445 nm and crime scene search (CSS) settings. The fingerprint image was
photographed using a digital camera (Nikon D3300) with a 520 nm long-pass filter. The sample
was placed on a black surface to enhance the contrast of fingerprint image during illumination
and taking pictures.
5.2.3 Results and discussion
To achieve stable incorporation of small molecules such as dyes, either covalent
copolymerization of the dye conjugate or strong non-covalent binding interactions between the
added dye molecules and the backbone of the cross-linked silicate matrix is needed. These
interactions are likely to arise from hydrophobic and hydrophilic groups in the dye molecules
and the silicate backbone. To identify the factors leading to stable incorporation of the
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fluorogenic molecules into the SNPs and efficient visualization of fingerprints, seven different
routes for preparing F-SNPs have been examined in this report. The produced SNPs have
embedded within them either FITC or its conjugate with APTES, FCA. Two of the most
commonly used sol-gel methods for SNPs preparation namely Stöber method and WORM
method were used. Moreover, covalent encapsulation of the FCA dye conjugate versus
encapsulation of the FITC dye itself non-covalently into the SNPs has been examined. In
addition, three organosilicate monomers namely TEOS, PTEOS, APTES and their binary
combinations were used to prepare the NPs. Finally, the adhesive agent, PVP was introduced
onto the surface of the less hydrophobic F-SNPs to investigate the enhancement effect on the
binding affinity of PVP-coated F-SNPs towards fingerprints residue.
5.2.3.1 Particle characterization
The physical nature and dimensions of the particles were derived from the DLS and TEM
scans for FCTPS and FCTPS-RM, (Fig. 5.2.1). The NPs are composed of discrete
monodispersed spherical particles with an average diameter of 110.4±31.1 and 4.1±0.6 for the
NPs prepared by WORM and Stöber methods, respectively. The NP diameter obtained from
TEM images, the mean hydrodynamic particle sizes by DLS, PDI, and zeta potential values are
summarized in Table 5.2.1.
TEM micrographs showed that the labeled F-SNPs prepared by WORM method had a
spherical shape and a narrow size distribution of 4.1±0.6 which was confirmed by the DLS
measurements. On the other hand, NPs prepared by Stöber method had a relatively larger
diameter of about 110.4±31.1 with lower control on the monodispersity of the size and shape.
The zeta potentials of FCTPS and SCTPS-RM in ethanol were ranging from -12.8 to -26.7 mV,
respectively, Table 5.2.1.
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Table 5.2.1 Diameter determined by TEM and DLS, polydispersity index (PDI), zeta potential of
0.1 mg/ml labeled SNPs in ethanol

F-SNPs

Diameter (TEM)
(nm)

Diameter (DLS)
(nm)

PDI

Zeta potential (mV)

FCTPS

110.4 ± 31.1

605.7 ± 131.5

0.48

-26.7 ± 14.3

FCTPS-RM

4.1 ± 0.6

5.3 ± 0.4

1.00

-12.8 ± 14.2

5.2.3.2 Preparation method of the F-SNPs
Two different F-SNPs, FCTPS and FCTPS-RM, were prepared to be used in this
investigation. Both of them were prepared using a mixture of TEOS and PTEOS alkoxysilane
precursors

21

. FCTPS were prepared using the Stöber method

4

whereas FCTPS-RM were

prepared using the WORM method 5. The Stöber method has the advantages of simplicity
besides avoiding using surfactants which requires extensive cleaning steps. However, controlling
the particle size is easily achieved using the WORM method, as nanoreactors of water droplets in
the oil phase define the particles dimension

28

. As expected, WORM method resulted in NPs

with smaller size of about 4.1±0.6 nm and better monodispersity in comparison with the Stöber
method as can be revealed from the SEM and DLS measurements. Due to the simplicity and cost
effectiveness of the Stöber method, it was chosen as the method of F-SNPs preparation to
investigate the other factors affecting fingerprints visualization.
5.2.3.3 Covalent versus non-covalent fluorophore encapsulation into the SNPs matrix
Two different F-SNPs, FDTPS and FCTPS, were prepared to be used in this
investigation. Both of them were prepared using the Stöber method with equal volumes of TEOS
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and PTEOS alkoxysilane precursors

21

. FITC (logP 5.03) was non-covalently doped into a

hydrophobic core composed of PTEOS (logP 3.25) then entrapped in a shell composed of TEOS
(LogP 1.68) and PTEOS in the case of FDTPS. The composition of the core and the shell of
FDTPS allowed stable non-covalent encapsulation of the hydrophobic FITC dye molecules with
minimal leakage under the used experimental conditions. For FCTPS, APTES was used for
crosslinking the FITC dye molecules with the silica matrix, where the binding between cyanate
groups of the dye and amine groups of APTES results in the formation of thiourea linkage

30

.

The formed FITC conjugate with APTES, FCA, was covalently copolymerized into the SNPs to
form FCTPS. Investigation of the emission spectra of these NPs, confirmed the successful
encapsulation of the hydrophobic FITC dye, (Fig 5.2.2). The fluorescence maximum for all the
NPs is within the same range of the pure dye. Different patterns were observed due to the
differences in the composition of the NPs.
It is reported that the incorporation yield of non-covalently bound fluorophores is poor, as
it is only based on physical adsorption forces

31

. Nevertheless, non-covalent incorporation of

FITC was made suitable using the hydrophobic alkoxysilane precursor, PTEOS, and this
observation is consistent with other reports

6, 21, 32, 33

. It was also noted that the intensity of

FDTPS fluorescence increased as the proportion of PTEOS in the initial monomer mixture
increased 21. A ratio of 1:1 (v/v) was used thereafter in all incorporation experiments. However,
the dye is prone to leaking from FDTPS under exposure to the used solvent for longer time so the
more stable FCTPS was found to be more suitable for developing fingerprints.
5.2.3.4 Type of the alkoxysilane precursor(s)
Three different organosilicate monomers have been used in this investigation, namely
TEOS (logP 1.68), PTEOS (logP 3.25), and APTES (logP -1.83) to incorporate FCA covalently
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into the silica platform. It is hypothesized that the planar aromatic phenyl groups of PTEOS
would form hydrophobic interactions with the planar rings of FITC and that negatively charged
Si–O groups present in the alkoxysilane precursors would form strong interaction with the polar
functional groups of FITC, and thus producing a highly fluorescent and stable complex on
encapsulation can be obtained [7]. Nevertheless, the nature of organosilicate monomers will not
have a significant effect on the dye loading and its leaking from the NPs as the dye was
covalently bonded into the silica matrix to form highly stable F-SNPs. Thus, the nature of the
organosilicate monomers is expected to influence mainly the binding affinity to the fingerprints
residue as it will be discussed in details in the following section.
5.2.3.5 Use of dye-encapsulated SNPs suspensions as developing agents for fingerprints
To investigate the binding affinity of F-SNPs to fingerprints, suspensions of these
particles were applied on a glass substrate as shown in Fig 5.2.3. The nature of the precursor
plays an important role in fingerprint detection. When the binary mixture of TEOS and PTEOS
used in three different preparation routes of F-SNPs namely FCTPS, FCTPS-RM, and FDTPS,
clear luminescent fingerprint ridges were obtained for the three F-SNPs suspensions at CSS
setting of the FLS viewed through a 520 nm long pass filter as shown in Fingers 3a, b, and c
(first row). The surface of NPs has been decorated with PTEOS which increases the hydrophobic
interaction between the phenyl group of PTEOS and the sebaceous secretion in the fingerprint
residue resulting in enhanced binding and detection of fingerprints. Despite the differences in the
preparation methods, the efficiency of these hydrophobic NPs as developing agents able to
produce clear luminescent fingerprints with high contrast was observed and attributed to the
PTEOS-modified hydrophobic surface. However, a more distinct definition in fingerprint
detection was noticed using another setting of FLS at excitation wavelength of 445 nm viewed
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through the same filter as shown in Fig. 5.2.3a, b, and c (second row). Fingerprints developed
with FDTPS appeared luminescent with clear ridge pattern. The luminescence intensity of
fingerprints decreased with FCTPS-RM and FCTPS, and the latter appeared more as dotted
marks. It was found that CSS setting of the crimescope was the best choice for fingerprints
visualization. When TEOS was used solely for the preparation of FCTS, weak luminescence and
poor contrast were obtained as shown in Fig. 5.2.3d in both settings of the FLS. Therefore, using
these particles as developing agents for fingerprint detection is not practical. On the other hand,
the binary mixture of TEOS and APTES used in preparing FCTAS resulted in highly
luminescent ridges with obvious background noise as shown in Fig. 5.2.3e using both CSS and
445 nm settings. The observed background noise could be due to undesirable interactions
between the polar APTES with the glass substrate. The presence of amine group in APTES
promotes interaction with any compounds bearing carboxyl groups in fingerprint residue to
produce amide linkage. The formation of this linkage was confirmed by the work of Moret et al.
in understanding the mechanism of fingerprint development using SNPs 34.
Friction ridge features of a fingerprint have been classified into three levels of detail

35

.

First- level detail describes the overall ridge pattern such as fingerprint orientation and ridge flow
direction. The general information obtained from the first-level detail are not decisive. Thus, it
cannot be used for personal identification. Second-level detail involves ridge formations and
pattern minutiae such as ridge ending, bifurcation, and dots. Third-level detail includes the
morphology of a ridge such as width, shape, and pores. Both second and third- level details
enable identification and fingerprint matching due to the unique individual features. The typical
features of second-level detail of fingerprint friction ridge of FCTPS, FCTPS-RM, and FDTPS

328

are shown in Fig. 5.2.4. Such features including bifurcations and ridge endings were slightly
clear in fingerprints developed by FCTPS-RM, and FDTPS compared with FCTPS.
5.2.3.6 Surface modification of fluorescent SNPs with PVP
In order to enhance the fingerprints detection, the less hydrophobic FCTS and FCTAS
were coated with the adhesive agent, PVP to improve their binding affinity to the hydrophobic
components present in the fingerprint residue. PVP has been used as adhesive agent or binder in
pharmaceutical industry because of its binding affinity to polar and nonpolar molecules
contributed to intrinsic amphiphilic property of PVP 36, 37. Thus, compared to uncoated NPs, their
PVP-modified counterparts, FCTS-PVP and FCTAS-PVP should show much higher contrast
fingerprints images on glass because of their high binding affinity 12. Fingerprints detection using
PVP-coated SNPs as fluorescent labeling markers should be well-defined in terms of finger ridge
details without background staining, resulting in a good definition of enhanced detection.
However, it was observed that the PVP-coated SNPs did not result in any enhanced visualization
as shown in Fig. 5.2.3f and g.
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Scheme 5.2.1 Preparation routes for F-SNPs
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Figure 5.2.1 TEM micrographs of (a) FCTPS and (b) FCTPS-RM
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Figure 5.2.2 Normalized emission spectra of (a) FITC (b) FCTPS, (c) FCTPS-RM, (d) FDTPS,
(e) FCTS, and (f) FCTAS in water: ethanol (1:1, v/v) at excitation wavelength of 455 nm
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Figure 5.2.3 Fluorescence images of the fingerprints developed using 5.0 mg/mL F-SNPs
suspensions in water: ethanol (1:1, v/v) of (a) FCTPS, (b) FCTPS-RM, (c) FDTPS, (d) FCTS, (e)
FCTAS, (f) FCTS-PVP, and (g) FCTAS-PVP at different FLS settings
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(ii)
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(ii)

Figure 5.2.4 Fluorescence images of fingerprints of (a) FCTPS, (b) FCTPS-RM, and (c) FDTPS,
at CSS setting of FLS, showing second-level detail of fingerprint friction ridge (i) bifurcation
and (ii) ridge ending
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5.3

Preparation of Fluorescently Labeled Silica Nanoparticles Using an Amino Acidcatalyzed Seeds Regrowth Technique: Application to Latent Fingerprints Detection
and Hemocompatibility Studies

Copyright © 0021-9797/2017 Elsevier Inc.
Journal of Colloid and Interface Science (2018) 512: 801–811
DOI 10.1016/j.jcis.2017.10.062

The efficiency of an amino acid catalyzed seed regrowth technique (ACSRT) in
synthesizing twelve fluorescently labeled core-shell silica nanoparticles (FLSNPs) with tunable
sizes, tailored hydrophobicity, low polydispersity as well as high labeling efficiency and
minimized dye leakage using different organosilicate monomers and fluorophores have been
systematically investigated in this report. The utilization of some of these FLSNPs in some
applications that are facilitated by hydrophobicity such as developing and visualizing latent
fingerprints (LFPs) on different surfaces was also investigated. The non-specific binding affinity
of the developed nanoparticles to human serum albumin (HSA) and immunoglobulin G (IgG)
has also been studied. Fluorescein, fluorescein isothiocyanate and its more hydrophilic
butenamine derivative (WA6) have been used in this study. Also, the alkoxysilane precursor,
tetraethoxyorthosilicate (TEOS) and its binary mixture with phenyltriethoxysilane (PTEOS) or 3aminopropyl triethoxysilane (APTES) have been used in preparing the FLSNPs with tailored
compositions for the core and shell of the nanoparticles. The mean diameters of the PTEOScoated FLSNPs were between 33.4±5.9 and 42.2±10.8 nm as shown by the SEM measurements.
The obtained results highlight the advantages of having a hydrophobic surface along with proper
selection of the monomers forming the core to match the properties of the fluorescent reporters
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for clear detection of LFPs even using dyes of low hydrophobicity such as fluorescein and WA6.
Furthermore, some of the developed FLSNPs were compared with bare silica nanoparticles in
terms of nonspecific protein adsorption and hemolysis. The obtained results proved that the
selected FLSNPs had a superior hemocompatibility in comparison with bare silica nanoparticles.
These FLSNPs could also be used in some bio-related and diagnostic studies such as
immunoassays and cell imaging purposes.
5.3.1 Introduction
Using APTES-based organosilane chemistry is the common approach to achieve proper
dye encapsulation via Stöber and WORM methods. Shakiba Shahabi et al.

6

reported that the

poor incorporation efficiency of non-covalently bound fluorophores could be enhanced using
ACSRT 31. The synthesis pathway of ACSRT eliminates the need for covalent crosslinking step
such as APTES-conjugation of dyes. Furthermore, enhanced dye stability and a higher labeling
efficiency can be obtained with ACSRT, even without using APTES. The use of L-arginine as a
catalyst also induces a stable crosslinking of some dyes into the silica matrix through a thiourea
linkage 6, 38.
In this report, the synthesis of twelve fluorophore-encapsulated SNPs with wellcontrollable size and tunable hydrophobicity for the core and shell of the particles based on the
ACSRT is presented, (Fig. 5.3.1, Table 5.3.1). Besides L-arginine, water, and the proper
organosilicate precursors, the fluorophore molecules were introduced in the nucleation step, to
form the fluorescent silica. The water-soluble organic fluorophore, fluorescein, or its more
hydrophobic derivative, fluorescein isothiocyanate (FITC) or the more hydrophilic butenamine
derivative of FITC (WA6) were directly incorporated into the seeds without covalent binding.
The structure formulae of the three dyes are presented in Fig. 5.3.1.
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Based on Shakiba Shahabi et al., work 6, particle size can be adjusted by controlling the
reaction parameters and the proportion of seeds and organosilicate precursors in the regrowth
step. The obtained fluorescent SNPs were characterized using scanning electron microscopy
(SEM), dynamic light scattering (DLS), and fluorescence spectrometry. In addition, the labeling
efficiency, dye leakage and colloidal stability were evaluated. The utilization of these particles in
some hydrophobicity-based detection applications such as developing latent fingerprints (LFPs)
39

was systematically investigated. Furthermore, the suitability of these FLSNPs for biological

studies was assessed by testing their non-specific binding to plasma proteins and by assessing
their hemocompatibility. SNPs have been successfully used in such applications because of their
unique advantages. Firstly, excellent physicochemical stability and cost-effective fabrication.
Secondly, SNPs have tunable structural properties such as particle shape, particle sizes, pore
structures, pore volumes, specific surface areas, hydrophobicity and so on. Thirdly, efficient
loading of a wide range of hydrophilic or hydrophobic organic molecules such as organic dyes.
Fourthly, SNPs are not toxic with great biocompatibility and biodegradability. Finally, facile
multi-functionalization on the abundant -Si-OH, where their surfaces can be modified to satisfy
the required purpose 39, 40.
The developed hydrophobic FLSNPs can be used for LFPs detection which is useful for
personal identification in forensic investigations. The common form of fingerprint evidence left
at the scenes of crime is LFPs, which is generally invisible to the naked eyes. Therefore, it needs
to be developed to enable its visualization

10

. This can be achieved by obtaining an obvious

contrast between the secretion residues of the LFPs pattern and the underlying substrates

41

.

Many micro- or nanometer-sized particles with various compositions, such as gold nanoparticles,
semiconductor quantum dots, magnetic particles, rare earth nanomaterials, silica particles,

336

composites, have been exploited as the developing agents using the powdering method

19

.

Among various compositions, the hydrophobic SNPs, which were doped with dyes, metals,
metal oxides or carbon, were used in developing clear LFPs 42.
Some reports concentrated on the incorporation of fluorophores into the colloidal silica
spheres and on the nature of these fluorophores

26-28

. Nevertheless, very few studies have been

carried out that focus on the nature of the SNPs core and shell composition used for dye
encapsulation and their effects on the efficiency of LFPs detection in a systematic manner.
Theaker et al reported that for effective dye doping mixtures of TEOS and PTEOS have to be
used in synthesizing the SNPs, hence it was concluded that analogous hydrophobic and
electrostatic interactions occur within these hydrophobic SNPs between compatible groups
within the fluorescein isothiocyanate (FITC) dye molecules or any other dye of a related
structure and the silica matrix

39

. Moreover, it was found that this dye was not subjected to

photo-bleaching under exposure to high intensity UV illumination. Hence, these FLSNPs can be
utilized as agents for developing LFPs, including aged prints where the residues mainly consist
of hydrophobic endogenous chemicals secreted by the donor, due to their hydrophobic nature 39.
It should also be noted that as the proportion of PTEOS increases, the hydrophobicity of the
resulting sol–gel also increases 29.
To the best of our knowledge, this is the first report that describes the synthesis of
fluorescent SNPs based on a basic amino acid-catalyzed approach for developing LFPs using
different combinations of hydrophilic and hydrophobic organosilicate precursors for modifying
the core and shell of the SNPs. Moreover, the efficiency of embedding three fluorescent reporters
with different LogP values in the core of theses SNPs has also been investigated. It was
attempted in this study to enhance the loading efficiency of the used dyes and decrease their
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leakage from the silica matrix just through non-covalent interactions between the dye and the
alkoxysilane molecules in the core of the SNPs as well as encapsulating the dye molecules
insides a shell with the suitable composition. Also, this is the first time to systematically study
the effect of organosilane precursors on the size and colloidal stability of the ACSRT-made silica
nanoparticles. Moreover, the scalable synthesis of silica nanoparticles from ultra-small size (13.9
nm) to large size (hundreds nm) with varying the nature of the core and shell compositions can
provide a great benefit to study the effect of these factors, which have been considered to play a
major role in the interaction with different surfaces, in vivo pharmacokinetics, and other biorelevant issues.
On the other hand, it is reported that bare SNPs exhibit a noticeable hemolytic behavior,
besides, their nonspecific binding to human serum albumin (HSA) and immunoglobulin G (IgG)
43

. In this report, some of the proposed hydrophobic FLSNPs were compared with bare silica

nanoparticles in terms of nonspecific protein adsorption and percentage of hemolysis.
Different requirements should characterize those SNPs to achieve the desired properties.
Therefore, hydrophobicity, labeling efficiency, dye leakage, monodispersity, colloidal stability as
well as hemocompatibility of the synthesized FLSNPs were carefully considered.
5.3.2 Experimental
5.3.2.1 Materials and reagents
All the chemicals used were of Analytical Reagent grade, and the solvents were of HPLC
grade. All the following chemicals were produced by Sigma-Aldrich, MO, USA: fluorescein
isothiocyanate (FITC) (isomer I, 90%), 1-heptanol (anhydrous, ≥99%), 3-aminopropyl
triethoxysilane (APTES) (≥98%), tetraethyl orthosilicate (TEOS) (99.99% trace metal basis),
sodium hydroxide (pellets, 97+%, A.C.S. reagent), cyclohexane (anhydrous, 99.5%), albumin
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from human serum (>96%), purified human immunoglobulin G (IgG), sodium phosphate,
dibasic (98+%), potassium phosphate monobasic (>95%), hydrochloric acid (37%), and Triton™
X-100 (laboratory grade). Fisher Scientific, Fair Lawn, NJ, produced ammonium hydroxide
solution (28%) and sodium chloride crystals (certified A.C.S). Phenyltriethoxysilane (PTEOS)
was supplied by Chem-Impex Int`l Inc., IL, USA. Ethanol (200 proof) was obtained from Decon
labs Inc (King of Prussia, PA USA) while KCl was obtained from J.T.Backer Inc. (NJ, USA). 3Buten-1-amine (97%) was purchased from Alfa Aesar (MA, USA).
5.3.2.2 Pre-modification of WA6
1-(but-3-en-1-yl)-3-(3',6'-dihydroxy-3-oxo-4a',9a'-dihydro-3H-spiro[isobenzofuran-1,9'xanthen]-5-yl)thiourea (WA6) was prepared by inducing a reaction between the isothiocyanate
groups in FITC with the amine group of 3-butene-1-amine. 0.22 mmole of FITC was added to
0.32 mmole of 3-butene-1-amine and refluxed for 24 h in a round-bottom containing 2 mL
ethanol, (Scheme 5.3.1). The residue was filtered and washed several times with methanol and
then dried under reduced pressure to obtain the pure form.
5.3.2.3 Synthesis of FLSNPs using ACSRT
All FLSNPs were synthesized by slightly modifying previous methods 6, 7.
5.3.2.3.1 Preparation of labeled seeds
One mmole L-arginine was dissolved in 16.9 ml DI H2O and stirred thoroughly at room
temperature. Afterward, 0.02 mmoles of the corresponding fluorescent dye dissolved in 500 μL
ethanol was added to the L-arginine solution. The mixture was stirred for 10 min and then heated
up to 70 °C, before the addition of 0.001 mmoles of TEOS. In the case of using a binary mixture
of the organosilicate monomer, 0.0005 mmoles from each monomer were used instead. The
mixture was stirred for 24 h at 70 °C in an oil bath. Finally, the dispersion containing the labeled
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seeds was used as stock for the regrowth step. The synthesis was carried out in the dark to
minimize photo-bleaching of the fluorescent dye.
5.3.2.3.2 Regrowth of labeled seeds
4.47 mmole L-arginine were dissolved in 1 mL water and 4 mL ethanol. Subsequently, 1
mL of the labeled seeds was added to the L-arginine solution. The mixture was stirred for 10 min
before heating up to 70 °C. Thereafter, 1 mL of TEOS was added. In the case of using a binary
mixture of the organosilicate monomer, 0.5 mL from each monomer was used instead. The
suspension was then stirred at 70 °C for 24 h in the dark. Twelve different types of FLSNPs with
different sizes were prepared only by varying the fluorophore and/or the organosilicate precursor
(Table 5.3.1), while the other parameters were kept constant. Then, the particles were collected
by centrifugation, washed with ethanol and water twice and left to dry at 60°C. A different set of
the SNPs namely; T-T, T-TP, TP-TP, TA-T, and TA-TP, was prepared for colloidal stability and
characterization studies according to the same procedure without labeling with any fluorophores
in the seeds preparation step. The effect of the amount of L-arginine on the size of the silica
nanoparticles was investigated by varying the concentration of the amino acid catalyst in the
regrowth step to be 0.0, 1.0, and 4.47 mmoles in the prepared particles; T-T-0, T-T-1, and T-T,
respectively.
5.3.2.4. Instruments and particle characterization
0.2 mg/mL FLSNPs suspensions dispersed in ethanol were subjected to particle size
determination analysis using a Malvern Mastersizer (Malvern Instruments Ltd., Malvern, UK.
Polydispersity index (PDI), and standard deviation were obtained from three independent
measurements of the dispersions of SNPs. Zeta potential of particles dispersions in ethanol and
water were also measured. Scanning electron microscopy micrographs were conducted by the

340

Tescan Vega3 LMU scanning electron microscope (TESCAN, Kohoutovice, Czech Republic)
and Denton Desk II sputter coated with a gold target (Denton Vacuum, NJ, USA). Nanoparticle
separation required an Allegra 64R Centrifuge (Beckman Coulter Inc., Brea, CA). A SympHonly
(SB20) pH-meter (Thermo Orion, MA, USA) was used for pH adjustment. Nano pure water was
prepared using a Barnstead NANO pure DIamond Analytical ultrapure water system (Fischer
Scientific, NJ, USA). All fluorescence spectra were performed on ISS K2 multifrequency crosscorrelation phase and modulation fluorimeter (ISS™ Focus and Discover, Champaign, IL, USA),
equipped with a 300W xenon arc lamp. A 1.0 cm disposable plastic was used for all fluorescence
measurements. The nuclear magnetic resonance spectra were obtained using high quality Kontes
NMR tubes (Kimble Chase, Vineland, NJ) rated to 500 MHz and were recorded on a Bruker
Avance 400 MHz spectrometer interfaced to a PC using Topspin 3.1. High-resolution accurate
mass spectra were obtained at the Georgia State University Mass Spectrometry Facility using a
Waters Q-TOF micro (ESI-Q-TOF) mass spectrometer or utilizing a Waters Micromass LCT
TOF ES+ Premier mass spectrometer.
5.3.2.5 Solvatochromic effect
The solvatochromic effect was studied by measuring the emission spectra of 5 mg/mL
WA6-TA-T as well as the free WA6 dye (3.3 x 10-7 M) in different solvents including water,
ethanol, and 0.1 M HCl using the ISS K2 fluorimeter.
5.3.2.6 Labeling efficiencies and dye leakage studies for the prepared FLSNPs
Labeling efficiencies are the fraction of added dye molecules actually incorporated in the
SNPs

44

by comparing the fluorescence intensities of the remained free dyes with standard

samples. For the dye leakage study, seven of the FLSNPs, sets of three samples of 22.5 mg for
each type of the FLSNPs dispersed by sonication in 3 mL of a dispersant composed of ethanol
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and water mixture (1:1, v/v) or (1:9, v/v) were prepared. After measuring the initial fluorescence,
the samples were kept in the dark at room temperature. After 1 hour, the SNPs were centrifuged
at 3200 rpm for 5 min. The supernatant was discarded, and the pellet of FLSNPs was
resuspended in the corresponding dispersant. Then, the fluorescence signal of the FLSNPs
suspensions was measured. This procedure was repeated with a different set of samples after 24
hours using a solvent composed of ethanol and water with a ratio of (1:9, v/v) 45.
5.3.2.7 LFPs detection using FLSNPs
Two methods for applying the resulting particles to latent prints were used; one used an
aqueous suspension which consisted of discrete nanoparticles, and the second used the
nanoparticles powder for dusting the LFPs. Fingerprints were collected from the same donor, a
26-year-old male and then developed after 24 hours of deposition. Fingerprints were obtained by
requesting the donor firstly; to wash his hands thoroughly with the soap then rub his finger with
his nose immediately prior to fingerprints deposition onto the tested surfaces. The photographs
were recorded with luminescence mode using the forensic light source (FLS), Mini-CrimeScope
400 MCS-400 (Spex Forensics, Edison, NJ, USA) at excitation wavelength of 445 nm or crime
scene search (CSS) settings. The fingerprint image was photographed using a digital camera
(Nikon D3300) with a 540 nm long-pass filter. The sample was placed on a black surface to
enhance the contrast of fingerprint image during illumination and taking pictures.
5.3.2.7.1 Use of FLSNPs suspensions as developing agents for LFPs
The particle suspension method was carried out with the glass slides substrates only as
follows: a specific concentration of 2.5 mg/mL suspensions for each of the twelve FLSNPs in 9:1
(v/v) DI water: ethanol dispersant was prepared as the working suspension, then they were
sonicated for 10 min to ensure sufficient particles dispersion. About 0.5-1.0 mL of the
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suspension was pipetted onto the sample using a transfer pipette. After 5 minutes, the excess
solution was removed, and the sample was gently washed with a mixture of 9:1 (v/v) DI water:
ethanol. After that, the developed fingerprint sample was left to dry at room temperature.
5.3.2.7.2 Use of FLSNPs powders as developing agents for LFPs on various substrates
Five different substrate surfaces were tested in this investigation, namely; glass slide,
petri dish (polystyrene), aluminum foil, common white paper, and the white area of paper
currency. F-TA-TP was selected as representative hydrophobic FLSNPs in this investigation.
The powder method was performed as follows: a commercial Lightning Powder Zephyr
Fiberglass Fingerprint Brush was used to pick up some F-TA-TP powder, and then carefully
applied to the surface of LFPs with a light brushing action. The excess powder was removed by
using a hair dryer for 90 seconds.
5.3.2.8 Protein adsorption
WA6-T-T particles were selected as a representative for FLSNPs without surface
hydrophobization whereas WA6-T-TP particles were selected as representative hydrophobic
FLSNPs in this investigation to be compared with bare SNPs in terms of non-specific protein
binding. HSA and IgG were used in this investigation where 1.5 mL of 10 mg/mL of IgG
solution and 72 mg of HSA were dissolved in 10 and 18 mL pure water to get a 1.5 and 4.0
mg/mL stock solutions, respectively. WA6-T-T, WA6-T-TP and bare SNPs were dispersed in 10
mM isotonic PBS (pH = 7.4) buffer with a concentration of 5 mg/mL. Then 2 mL of each of the
SNPs suspension were mixed with 2 mL of the corresponding protein solution and shook at 37
°C for 6 h at 100 rpm in the incubator. Finally, the mixture was centrifuged and the supernatant
was measured using a UV spectrophotometer, the adsorbed protein was presented as adsorption
efficiency (AE(wt.%)) and calculated. The absorption efficiency was calculated using the
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following formula: AE (wt.%) = (Ci−Cf)/Cn × 100% Ci and Cf represents the initial and final
protein concentration in the solution, respectively, Cn represent the concentration of the
nanoparticles 46.
5.3.2.9 Hemolysis study
A hematology-3, sample hem-02, American proficiency institute (manufactured by
Streck, LaVista, NE, USA) was used in this study. Red blood cells (RBCs) were isolated from a
2-mL sample by centrifugation for 10 min, and washed three times with sterile isotonic PBS
solution. Following the last wash, RBCs were diluted 1:5 in sterile isotonic PBS solution. The
RBCs suspension from the diluted sample (0.4 mL) was added into 1.2 mL of nanoparticles
isotonic PBS suspension to reach a final concentration of 2 mg/mL. Bare SNPs, WA6-T-T,
WA6-T-TP, WA6-TP-TP, WA6-TA-T, and WA6-TA-TP were used. The RBCs incubated with
pure water and isotonic PBS solution were set as positive and negative controls, separately. The
mixtures were shaken before being incubated for 1.5 h at 37 °C. Finally; the mixtures were
centrifuged for 10 min, then the absorbance of the clear upper solutions at 538 nm were recorded
by a UV spectrophotometer.
5.3.3 Results and discussion
5.3.3.1 Preparation method of the FLSNPs and labeling efficiency
The labeling efficiency and photophysical properties of FLSNPs intrinsically depend on
the applied synthesis method. In this investigation, an amino acid-catalyzed seed regrowth
method was used for the synthesis of twelve FLSNPs and tested for efficient control on the core
and shell composition of the SNPs in order to achieve proper non-covalent embedding of the
fluorescent reporters. The Stöber method has the advantages of simplicity besides avoiding using
surfactants which requires extensive washing steps whereas controlling the particle size is easily
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achieved using the WORM method, as nanoreactors of water droplets in the oil phase define the
particles dimension 28. Unlike the conventional methods such as Stöber 4 and WORM 5, ACSRT
permits the synthesis of fluorescent SNPs in a water-based system, without the use of any
surfactants or co-surfactants. By this approach, additional linkers for covalent coupling of the
fluorophore to silica matrix were omitted, while a remarkable doping efficiency was achieved,
Table 5.3.1 7. L-arginine was applied as a catalyst while the dye molecules were incorporated
into the particle nuclei formed by hydrolysis and recondensation of three different organosilane
monomers, namely; TEOS (logP 1.68), PTEOS (logP 3.25) and APTES (logP -1.83). Particle
regrowth was achieved in the second stage due to the polymerization of either TEOS or its binary
mixture with the more hydrophobic organosilicate precursor, PTEOS, or the polar oeganosilicate
precursor, APTES, Table 5.3.1. Fluorescein (logP 3.4), Fluorescein isothiocyanate (logP 4.8) and
WA6 (logP -1.1) have been used in this study. The logP of the novel WA6 dye was determined
using the shake flask method based on the distribution between equal volumes of chloroform and
water. Twelve different FLSNPs were prepared with tailored compositions for the core and the
shell of the SNPs. From the results presented in Table 5.3.1, it was found that using TEOS as the
sole organosilane precursor in the core and shell of F-T-T, FITC-T-T and WA6-T-T resulted in
poor labeling efficiency of 15.8, 8.0, and 16.3 %, respectively, due to absence of efficient noncovalent interactions between the used dyes and the silica matrix. However, a labeling efficiency
of 37.4% was obtained in the case of WA6-TA-T due to strong hydrogen bonding between the
amino groups in APTES and the thiourea and hydroxyl groups in WA6. On the other hand, in
case of F-T-TP and F-TP-TP, the incorporation of the hydrophobic PTEOS either in the shell
only or both in the core and in the shell resulted in intermediate labeling efficiency of 44.9 and
52.6%, respectively, which can be attributed to the reasonable interactions between fluorescein
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and the core as well as the successful encapsulation of the dye inside the hydrophobic silica
shell. For F-TA-TP and WA6-TA-TP, the use of a mixture of TEOS and the polar APTES in the
core of the SNPs allowed proper embedding of fluorescein and WA6 dye molecules with high
labelling efficiency of 79.2% and 78.4%, respectively, through strong non-covalent interactions
which were then entrapped by a hydrophobic shell composed of a mixture of TEOS and the
hydrophobic PTEOS. Furthermore, FITC-T-TP should higher labeling efficiency than FITC-TPTP of 74.5 and 53.6%, respectively. This can be attributed to the use of L-arginine that induces
the stable incorporation of FITC into the TEOS based silica matrix in the core of FITC-T-TP. As
the thiocyanate groups of FITC are reactive that they can bind to the amine groups of L-arginine
forming a stable thiourea linkage. It is suggested that L-arginine, used as the catalyst in ACSRT,
also plays a crosslinking role to bind the dye molecules to the silica matrix 6. Finally, WA6-T-TP
and WA6-TP-TP showed satisfactory labeling efficiencies of 63.9 and 72.4%, respectively which
highlights the virtue of using a hydrophobic shell in achieving a successful encapsulation of dye
molecules even the ones of low lipophilicity such as WA6 and fluorescein. It is worth noting
that, APTES was not used for encapsulating FITC to avoid any interferences in the obtained
labeling efficiency results as APTES can form a covalent thiourea linkage with FITC 38.
5.3.3.2 Particle characterization
The synthesized FLSNPs were characterized via different methods prior to the
application to LFPs detection and hemocompatibility studies. The physical nature and
dimensions of the particles were derived from the SEM scans and DLS for WA6-T-T, WA6-TTP, WA6-TP-TP, WA6-TA-T and WA6-TA-TP, (Fig. 5.3.2, Table 5.3.2). Also, the mean
hydrodynamic particle sizes and PDI measurements in deionized water by DLS for the used three

346

unlabeled seeds T, TP, and TP as well as for the unlabeled particles; T-T, T-TP, TP-TP, TA-T,
and TA-TP were summarized in Table 5.3.3.
SEM micrographs showed that the labeled FLSNPs prepared using PTEOS had a smaller
diameter and narrow size distribution in comparison with WA6-T-T and WA6-TA-T which were
prepared under the same conditions, Table 5.3.2. The hydrophobic SNPs were composed of
discrete monodispersed globular particles with an average diameter (SEM) of 33.4.6±5.9,
42.2±10.8, and 39.8±3.0 nm, for WA6-T-TP, WA6-TP-TP, and WA6-TA-TP, respectively,
whereas the WA6-T-T and WA6-TA-T had an average diameter (SEM) of 1511.0±354.8 and
1428.26±116.3, respectively. The bigger size of the particles that don`t have PTEOS in their
shell composition may be attributed to the higher rate of hydrolysis and recondensation of TEOS
in comparison with PTEOS.
The hydrodynamic diameters for the seeds; T, TP, and TA as well as for the SNPs; T-T,
T-T-1, T-TP, TP-TP, TA-T, and TA-TP were characterized using DLS, Table 5.3.3. The
obtained hydrodynamic size data for the seeds and for the core-shell nanoparticles reflect the size
of the regrowth shell which proved to be dependent on the nature of the used organosilane
precursors and on the amount of the L-arginine catalyst in the regrowth step. When TEOS was
used solely in the regrowth step, bigger particles was obtained.
The effect of the amount of L-arginine on the size of the prepared unmodified silica
nanoparticles was investigated by varying the concentration of the amino acid catalyst in the
regrowth step to be 0.0, 1.0, and 4.47 mmoles. As a control, no silica product was obtained at
x=0, likely because of the lack of catalysis for the hydrolysis of TEOS followed by condensation
of the resultant products. The DLS hydrodynamic diameter measurements with the composition
of arginine varied are shown in Table 5.3.3. When the concentration of the basic amino acid was
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decreased from 4.47 mmoles in the case of T-T to 1.0 mmoles in the case of T-T-1, the
hydrodynamic dimeter decreased.
The zeta potential measurements for five unlabeled SNPs; T-T, T-TP, TP-TP, TA-T, and
TA-TP were presented in Table 5.3.3 and Fig. 5.3.3. The obtained results showed that zeta
potentials of the PTEOS-modified particles, T-TP, TP-TP and TA-TP, were less negative than
the unmodified particles.
5.3.3.4 Dye leakage
The leakage of fluorescein, FITC and WA6 dye molecules from SNPs was also examined
in this report. Fig. 5.3.4a shows the changes in fluorescence intensities from nine FLSNPs kept
for 1 hour at room temperature in two different solvents composed of ethanol and water in the
ratio of (1:1, v/v) or (1:9, v/v). The obtained results clearly highlight the advantage of using a
lower ratio of ethanol to avoid a significant dye leakage as hydrophobicity of the dye plays an
important role in this process. In Fig. 5.3.4b, the experiment was repeated for the seven FLSNPs
in a solvent composed of ethanol and water in the ratio of (1:9, v/v) for 24 hours.
The obtained results show the virtue of using the polar APTES in the core of WA6-TA-T
and F-TA-TP in achieving a stable non-covalent encapsulation of WA6 and fluorescein with
only 21% and 33% decrease in fluorescence intensity after 1 hour in comparison with 72%
decrease for WA6-TP-TP and F-T-TP and 69% for F-TP-TP, respectively. For FITC-T-TP and
FITC-TP-TP, decreases of 45% and 43%, respectively, were obtained after 1 hour indicating the
importance of having a core with a hydrophobic nature in minimizing the leakage of the
relatively hydrophobic FITC dye molecules. On the other hands, WA6-TA-TP and WA6-T-TP
showed average leakage results with decreases of 54% and 47% after an hour, respectively.
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It is worth noting that using 10% ethanol in water was necessary to help the dispersion of
the FLSNPs for the LFPs detection application. Moreover, it can be concluded that using the
hydrophilic dye molecules in this study, WA6 and fluorescein along with keeping a
nonhydrophobic composition for the core are extremely important in minimizing the dye leakage
under the prescribed experimental conditions for developing LFPs using the pipetting method
which is just a 20 min process.
5.3.3.5 Solvatochromic effect
Solvatochromic characteristics were studied for WA6-TA-T, which showed minimal dye
leakage (Fig. 5.3.4), and compared to WA6 free dye by measuring their fluorescent spectra in
three different solvents namely water, ethanol and 0.1M HCl, (Fig. 5.3.5 a&b). The normalized
absorbance spectra of WA6-TA-T and the free dye were measured in water and ethanol, (Fig.
5.3.5 c &d). Free WA6 showed different fluorescence behaviors in the selected solvents, (Fig.
5.3.5a, Fig. 5.3.6).
This solvatochromic shift indicated the changes in the excited state energies of WA6
depending on solvents polarity
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. According to previous reports

6, 48

, the response profiles of

SNPs prepared by Stöber and WORM show obvious solvent-dependent characteristics. This
suggests that dye molecules are randomly localized near the SNP surface. As a consequence, the
solvatochromic characteristics of these SNPs are the outcome of the behaviors of dye molecules
with inhomogeneous localizations which can be minimized by using the ACSRT due to the
protective architecture of silica in these FLSNPs 6. A dense localization of fluorophores in the
seeds can be reached before they get completely covered with silica in the regrowth step using
ACSRT.
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It was observed that WA6 showed no fluorescence at all in 0.1M HCl due to protonation
of the carboxylic group in the presence of an acidic medium, (Fig. 5.3.5a). However, when the
dye molecules were properly embedded in the seeds of WA6-TA-T, the fluorescence was
retained, (Fig. 5.3.5b). Also, the normalized fluorescence spectra of the free WA6 dye in ethanol
and water showed obvious stokes shift of about 18 nm (Fig. 5.3.5c) which was minimized to less
than 9 nm in the case of WA6-TA-T, (Fig. 5.3.5d). These observations confirm that the
incorporated dye molecules are inside the silica matrix and can be shielded effectively from the
outside exposure featuring a higher photo-stability.
5.3.3.6 LFPs detection using FLSNPs
Two methods; dusting and SNPs suspensions pipetting were investigated to develop the
resultant LFPs.
5.3.3.6.1 Use of FLSNPs suspensions as developing agents for LFPs
To investigate the binding affinity of FLSNPs to LFPs, suspensions of these particles
were applied on a glass substrate as shown in Fig. 5.3.7 and Fig. 5.3.8. The nature of the
precursors in the shell of the SNPs plays an important role in fingerprint detection. Also, the
photographs for the developed fingerprints using white light source were presented in Fig. 5.3.9.
When a binary mixture of TEOS and PTEOS used in eight different FLSNPs, clear
luminescent fingerprint ridges were obtained using CSS setting of the FLS viewed through a 540
nm long pass filter. The surface of the FLSNPs has been decorated with PTEOS which increases
the hydrophobic interaction between the phenyl group of PTEOS and the sebaceous secretion in
the fingerprint residue resulting in enhanced binding and detection of fingerprints. Despite the
differences in hydrophobicity in the used fluorescent reporter, the efficiency of these
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hydrophobic FLNPs as developing agents able to produce clear luminescent fingerprints with
high contrast was observed and attributed to the PTEOS-modified hydrophobic surface.
When the surface was not coated with PTEOS in the case of F-T-T, FITC-T-T, WA6-T-T
and WA6-TA-T, weak luminescence and poor contrast were obtained as shown in Fig. 5.3.8 a&e
and Fig. 5.3.7a&e, respectively. Therefore, using these particles as developing agents for
fingerprint detection is not practical.
Friction ridge features of a fingerprint have been classified into three levels of detail
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.

First- level detail describes the overall ridge pattern such as fingerprint orientation and ridge flow
direction. The general information obtained from the first-level detail are not decisive. Thus, it
cannot be used for personal identification. Second-level detail involves ridge formations and
pattern minutiae such as ridge ending, bifurcation, and dots. Third-level detail includes the
morphology of a ridge such as width, shape, and pores. Both second and third- level details
enable identification and fingerprint matching due to the unique individual features.
The typical features of second-level detail of fingerprint friction ridge developed using
WA6-TP-TP are shown in Fig. 5.3.7c, where well-defined ridges of fingerprint were observed
displaying the sweat pores of the fingerprint, which is the typical feature of tertiary structure of
fingerprint.
5.3.3.6.2 Use of FLSNPs powders as developing agents for LFPs on various substrates
The colloidal particle suspension method is not very suitable to be used in actual crime
scenes due to its tedious procedure and low efficiency

19

. Subsequently, powder method was

examined using F-TA-TP as developing agents to test the contrast and selectivity in LFPs
detection. Five different substrate surfaces were tested in this investigation, namely; glass slide,
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petri dish (polystyrene), aluminum foil, common white paper, and the white area of currency
paper and the results are presented in Fig. 5.3.10 (CSS) and Fig. 5.3.11 (CSS and white light).
As shown in Fig. 5.3.10 and Fig. 5.3.12, F-TA-TP as developing agents can realize the
LFPs development on the surface of nonporous substrates such as glass slides (Fig. 5.3.10a),
common transparent polystyrene petri-dish (Fig. 5.3.10b), regular aluminum foil (Fig. 5.3.10c) as
well as a porous surface such regular white papers (Fig. 5.3.10d). No clear contrast was obtained
when F-TA-TP was tried to detect the details of LFPs on the surface of currency paper, (Fig.
5.3.10e). However, the margins of the LFPs and some details can still be observed.
5.3.3.7 Colloidal Stability
The aqueous dispersion stability of five SNPs namely; T-T, T-TP, TP-TP, TA-T, and TATP, has been investigated over seven days. 0.5 mg/mL suspensions in deionized water from each
SNPs type were used in this study. As shown in Fig. 5.3.13a&b, the five SNPs showed good
suspension stability for 1 and 3 hours, respectively. After two days (Fig. 5.3.13c) and seven days
(Fig. 5.3.13d), only the hydrophobic NPs; T-TP, TP-TP, and TA-TP remained as one phase
showing a good colloidal stability whereas T-T and TA-T, which were not modified with
PTEOS, started to show phase separation. Moreover, the DLS measurements of the
hydrodynamic diameter of the PTEOS-modified SNPs did not show any significant increase in
size after seven days whereas T-T and TA-T showed an obvious increase in size, Table 5.3.3.
These results suggest the potential of using these hydrophobic NPs at low concentrations for biorelated applications 49.
5.3.3.8 Protein adsorption
The adsorption of proteins to surfaces involves electrostatic interactions and Van der
Waals binding forces

50

. Therefore proteins tend to adsorb more strongly to nonpolar than to
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polar, and to charged than to neutral substrates

51

. Bare unmodified SNPs with rich surface

silanol groups possess negatively charged surface potential is expected to show nonspecific
binding to HSA and IgG. Hence, in this study, WA6-T-T (-34.1 ± 8.1 mV) with comparable
charge to bare SNPs (Table 5.3.3) and WA6-T-TP (-26.1 ± 7.5 mV) with the surface coated with
PTEOS of a lower charge were tested for reducing nonspecific protein adsorption. To evaluate
the efficiency of this modification in minimizing nonspecific protein adsorption, the amount of
HSA or IgG adsorbed on the surface of WA6-T-T, WA6-T-TP and bare SNPs were quantified.
The adsorption efficiency (%) of HSA decreased from 2.64 wt.% for bare SNPs to 0.0 wt.% for
WA6-T-T and WA6-T-TP whereas for IgG it dropped from 7.55 wt.% of bare SNPs to 1.36%
and 3.77% wt.% for WA6-T-T and WA6-T-TP, respectively (Fig. 5.3.14). These results indicate
the reduced non-specific protein binding of the tested FLSNPs and promising potential for
biological applications.
5.3.3.9 Hemolysis study
In-vivo applications of bare SNPs for drug delivery are highly limited by their
nonnegligible hemolytic effect

46

which is caused by the generation of reactive oxygen species

induced by the surface of silica, denaturation of membrane proteins, and the high binding affinity
of the tetra-alkyl ammonium groups that are abundant in the membranes of RBCs for the silanol
groups

52

. To assess the effect of surface modification and hydrophobization on the

hemocompatibility of FLSNPs, hemolytic effect of samples to RBCs was investigated. Five
SNPs with different composition namely, WA6-T-T, WA6-T-TP, WA6-TP-TP, WA6-TA-T, and
WA6-TA-TP were compared with the same concentration of unmodified bare SNPs in this study.
In addition, to quantify the extent of hemolysis, concentration of hemoglobin released in the
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supernatant was measured by UV absorbance of the supernatant at 538 nm. As shown in Fig.
5.3.15.
In the chosen concentration 2 mg/mL, none of the selected FLSNPs suspension showed
obvious hemolysis after 1.5 h in comparison with the bare SNPs, which caused a hemolysis of
14.02%, where the three hydrophobic FLSNPs WA6-T-TP, WA6-TP-TP and WA6-TA-TP
resulted in very low hemolysis of 1.29, 1.02, and 1.13%, respectively. Also, WA6-T-T and
WA6-TA-T resulted in a low hemolysis of 2.06 and 1.61%, respectively. The obtained results
indicated that increasing the surface hydrophobicity of the FLSNPs resulted in very good
hemocompatibility at concentrations up to 2mg/mL. For FLSNPs modified with PTEOS, the
interactions between the exposed silanol groups and the membrane surface of RBCs are
minimized, thereby reducing hemolytic effects.

Scheme 5.3.1 Synthesis of WA6
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Table 5.3.1 Used fluorophores and composition for the core and shell of the labeled SNPs and
their labeling efficiencies
FLSNPs

Fluorophore Core composition Shell composition

Labelling
efficiencies (%)

F-T-T

Fluorescein

TEOS

TEOS

15.8

F-T-TP

Fluorescein

TEOS

TEOS + PTEOS

44.9

F-TP-TP

Fluorescein

TEOS + PTEOS

TEOS + PTEOS

77.6

F-TA-TP

Fluorescein

TEOS + APTES

TEOS + PTEOS

79.2

FITC-T-T

FITC

TEOS

TEOS

8.0

FITC-T-TP

FITC

TEOS

TEOS + PTEOS

74.5

FITC-TP-TP

FITC

TEOS + PTEOS

TEOS + PTEOS

53.6

WA6-T-T

WA6

TEOS

TEOS

16.3

WA6-T-TP

WA6

TEOS

TEOS + PTEOS

63.9

WA6-TP-TP

WA6

TEOS + PTEOS

TEOS + PTEOS

72.4

WA6-TA-T

WA6

TEOS + APTES

TEOS

37.4

WA6-TA-TP

WA6

TEOS + APTES

TEOS + PTEOS

78.4
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Table 5.3.2 Diameter determined by TEM and DLS, polydispersity index (PDI), zeta potential of
0.1 mg/ml labeled SNPs in ethanol
FLSNPs

Diameter (SEM)
(nm)

Diameter (DLS)
(nm)

PDI

WA6-T-T

1511.0 ± 354.8*

1096.0 ± 40.9

0.999

WA6-T-TP

33.4 ± 5.9*

217.1 ± 34.9

0.903

WA6-TP-TP

42.2 ± 10.8*

138.2 ± 11.4

0.774

WA6-TA-T

1428.26 ± 116.3*

994.2 ± 177.2

0.449

WA6-TA-TP

39.8 ± 9.4*

196.6± 28.5

0.724

*

SD where n=21
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Table 5.3.3 Diameter determined by DLS, polydispersity index (PDI), zeta potential of 0.1
mg/ml unlabeled SNPs in water

After seven days

Fresh samples

FLSNPs

Diameter (DLS) (nm) PDI

Zeta potential (mV)

T seeds

13.1 ± 2.3

0.317

TP seeds

219.5 ± 68.4

0.557

TA seeds

396.1 ± 55.5

1.000

T-T

911.9 ± 177.6

0.672

-34.1 ± 8.1

T-TP

385.2 ± 146.6

0.328

-26.1 ± 7.5

TP-TP

471.8 ± 280.6

0.291

-28.6 ± 6.0

TA-T

1051 ± 373.6

0.365

-21.9 ± 6.6

TA-TP

465.1 ± 284.5

0.363

-24.2 ± 8.2

T-T-1

178.8 ± 49.7

0.473

T-T

1239.0 ± 341.7

0.278

T-TP

333.3 ± 135.4

0.281

TP-TP

392.3 ± 178.7

0.375

TA-T

1438.0 ± 546.3

0.233

TA-TP

343.2 ± 155.3

0.430
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Figure 5.3.1 The structure formulae for (a) fluorescein, (b) FITC, and (c) WA6 as well as (d)
illustration of core and shell composition of the proposed FLSNP
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(a)

(b)

(d)

(e)

(c)

Figure 5.3.2 SEM micrographs of (a) WA6-T-T, (b) WA6-T-TP, (c) WA6-TP-TP, WA6-TA-T
and (e) WA6-TA-TP
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Figure 5.3.3 Zeta potential measurements of 0.1 mg/ml SNPs dispersions in deionized water; (a)
T-T, (b) T-TP, (c) TP-TP, (d) TA-T, and (e) TA-TP
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Figure 5.3.4 Dye leakage from nine of the FLSNPs. Fluorescence intensity change of 7.5 mg/mL
FLSNPs kept at room temperature in dark at λex of 485 nm (a) after 1 hour in a solvent
composed of ethanol and water in the ratio of (1:1, v/v) or (1:9, v/v), (b) after 24 hours in a
solvent composed of ethanol and water (1:9, v/v)
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Figure 5.3.5 Fluorescence spectra for (a) free WA6 dye (b) WA6-TA-T in water, ethanol and 0.1
M HCl and the normalized fluorescence spectra for (c) free WA6 dye (d) WA6-TA-T in water
and ethanol, indicating the solvatochromic behavior
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Figure 5.3.6 Fluorescence spectra for (a) free WA6 dye in water, ethanol, methanol, acetonitrile,
0.1 M HCl, and 0.1 M NaOH (b) normalized fluorescence spectra for free WA6 dye in water,
ethanol, methanol, acetonitrile and 0.1 M NaOH (c) normalized fluorescence spectra for free
WA6 dye in water: ethanol (9:1, v/v) and 0.1M NaOH: ethanol (9:1, v/v), and (d) ) normalized
fluorescence spectra for WA6-T-TP dye in water: ethanol (9:1, v/v) and 0.1M NaOH: ethanol
(9:1, v/v), indicating solvatochromic behavior
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Figure 5.3.7 Fluorescence images of the fingerprints on glass slides developed using 2.5 mg/mL
FLSNPs suspensions in water: ethanol (9:1, v/v) of (a) WA6-T-T, (b) WA6-T-TP, (c) WA6-TPTP, (d) WA6-TA-TP, and (e) WA6-TA-T at CSS FLS setting and emission filter of 540 nm, (II)
is the magnified part in (I)
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Figure 5.3.8 Fluorescence images of the fingerprints on glass slides developed using 2.5 mg/mL
FLSNPs suspensions in water: ethanol (9:1, v/v) of (a) F-T-T, (b) F-T-TP, (c) F-TP-TP, (d) FTA-TP, (e) FITC-T-T, (f) FITC-T-TP, (g) FITC-TP-TP, (h) WA6-TA-T, (i) WA6-T-T, (j) WA6T-TP, (k) WA6-TP-TP, and (l) WA6-TA-TP at CSS FLS setting and emission filter of 540 nm,
(II) is the magnified part in (I)
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(a)

(b)

(c)

(d)

(e)

(I)

(II)

Figure 5.3.9 Images of the fingerprints on glass slides developed using 2.5 mg/mL FLSNPs
suspensions in water: ethanol (9:1, v/v) for (a) WA6-T-T, (b) WA6-T-TP, (c) WA6-TP-TP, (d)
WA6-TA-TP, and (e) WA6-TA-T at (I) CSS FLS setting and emission filter of 540 nm, and (II)
white light source
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(a)

(b)

(c)

(d)

(e)

(I)

(II)

Figure 5.3.10 Photographs LFPs developed with F-TA-TP powder on different substrates: (a)
glass slide, (b) petri dish (polystyrene), (c) aluminum foil, (d) common white paper, and (e) the
white area of currency paper, (II) is the magnified part in (I)
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(a)

(b)

(c)

(d)

(e)

(I)

(II)

Figure 5.3.11 Photographs LFPs developed with F-TA-TP powder on different substrates: (a)
glass slide, (b) petri dish (polystyrene), (c) aluminum foil, (d) common white paper, and (e) the
white area of currency paper using (I) CSS FLS setting and emission filter of 540 nm, and (II)
white light source
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Figure 5.3.12 Photographs LFPs developed with F-TA-TP powder on different substrates: (a)
glass slide, (b) polystyrene, (c) Aluminum foil, (d) common white paper, and (e) the white area
of money paper, (II) is the magnified part in (I)
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Figure 5.3.13 Photographs of sealed vials that show the phase behavior of 0.5 mg/ml SNPs
dispersions in deionized water at (a) 1 h, (b) 3 h, (c) 2 days, and (d) 7 days
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Figure 5.3.14 UV–Vis absorbance of (a) HSA and (b) IgG solutions after interaction with WA6T-T, WA6-T-TP and bare SNPs suspensions
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Figure 5.3.15 Hemolysis test results after 1.5 h incubation with 2mg/mL from each of bare
SNPs, WA6-T-T, WA6-T-TP, WA6-TP-TP, WA6-TA-T, and WA6-TA-TP suspensions: (a)
optical images and (b) relative hemolysis (%) from measuring the UV absorbance at 538 nm

372

5.4 Conclusions
Uniform F-SNPs with a small particle size with diameters in the range of 4.1-110.4 nm
were fabricated using seven different routes and characterized by DLS and SEM and
spectrofluorometric measurements in section 5.2. In this study, a systematic investigation of
several factors affecting the efficiency of developing fingerprints was carried out. FITC as a
representative dye was loaded into the NPs matrix in order to increase the contrast of the
developed fingerprints while the nanometer-sized particles improve the resolution of the
developed fingerprints. It was found that the most important factor affecting this application was
the hydrophobic nature of the F-SNPs. This can be obtained by using a mixture of TEOS and
PTEOS alkoxyilane precursors during the formation of the NPs. This allowed proper loading of
the used hydrophobic fluorophore and at the same time increased the binding affinity to
hydrophobic components of the fingerprints. The obtained results indicated that the developed
NPs are effective in fingerprint detection when the surface is modified with functional groups
have the potential to react particularly with the most abundant components present in the
fingerprint residue and not with the substrate. Therefore, FCTPS, FCTPS-RM, and FDTPS are
considered good fingerprints developing agents as they developed clear luminescent fingerprints
with good contrast. Both Stöber and WORM methods can be used for F-SNPs synthesis.
However, Stöber method is simpler and more cost-effective. Moreover, FITC can be noncovalently or covalently encapsulated after being conjugated with APTES into the silica matrix
with efficient fingerprints detection results obtained. However, the FCA covalently bonded-SNPs
are more stable and show no dye leakage. In addition, although the less hydrophobic F-SNPs
were coated on the surface with PVP to increase the binding affinity to fingerprints, they did not
result in any enhancement effect on fingerprints development. Thus, these systematic
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investigations demonstrate the features that the dye-encapsulated NPs should hold in order to be
utilized as reliable developing agents for fingerprints forensic applications. This insight may be
applied to the preparation of a range of stable dye covalently or non-covalently loaded-NPs. In
addition, a major understanding of these factors will provide the elemental basis for the effective
utilization of similar dye-encapsulated NPs in other fields such as nanomedicine, tissue imaging,
drug delivery and theranostics.
On the basis of the previously reported basic amino acids-catalyzed approaches for
preparing silica nanoparticles 6-8, the work presented in section 5.3 has demonstrated that the dye
encapsulation efficiency and other photophysical properties of the FLSNPs intrinsically depend
on the applied synthesis route and on the composition of the core-shell structures. In this study,
an amino acid-catalyzed seed regrowth method was used for the synthesis of twelve FLSNPs
with controllable size and tunable hydrophobicity for both the core and shell of the SNPs. The
mean diameters of the hydrophobic FLSNPs were between 33.4±5.9 and 42.2±10.8 nm as shown
by the SEM measurements. The obtained results clearly highlight the advantages of surface
hydrophobization for clear visualization of LFPs, broadly similar to what was observed from
reported doped hydrophobic SNPs

39

. With maximizing the non-covalent interactions between

the core of the SNPs and dye molecules, as in the case of F-TA-TP, even dyes of low
hydrophobicity such as fluorescein and WA6 were used successfully in developing LFPs.
Moreover, high dye encapsulation efficiency, high fluorescence intensity, enhanced stability
against dye leaking were obtained, for example, WA6-TA-T, where the composition of both the
core and the shell of the FLSNPs was made suitable for achieving strong non-covalent
interactions with the dye molecules. Furthermore, the selected FLSNPs had superior
hemocompatibility in comparison with bare silica nanoparticles in terms of minimizing the non-
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specific binding with plasma proteins and decreasing the hemolysis rates. On the other hand,
dyes with alkene side chain such as WA6 have the potential to be covalently copolymerized into
the silica matrix in order to achieve higher stability instead of the commonly used APTESconjugation route, a feature similar to those reported about several other silane-modified organic
dye molecules

53

. Moreover, it is reported that the globular and less ordered hydrophobic

materials have lower hemolytic effects compared with the ordered structures which match the
obtained hemocompatibility results presented in this work 54.
Finally, the modified hydrophobic nanoparticles developed here have a great potential to
impact many bio-related and diagnostic applications such as immunoassays and cell imaging
purposes 54.
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APPENDIX
1H

NMR, and HRMS Spectra

LC-MS ion chromatograms for (a) intact AZL (b) acid induced degradation products of AZL.
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1

HNMR spectra (400 MHz, DMSO-d6) for (a) intact AZL (b) acid induced degradation products

of AZL.
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LC-MS ion chromatograms for (a) intact CLT and (b) alkaline induced degradation products of
CLT.
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1

HNMR spectra (400 MHz, DMSO-d6) for (a) intact CLT (b) alkaline induced degradation

products of CLT.
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1

H NMR spectrum ((400 MHz, CDCl3) for L-ACM

387

MS for L-ACM

388

M03(d)

3.33

0.40

M01(m)

0.01
0.00

M02(m)

3.36
3.35
3.34

M04(d)

2.52
2.51
2.51
2.50

CYS-ACM_DMSO.001.esp

Normalized Intensity

0.35
0.30
0.25
0.20
0.15
0.10
0.05
0
2.00 3.69 3.55 2.13
5.0

1

4.5

4.0

3.5

3.0
2.5
2.0
Chemical Shift (ppm)

1.5

1.0

0.5

H NMR spectrum for CYS-ACM in DMSO-d6 using a 400 MHz Bruker instrument

0

389

The 1H NMR spectra for (a) WA6 and (b) FITC in DMSO-d6 using a 400 MHz Bruker
instrument. 1H NMR δ 1.22 (t, 2H), 1.35 (q, 2H), 5.1 (m, 1H), 5.77 (t, 2H), 6.55 (m, 9H), 6.87 (t,
1H), 6.95 (m, 2H) and 10.12 (s, 1H). 77% yield

